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ABSTRACT 
Vertebrate telomeres are specialized structures localized at the end of chromosomes that are 
composed of TTAGGG tandem repeats. Progressive telomere shortening with every cell 
division, finally leads to telomere dysfunction and the induction of a DNA damage response at 
chromosome ends. DNA damage signaling provokes senescence or apoptosis, phenomena 
linked to organismal aging. In order to maintain telomere function the telomerase reverse 
transcriptase complex, composed by the RNA component (hTERC) and the catalytic subunit 
(hTERT) replenishes telomere repeats in cells with high replicative potential.   
Two main complexes are involved in the regulation of telomeres: shelterin and the telomerase 
complex. Shelterin is composed of six main proteins: TRF1, TRF2, POT1, TPP1, TIN2, and RAP1 
and controls various aspects of telomere function such as telomere length, recombination and 
protection from the DNA damage response factors.  The escape from replicative senescence is a 
key step in tumorigenesis and it is achieved by the reactivation of telomerase activity, as 
observed in 90% of human cancers. However, increasing body of evidence also indicates a 
central role of shelterin in cancer formation or progression. The expression of telomerase and 
shelterin complex is tightly regulated at transcriptional and post-translational level, however 
the role of miRNAs in telomere regulation is not understood. 
The aim of my PhD thesis project was to identify miRNAs that control the expression of 
components of the shelterin or telomerase complex and to evaluate the clinical relevance of 
these miRNAs in the context of human breast cancer. 
To achieve this goal we performed a high-throughput luciferase reporter screening in HeLa cells 
and identified a panel of miRNAs that target the 3’UTR of shelterin (TRF1, TRF2, POT1) or 
telomerase complex components (TERT, DKC1).  
In this screening we identified the onco-miRNA miR-155 as efficient regulator of TRF1 
expression. miR-155 is efficiently upregulated in across all types of human breast cancer and 
high miR-155  levels correlate with low TRF1 expression levels.  We validated targeting of TRF1 
by miR-155 in additional luciferase reporter assays and found that miR-155 controls TRF1 
expression on the translational level. Importantly, low TRF1 mRNA expression but also low 
expression of miR-155 target genes is linked to reduced distant metastasis-free survival and 
relapse-free survival of estrogen receptor positive luminal breast cancer patients. This indicates 
that targeting of TRF1 by miR-155 is part of a miR-155 signature that mediates poor survival in 
viii 
 
ER+ luminal breast cancer. Importantly, we found that targeting of TRF1 expression by miR-155 
leads to increased telomere fragility, telomere sister chromatid fusions and telomere 
elongation. Our work demonstrates, for the first time, that post-transcriptional regulation of 
TRF1 by miR-155 is an efficient mechanism to control telomere fragility and genomic stability in 
the context of human breast cancer. 
Concentrating on miRNA dependent mechanisms of telomerase regulation in human breast 
cancer we studied miR-296-5p and miR-512-5p that were found to efficiently target hTERT in 
the high throughput luciferase reporter assay. Both miRNAs target specific motifs in the hTERT 
3’UTR, leading to degradation of the hTERT mRNA and reduction of telomerase activity. Clinical 
data reveal that miR-296-5p and miR-512-5p are downregulated in breast cancer tissues. 
Importantly, we found that increased hTERT expression but also high expression of miR-296-5p 
or miR-512-5p target genes is linked to poor survival in basal breast cancer patients. This 
highlights the clinical relevance of miR-512-5p and miR-296-5p in basal breast cancer. On the 
molecular levels we showed that miR-296-5p and miR-512-5p impair cell proliferation and 
provoke progressive telomere shortening in basal breast cancer cell lines.  We further found 
that epigentic de-repression of the miR-296 and miR-512 genes in a basal breast cancer cell line 
increase the expression of miR-296-5p and miR-512-5p levels to reduce hTERT expression. Our 
data suggest that the use of drugs that release miR-296-5p or miR-512-5p expression might be 
a promising strategy to impair telomere maintenance mechanisms and hTERT function in 
human breast cancer. 
Altogether, my work demonstrated that miRNAs represent new regulators of telomere function 
that impact on telomere homeostasis in human cancer. This identifies miRNAs as novel targets 
to modulate telomere function in telomere related maladies such as cancer and aging.
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1. Introduction 
 
1.1 Telomeres 
 
1.1.1 Historic background of telomere biology 
 
1.1.1.1 Telomere function, the hayflick limit and the end replication problem   
Telomeres are specialized nucleoprotein structures localized at the ends of eukaryotic 
chromosomes that maintain genomic stability and integrity. Consequently, telomeres are 
essential for viability. In the 1930s, the pioneers of modern genetics Hermann Muller and 
Barbara McClintock focused their attention on the control of genomic stability, using fruitflies 
or maize as model system. Muller working with Drosophila melanogaster treated chromosomes 
with X-rays and observed that the ends of irradiated chromosome, differently from the rest of 
genome, did not present alteration such as deletions or inversions. This suggested the existence 
of a special structure located at chromosome ends that is required for chromosome stability. 
Muller named the natural ends of chromosomes with the term Telomere, from the Greek words 
“telos” (end) and “meros” (part) (Muller H.J. et al. 1938).  
Independently, McClintock performed experiments in maize and observed that X-ray irradiation 
of cells induced single chromatid breaks which led to chromosome end to end fusions in mitotic 
anaphase. These fusions cannot separate freely from one another in the following mitotic 
anaphase consequently causing the formation of dicentric chromosomes. McClintock 
concluded that natural chromosome end was functionally different from chromosome breaks, 
defining natural chromosome end as protective cap (McClintock B. et al. 1939).  
These pioneering studies were crucial to identify the important role of telomeres in 
chromosome end protection, genome stability and faithful segregation of chromosomes into 
daughter cells during cell division.  
In the early 1960s, Leonard Hayflick observed that primary human fibroblasts have a limited 
proliferative capacity in cell culture. He found that primary cells could divide between 60 and 
80 times before they enter in a state, called senescence, in which the cells are arrested in cell 
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cycle but remain metabolically active (Hayflick L. 1965). Only after the studies on DNA 
replication mechanism, Alexei Olovnikov could propose that human somatic cells are subject to 
telomere shortening with consequent loss of genetic information (Olovnikov A.M. 1971) . 
In fact,  work from the 1950s and 1960s revealed that all eukaryotic chromosomes consist of 
linear DNA molecules and that replication occurs via a semiconservative mechanism (Meselson 
M. and Stahl FW. 1958) (Fig. 1.1). Starting from 5’ end RNA primers the two DNA strands are 
synthesized de novo by a specific DNA polymerase in 5’-3’ direction. One strand, called as 
leading strand, is synthesized continuously by DNA polymerase ε. The other strand, referred to 
lagging strand, is synthesized by Pol δ in short fragments that are called Okazaki fragments. 
(Kunkel T.A. 2011; Ogawa T. and Okazaki T. 1980).  
 
 
Figure 1.1. DNA replication fork at the end of chromosomes (Vega L.R. et al.2003) 
 
In the leading strand, RNA primers are removed by RNAse H and the gaps are filled by DNA 
polymerase ε. Instead, removing the distal RNA primer from the lagging strand generates gaps 
that cannot be filled up (Watson J.D. 1972; Olovnikov A.M. 1973). In this way, proliferating 
human somatic cells show progressively shorter telomeres (due to incomplete replication) after 
each round of cell division. It took years before connecting the limited number of cell division 
observed by Hayflick with this phenomenon of telomere replication, referred to as the “end 
replication problem”.  
The fact, that cells undergo cell cycle arrest when telomere are very short support the 
hypothesis by Olovnikon that telomere shortening could determine the possible number of cell 
division (Olovnikov A.M. 1973). Telomere dysfunction by progressive telomere shortening has 
been demonstrated to induce the activation of genes located in subtelomeric region and a DNA 
damage signal. This phase is referred to as “pre-crisis” or mortality stage (M1), in which tumor 
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suppressor genes like p53 and pRb arrest cellular proliferation (Chatziantonou V.O. 2001). The 
abrogation of these genes permits cell division causing further telomere shortening, genomic 
instability and a massive cell death. This phenomenon is called crisis or mortality stage 2 (M2). 
(Shay J.W. and Wright W.E. 2005) (Fig. 1.2). 
 
 
 
 
Figure 1.2. Cell fate in response to telomere shortening. Somatic cells can divide for a limited number of cells 
division. When cells reach Hayflick limit, they enter into cell cycle arrest (senescence), called M1 phase. The cells 
can bypass M1 phase by the abrogation of Rb and p53. Thus, telomeres get shorter finally leading to cell deth, 
called M2 phase. Telomerase re-activation or induction of ALT mechanism in M2 phase lead to telomere 
maintenance with consequent cell immortalization (modified from Shay J.W. and Wright W.E. 2005).  
 
The ectopic expression of the catalytic subunit of the reverse trascriptase, hTERT, results in 
immortalization of human cells if telomeres are rate-limiting for continued cell proliferation. 
hTERT replenishes telomeres in a reverse transcription reaction (see 1.3.3). 
Telomeres are thus important in both senescence (M1) and crisis (M2) as hTERT introduction 
either before M1 or after M1 results in cell immortalization.  
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1.1.1.2 Telomeres consist of short tandem DNA repeats 
After discovering the importance of chromosome ends, the identification of the telomeric DNA 
sequence was a fundamental step to understand telomeres at the molecular level. The first 
terminal sequence was identified in Ciliates such as Tetrahymena and Oxytricha.  
In 1974, Joseph G. Gall started to work with Tetrahymena thermophila that has a distinct 
organization of genomic DNA than other eukaryotic organisms. In particular, Tetrahymena and 
Oxytricha contain a micronucleous with normal chromosomes and a macronucleous that 
contains fragmented chromosomes consisting of multiple small segments of DNA that encode 
ribosomal RNA (rDNA) (Blackburn E.H and Gall J.G. 1978; Gall J.G 1974).  
The ends of these DNA were found to contain multiple repetitions of a hexanucleotid 
CCCCAA/GGGGTT, that were subsequently also identified at the end of chromosomes located in 
the micronucleous (Yao M.C. et al. 1981). 
Importantly, Jack W. Szostak and Elizabeth H. Blackburn were able to demonstrate that 
repetitive sequences of Tetrahymena located at the end of a linear plasmid stabilize DNA 
fragment in Saccaromyces Cerevisiae, thus acting as telomere (Szostak J.W. and Blackburn E.H. 
1982). Based on the fact that yeast was able to recognize the Tetrahymena telomeres and use 
them in DNA replication, they hypotisized that the function of repeated sequences is highly 
conserved in evolution (Szostak J.W. and Blackburn E.H. 1982). 
 
To verify this hypothesis, they removed one Tetrahymena telomere by restriction enzyme 
digestion and added the yeast telomeres to the ends of Tetrahymena telomeres. In this way, 
they demonstrated that yeast telomeres behaved as rDNA telomeres, confirming that telomere 
function is conserved in evolution (Shampay J. et al. 1984).  
Using the same strategy human telomeres were joined to artificial chromosome in S. Cerevisiae. 
As expected, the chimeric yeast-human chromosomes propagated like linear chromosomes 
(Riethman H.C. et al. 1989). 
This experiment demonstrated that human telomere structure is capable of functioning in 
yeast, demonstrating that telomere function is evolutionarily conserved between yeast and 
human (Cheng J.F. et al. 1989). 
In humans, chromosome ends are composed of 5’-TTAGGG-3’ tandem repeats (G-rich strand) 
and a complementary sequence 3’-AATCCC-5’, defined as C-rich strand. Telomeres consist of 5-
15 kb double-stranded DNA followed by a single-stranded region of 50-500 nucleotides at the 
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3’end of the G-rich strand, referred to as the “G-overhang” (Chai W. et al. 2006; Palm W. and de 
Lange T. 2008).  
The study of telomere sequences of diverse species revealed that telomeres consist of T4 rich 
tandem repeats that have a size range from several hundred base pairs in yeast to tens of 
kilobases in mammals (Meyne J. et al. 1989) (Table 1). 
 
 
 
 
Table 1. Telomere length and telomere sequence in different species (Oeseburg H. et al. 2010). 
 
 
After the identification of telomere repeat sequences, research was focused on the physical 
structure of chromosome ends. 
Experiments performed in mouse and human telomeres revealed that protein-free DNA is 
organized in a large, looped structure called “t-loop” (Griffith J.D. et al. 1999) (Fig. 1.3). A 
current model proposes that the 3’-end of telomere, called G-overhang, invade a region of 
telomeric double-stranded DNA (dsDNA) to form a displacement-loop (D-loop) and a looped 
region of double stranded telomere repeats (T-loop) (Nikitina T. and Woodcock C.L. 2004). On 
the functional level the T-loop structure masks the DNA terminus from DNA double-stranded 
break (DSB) repair machinery and limit the access to telomerase (Griffith J.D. et al. 1999). 
Importantly, telomeric proteins of the Shelterin complex (see 1.2) are thought to play a critical 
role in t-loop formation. 
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Figure 1.3. Telomere structure. Telomeric 3’-overhang folds up and invades the double-stranded DNA forming the 
D-loop and T-loop structure (left image). Representative image of T-loop structure captured by electron 
microscope (right image).    
 
 
1.2  Shelterin complex is a key regulator of telomere homeostasis 
Shelterin represents the core of the mammalian telomeric complex  that play an important role 
on telomere length regulation, recombination, replication and chromosome ends protection 
from inappropriate DNA damage repair pathway. 
The Shelterin complex is composed of six proteins: Telomere Repeat Binding Factors 1 and 2 
(TRF1 and TRF2) which bind the double-stranded DNA, Protection Of Telomeres 1 (POT1) that is 
associated with the single-strended TTAGGG repeats present at the 3’-overhang; as well as 
TPP1, RAP1 and TIN2,  that are indirectly associated to telomeric DNA (Fig. 1.4). The shelterin 
complex binds in a sequence specific manner to telomere DNA sequences. Moreover, this 
complex allow cells to repress DNA damage pathway at telomeres, access of telomerase, 
recombination and replication (Diotti R. and Loayza D. 2011).  
The Shelterin complex was discovered by biochemical purification but also in studies on 
protein-protein interaction (Liu D. et al. 2004; Houghtaling B. R. et al. 2004; Ye, J. Z. et al. 2004; 
Liu D. et al. 2004; Kim S. H. et al. 2004; O’Connor M. S. et al. 2006). 
TRF1 was the first mammalian component identified through purification experiments using 
double-stranded TTAGGG repeats (Zhong Z. et al. 1992, Chong L. et al. 1995). TRF2 was 
identified as a TRF1 paralog using sequence studies (Broccoli D. et al. 1997). TIN2 and RAP1 
were discovered in two-hybrid screens focusing on the discovery of interaction partners of TRF1 
and TRF2, respectively (kim S.H. et al. 1999). POT1 was identified by sequence homology to 
telomere end-binding factors in Oxitricha nova (Baumann P. and Cech T.R. 2001). Finally,  the 
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last shelterin component TPP1 has been identify in parallel by three groups (Houghtaling D. et 
al. 2004; Liu B.R. et al 2004;Ye J.Z. et al 2004).  
 
 
 
Figure 1.4. Schematic representation of Shelterin on telomeric DNA. A) six proteins form Shelterin complex (TRF1, 
TRF2, POT1, TIN2, TPP1, Rap1). B) TRF1, TRF2 and POT1 directly bind telomeric DNA allowing the recruitment of 
TIN2, TPP1 and Rap1 to telomere (de Lange T. 2005). 
 
 
1.2.1 Structure and function of telomere repeat binding proteins TRF1, TRF2 and POT1  
TRF1 and TRF2 share a common TRFH domain (TRF homology) and a C-terminal SANT/Myb DNA 
binding domain, which are linked by a flexible hinge domain (Bianchi A. et al. 1997; Broccoli D. 
et al 1997; Chen Y. et al. 2008; Chong L. et al. 1995). The SANT/Myb domains in both proteins 
are nearly identical and confer specificity for the half-site 5’YTAGGGTTR3’in double-standed 
DNA (Bianchi A. et al 1999; Court R. et al. 2005; Hanaoka S. et al. 2005). This domain is 
fundamental for the binding of TRF1 and TRF2 to telomeres. 
TRF1 and TRF2 form homodimers or oligomers through their TRFH domain, however they 
cannot form heterodimers. The structural difference of these two proteins resides in the N-
terminus domain (Bianchi A. et al. 1997; Fairall L. et al. 2001).  
TRF1 binds at a distance or in different relative orientations to TTAGGG sequence using the 
flexible Myb domain leading to the formation of a loop on telomeric DNA (Bianchi A. et al. 
1997; Griffith J. et al. 1998). In addition to double stranded telomeric DNA, TRF2 is localized at 
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the loop junction in looped DNA molecules containing telomeric tracts, demonstrating that 
TRF2 is involved in t-loop structure formation (Stansel R.M. et al. 2001).  
POT1 binds the single-stranded DNA (ssDNA) at chromosome end. POT1 has been identified by 
sequence similarity to alpha subunits of the TEBP α/β telomeric binding complex in Oxytricha 
nova (Baumann P. et al. 2001). POT1 has two OB fold in its N-terminus domain which are 
important to recognize the telomeric single-stranded DNA in vitro (Baumann P. et al. 2001; Lei 
M. et al. 2004; Loayza D. et al. 2004). The G-overhang is not completely occupied by POT1 but, 
its steric hindrance prevents base pairing between telomeric ssDNA and telomerase RNA 
template (Kelleher C. et al. 2005). Consequently, POT1 negatively regulates the telomerase 
activity by blocking the access of enzyme to telomeres (Kelleher C. et al 2005). 
Binding to telomeric DNA is a common capacity of TRF1, TRF2 and POT1, however these 
proteins have distinct functions in controlling telomere homeostasis and protection. 
Important insights into the biological function of TRF1 and TRF2 come from mouse model 
systems. Deletion of Trf1 or Trf2 in mice result in early embryonic lethality, demonstrating a 
fundamental role of these proteins in organism viability (Celli G.B. and de Lange 2005; Beier F. 
et al. 2012; Martinez P. et al. 2009). Specifically, conditional deletion of mouse Trf1 showed an 
induction of senescence and an increase of DNA damage response on telomeres. The 
abrogation of p53 and pRB pathways in Trf1-deleted cells allowed cell divisions causing an 
increase of telomere fragility and chromosomal instability, promoting cancer formation 
(Martinez 2009; Sfeir A. et al. 2009). Furthermore, Trf1 dominant-negative allele led to 
telomere elongation due to the displacement of TRF1 from telomeres (van Steensel B. and T. de 
Lange. 1997). TRF1 overexpression in epithelial mouse cells has been demonstrated to induce 
aberrant mitotic spindles and a gradual shortening of telomeres demonstrating a specific role 
of TRF1 in mitosis and telomere length regulation (Munoz P. et al. 2009). 
Together this demonstrate that TRF1 has a role in telomere length regulation, chromosome end 
protection and genome stability. 
Conditional deletion of mouse TRF2 p53-/- null showed a strong telomere damage response at 
telomeres with a loss of 3’overhang at telomeres, leading to chromosome end to end fusion by 
the non-homologous end-joining pathway (Celli G.B. and Titia de Lange 2005). 
Together this demonstrate the important role of TRF1 and TRF2 in telomere elongation, 
protection and recombination. 
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Importantly, the overexpression of TRF2 in mouse skin caused a severe phenotype in reponse 
to light such as hyperpigmentation and increased skin cancer. The skin cell of these mice 
showed telomere shortening, loss of telomeric G-strand overhang and increased chromosomal 
instability. These experiments demonstrate a key role of TRF2 in telomere regulation and 
highlight the oncogenic role in cancer formation  (Munoz P. et al. 2005).   
All data from mouse model demonstrate that TRF1 and TRF2 are essential for the survival of the 
organism and play a critical role on telomere replication, length regulation, and protection from 
DNA damage response and repair. 
 
Shelterin components TRF1 and TRF2 play a critical role in controlling two different states of 
telomere structure. In the “open state” telomerase can elongate telomere ends, where as in 
the “closed state” telomerase cannot access to telomere. Thus, the T-loop structure and the 
amount of TRF1 and TRF2 at telomere are critical for the switching from a capped to uncapped 
structure (Blackburn E.H. 2000; van Steensel B. and de Lange T. 1997). In particular, it has been 
observed that short telomeres contain insufficient amounts of TRF1, TRF2 and associate 
proteins to generate a closed state. This allows telomerase to access and to prevent a critical 
loss of telomeric DNA. 
On the contrary long telomeres with high amount of TRF1 and TRF2 support the T-loop 
formation blocking the access of telomerase (Smogorzewska A. et al. 2000). In line with this, 
TRF2 was demonstrated to specifically recognize telomeric ss/ds DNA junction promoting the  
T-loop formation (Griffith J.D. et al. 1999; Stansel R.M. et al. 2001).  
This highlight the importance of TRF1 and TRF2 in the regulation of telomere homeostasis by a 
telomere secondary structure.  
The third DNA binding Shelterin component POT1 binds to the G-overhang, and acts as a 
negative regulator of telomere length similar to TRF1 and TRF2. In fact, it has been observed 
that reduction of POT1 by RNA interference leads to a loss of the G-overhang allowing telomere 
elongation (Loayza D. and de Lange  T. 2003).This indicate that ss of telomeric DNA remained 
accessible for telomerase activity.  
Functional experiments involving mouse models brought important insights into the function of 
POT1 in vivo. 
The mouse genome contains two POT1 orthologs, Pot1a and Pot1b. Conditional deletion of 
Pot1a has been demonstrated to elicit a DNA damage response at telomeres leading to 
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senescence (Wu L. et al. 2006). In addition double-knockout of POT1a/b in mouse cells revealed 
that POT1 is required to repress DNA damage signal at telomere and senescence demonstrating 
the protective role of POT1 at chromosome ends (Hockemeyer D. et al. 2006).  
Moreover, Pot1a-deficient cells exhibit an increase of telomere length and the 3' overhang 
elongation, but also show aberrant homologous recombination (HR) at telomeres. Pot1 
deletion, like Trf1 and Trf2, results in chromosomal instability and and sister chromatid 
exchange formation (Wu L. et al. 2006). This demonstrates the important role of POT1 in 
telomere regulation by promoting access of telomerase at 3’-overhang and its role in 
suppression of HR events. 
Together these results, demonstrate the critical role of POT1 in telomere regulation and 
suppression of DNA damage response, homologous recombination and genomic instability. 
 
1.2.2 Structure and function of shelterin complex associated with TRF1, TRF1 and POT1   
RAP1, TIN2 and TPP1 are integral components of the Shelterin complex that bind indirectly to 
telomeric DNA (Fig. 1.4). 
RAP1 has been observed to bind TRF2 with a ration of 1:1 and its telomeric localization and 
stabilization depend on TRF2 (Li B. et al. 2000; Li B. and de Lange T. 2003). RAP1 contains three 
critical domains: a Myb domain that mediates direct binding to the double-stranded telomere 
DNA (Fujita I. et al. 2012), an N-terminal BRCT motif that is involved in the interaction with 
other proteins such as Gcr1 in Saccharomyces Cerevisiae (Zhang W. et al. 2011) ; and a C-
terminal RCT domain that acts as a protein-protein interaction module as demonstrated by the 
interaction with TRF2 (Fujita I. et al. 2012).  
RAP1 has been demonstrated to be essential for the repression of homology-directed repair 
(HDR) by its specific interaction with TRF2. In fact has been observed that  Rap1 deletion from 
mouse telomeres or replacing TRF2 with a mutant that does not bind RAP1 caused HDR events 
in absence of DNA damace foci (Sfeir A. et al. 2010).  Unlike TRF1, TRF2 and POT1 this protein is 
not essential for telomere protection but is important to repress HDR at telomere.  
Furthermore, depletion of RAP1 via RNA interference and deletion experiments demonstrate 
that also RAP1 negatively modulates telomere length in vivo (O’Connor M.S. et al. 2003). 
In addition, by using chromatin immunoprecipitation sequencing (ChIP-seq) has been 
demonstrated that mouse RAP1 binds in vivo to telomeric repeats but also to nontelomeric 
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RAP1-binding sites. RAP1  deletion in mouse induced deregulation of genes that contained 
RAP1-binding sites, with critical roles in adhesion and metabolism pathways (Martinez P. et al. 
2013). 
Together these results, demonstrate that RAP1 plays an essential role in the suppression of 
homologous recombination at telomere but also has an important nontelomeric function. 
 
The protein TIN2 creates a bridge between telomeric ssDNA and dsDNA by binding to TRF1, 
TRF2 and TPP1. The TRFH domain of TRF1 interacts with the FxLxP motif of C-terminus of TIN2, 
whereas the N-terminus binds the hinge domain of TRF2 and also recruits TPP1 (O’Connor M.S. 
et al. 2006; Chen Y. et al. 2008).  
TIN2, which links TPP1/POT1a (and POT1b) to TRF1 and TRF2 on the double-stranded telomeric 
DNA has been demonstrated to repress the ATR signaling. In fact, Tin2 deletion in mouse cells 
led to loss of TPP1/POT1a at telomeres causing the accumulation of RPA and the induction of 
ATR pathway (Takai K.K. et al. 2011). Moreover, deletion of Tin2 showed the same phenotypes 
of the Pot1a/b deletion, in particular the suppression of DNA damage response and telomere 
length regulation. Thus, the major role of TIN2 is to stabilize TPP1/POT1a on the ss telomeric 
DNA, thus repressing the activation of ATR pathway (Takai K.K. et al. 2011). 
Recently, TIN2 mutations have been linked with dyskeratosis congenita (DC). Mouse model 
carrying the specific mutation (TIN2+/DC) revealed an increase of telomere shortening. 
Unexpectedly, telomere shortening was accelerated in TIN2+/DC mTR–/– mice demonstrating 
that telomere shortening was not solely due to diminished telomerase action. In addition, TIN2 
mutation lead to the activation of ATR pathway at telomeres and an increase of telomere 
fragility. These data demonstrate the important role of TIN2 in telomere regulation, replication 
and DNA damage suppression (Frescas D. and de Lange T. 2014). 
 
The last Shelterin component, TPP1, bridges TIN2 and POT1 using its central POT1 interaction 
domain and its C-terminal TIN2 interaction domain (Liu D. et al. 2004; Ye J.Z. et al. 2004). 
TPP1 was demonstrated to recruit or regulate telomerase through an association with the 
telomerase reverse transcriptase TERT Specifically, the TPP1 OB-fold domain is sufficient to 
recruit telomerase (Xin H. et al. 2007; Ye J.Z. et al. 2004; Zhong F.L. et al 2012). 
Importantly, deletion of TPP1 from mouse embryonic fibroblasts resulted in a release of POT1a 
and POT1b from telomere. Furthermore, the telomere dysfunction phenotypes associated with 
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deletion of TPP1 were identical to those of POT1a/POT1b knock-down cells, specifically the 
suppression of DNA damage response, telomere and 3’overhang elongation. 
These data underline the main role of TPP1, which is to allow POT1a and POT1b recruitment at 
telomere playing a protective role at chromosome ends (Kibe T. et al. 2010). 
In addition to control of telomere homeostasis shelterin proteins were demonstrated to have a 
non-canonical function in DNA damage response, mitochondria or gene regulation. 
Moreover, human TIN2, TPP1 and POT1 were localized in the nucleus but also in the cytoplasm. 
These three proteins were demonstrated to interact the one with the another leading to the 
movement of  TIN2, TPP1 and POT1 from the cytoplasm to the nucleus. This shows that TIN2, 
TPP1 and POT1 in the cytoplasm regulate the assembly and function of the telosome in the 
nucleous (Chen L.Y. et al. 2007). This suggests that these components interact with other 
protein or non-canonical sequences. In fact, genome-wide ChIP-seq showed that Rap1 and TRF2 
bind to non-TTAGGG-containing motifs suggesting that TRF2 and RAP1 possess binding capacity 
for non-telomeric DNA sequences. In particular, RAP1 was demonstrated to bind also 
extratelomeric sites through the TTAGGG consensus motif. 
These results indicate that human telomeric proteins could bind interstitial sites and regulate 
gene transcription. (Yang D. et al. 2011; Martinez P. et al. 2010).  
Recently, TIN2 was found to be posttranslationally processed in mitochondria and regulates 
mitochondrial oxidative phosphorylation in human cells, demostrating a novel connection of 
metabolism and telomeric proteins (Chen L.Y. et al. 2012). 
 
 
 
 
 
 
 
 
 
 
1.2.3 Proteins indirectly associated with telomeres 
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In addition to Shelterin, other factors interact dynamically with mammalian telomeres 
influencing its stability. Shelterin components are present at chromosome end throughout the 
cell cycle, while accessory factors are transiently recruited to telomeres (de Lange T 2005). All 
these associated factors are normally involved in non-telomeric functions and are localized in 
the nucleus and cytoplasm.  
The proteins that have been found to interact with TRF1 are involved in different role such as 
telomere protection, telomere length regulation and telomerase inhibition (Fig. 1.5 a). TRF2 
associated proteins play a critical role in recombination, telomere length regulation, telomeric 
overhang processing and telomere protection (Fig. 1.5 b). 
poly-ADP-ribose polymerase (PARP) tankyrase associated with TRF1 is important in the nucleus 
for chromatid separation specifically at telomere (Fig. 1.5 a). In fact, modification of TRF1 by 
tankyrase was demonstrated to induce sister chromatid fusion after DNA replication due to 
unprotected telomeres (Hsiao S.J. et al. 2009). Importantly, PARsylation leads to loss of TRF1 
from telomere (Hsiao S.J. et al. 2009) and subsequent degradation by the ubiquitin/ 
proteasome pathway (Chang W. et al. 2003). The proteins involved in this mechanism are the F-
box proteins, such as FBX4, that function as substrate-specific receptor for SCF ubiquitin ligases. 
Specifically, overexpression of FBX4 was demonstrated to interact with TRF1 leading to 
degradation and subsequent telomere elongation (Lee T.H. et al 2006). Together these results, 
demonstrate the important role of telomere-associated proteins in telomere homeostasis.  
Finally, TRF1 and telomerase interact simultaneously with a TID domain of PINX1 (Fig. 1.5 a). 
This protein is important to inhibit telomere elongation through interaction with TRF1. In fact it 
was demonstrated that mutants of PINX1 or knock down of endogenous TRF1 by RNAi 
abolished the ability of PinX1 to localize to telomeres and to inhibit telomere elongation in 
human cells. Importantly, no effect on telomerase activity was detected. 
These data highlight a critical link between the telomerase inhibitor PINX1 and TRF1 to prevent 
telomere elongation and maintain telomere homeostasis (Zhou X.Z. et al. 2001; Soohoo C.Y. et 
al. 2011).  
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Figure 1.5. Schematic representation of Shelterin associated factors. a) proteins interacting with TRF1. b) proteins 
interacting with TRF2. Interaction domains are indicated (Palm W. and de Lange T. 2008). 
 
 
A series of proteins was found to associate with TRF2 and are involved in diverse mechanisms 
related to telomere homeostasis. Examples of these factors is represented by the MRE 
complex, Apollo, PNUTS, MCPH1, and WRN (Fig. 1.5 b).  
Apollo is an important nuclease that affects telomere end-processing, specifically at leading-
end telomeres (Wu P. et al. 2010; Lam Y.C. et al. 2010). Apollo was demonstrated to be 
recruited to telomeres by the shelterin subunit TRF2 (Chen Y. et al. 2008; van Overbeek M. and 
de Lange T. 2006; Lenain C. et al. 2006; Bae J.B. et al. 2008). Importantly, Apollo deficient cells 
results in a 25–35% reduction in the overhang signal (Wu P. et al. 2010; Lam Y.C. et al. 2010). 
Thus, the primary role of TRF2 is to recruit Apollo and ensure correct formation of the 3’-
overhang leading to telomere protection (Wu P. et al. 2012).  
In fact, Apollo deleted mouse showed a DNA damage response at telomere with a significant 
increase in telomere doublets observed on metaphase chromosomes suggesting that the 
telomere damage observed were related to replication. This data demonstrate the key role of 
Apollo in 3’-overhang regulation, telomere protection and replication. 
The MRN complex constituting of MRE11, RAD50 and NBS1, was also observed to be involved in 
the 3’-overhang generation through the interaction with TRF2 (Deng Y. et al. 2009; Dimitrova N. 
and de Lange T. 2009; Attwooll C.L. et al. 2009). The role of MRN at dysfunctional telomeres  
was studied in embryonic fibroblasts derived from mice harboring MRN mutations and 
deletions, combined with TRF2 removal by conditional deletion or shRNA knockdown. These 
studies demonstrate that MRN complex, linked to TRF2, functions to detect and signal the 
presence of dysfunctional uncapped telomeres.  
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In addition it was demonstrated in TRF2 deficient cells that MRN and TRF2 play a fundamental 
role in telomere fusion by NHEJ.  Specifically, MRN can either promote or suppress the NHEJ-
mediated fusion of dysfunctional telomeres (Lamarche B.J. et al 2010).  
 
Another important class of proteins interacting with TRF2 are the DNA helicases such as WRN 
(Werner syndrome protein) and BLM (Bloom syndrome protein). TRF2 has been demonstrated 
to stimulates the helicase activity of both WRN and BLM via physical protein interactions to 
unwind secondary structure during replication fork progression (Edwards D.N. 2014; Diotti R. 
and Loayza D. 2011; Opresko P.L. 2002). Mutation on WRN and BLM genes show telomeric 
abnormality and constitute the principal causes of premature aging and elevated cancer 
incidence (Edwards D.N. 2014). Thus, TRF2 with the cooperation of the helicases is critical for 
telomere replication and chromosomal instability. 
 
 Other factors which interact with shelterin components and play a fundamental role at 
telomere are involved in DNA damage signaling, such as ATM and ATR (Karlseder J. et al. 2004; 
Kishi S. et al. 2001; Gong Y. et al. 2010) or in non-homologous end joining (NHEJ) such as 
Ku70/Ku80 (Hsu H.L. et al. 2000; Wang Y. et al. 2009). All together, these proteins are essential 
to regulate telomere homeostasis and maintain telomere protection.   
 
1.3 Telomere maintenance by telomerase 
Normal somatic cells can perform a limited number of cell division before entering to 
senescence. In contrast, stem cells or cancer cells can proliferate indefinitely, due to the activity 
of a reverse transcriptase named telomerase. 
This enzyme has been identified for the first time by Elizabeth Blackburn and Carol Greider in 
Tetrahymena thermophila. In pioneering studies they showed that Tetrahymena cell free 
extracts were able to elongate synthetic telomere primers in vitro. This demonstrated for the 
first time the existence of telomere terminal transferase, that can elongate telomeric repeats to 
overcome the end replication problem in eukaryotes (Greider C.W. and Blackburn E.H 1985). 
This particular characteristic implied the use of internal template by telomerase. In fact, this 
hypothesis was confirmed by the isolation of telomerase RNA named TERC (Greider C.W. and 
Blackburn E.H 1989). Consequently, the telomerase complex is composed by telomerase 
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reverse transcriptase catalytic subunit (TERT) and by the RNA component (TERC) which acts as 
template for reverse transcription (Smogorzewska A. and de Lange T. 2004). In addition, other 
proteins that associate with TERC regulate the biogenesis and correct assembly of telomerase 
in vivo.  
 
1.3.1 TERT structure 
Human TERT gene is located at chromosome 5p15,23 encoding an mRNA containing 16 exons 
(Bryce et al. 2000). 
Human telomerase has is formed of two subunits of TERT and two  TERC molecules (Cohen S.B. 
et al. 2007) (Fig. 1.6 A). The catalytic subunit is 127 kDa protein that contains four functional 
domains: N-terminal domain (TEN), a RNA binding domain (TRBD), the reverse transcriptase 
domain (RT) and the conserved C-terminal domain (CTE) (Fig. 1.6 B).  
 
 
Figure 1.6. Telomerase complex. A) telomerase catalytic subunit TERT and RNA component TERC with associated 
telomerase factors (dyskerin and TCAB1). B) Predicted linear architecture of hTERT. NTE, RT and CTE domains are 
indicated (Artandi E.S. and DePinho R.A. 2010; Wyatt H.D.M. et al. 2010).  
 
 
These domain are important for the correct function of telomerase, allow the enzyme to bind 
to the G-overhang, to perform the catalytic reaction and ensur the processivity at chromosome 
end. 
The N-terminal (TEN) is an anchor domain of telomerase and has been shown to be involved in 
single-stranded telomeric DNA binding and processivity. (Chen J. L. and Greider C. W. 2003; Lai 
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C. K. et al. 2003 ; Jacobs S. A. et al. 2006; Mitchell M. et al 2010). The TRBD is an RNA binding 
domain that contains mainly helical motifs and is essential for ribonucleoprotein assembly 
(Rouda S. and Skordalakes E. 2007; Mitchell M. et al 2010). The main domain is the catalytic 
domain (RT) which has two subdomains (palm and finger) typical of all retroviral RT (Fig. 1.6 B). 
The last domain is the C-terminal domain (CTE) that shows low conservation and presumably 
contributes to species-specific function. The CTE, formed by the Thumb domain (Fig. 1.6 B), 
contains an helix bundle and is especially implicated in DNA-RNA binding and processivity (Gillis 
A. J. et al. 2008; Mitchell M. et al 2010).  
 
1.3.2 TERC structure 
The second key telomerase component is TERC and its gene is located at chromosome 3q26,3 
(Soder A. I. et al. 1997). The RNA component is transcribed by RNA polymerase II and has a size 
of 451 nucleotides in humans (Feng J. et al. 1995). This RNA is fundamental for the function of 
telomerase because contains a sequence that acts as mold for telomeric DNA synthesis 
(Theimer C.A. and Feigon J. 2006). 
TERC molecule differs in other organism not only in sequence but also in length. In fact, TERC 
sequence length ranges from 147 to 205 nt in ciliates (Greider C.W. and Blackburn E.H 1989), in 
vertebrates from 312 to 559 nt (Chen J.L. et al. 2000) and in yeast from 779 to >2,030 nt 
(Gunisova S. et al. 2009). 
TERC contains a core domain, encoding the template (5’-CUAACCCUAAC-3’) for reverse 
transcription;  conserved regions (CR3, CR4, CR6, CR7, CR8) that are used as anchor points for 
the sequence alignment and together comprise the catalytic core of TERC; finally it contains the 
H/ACA box (Chen J.L. et al. 2000) (Fig. 1.7).  
The H/ACA domain defines a specific class of non-coding RNA, that can be divided into two 
groups: small nucleolar RNAs (snoRNA) which accumulate in the nucleous and are involved in 
the modification of ribosomal RNAs and the Small Cajal-body specific RNAs (scaRNA) which 
accumulate in the cajal-bodies and are involved in the posttranscriptional modification of other 
RNAs. In adittion to the H/ACA box scaRNAs also contain the CAB box. 
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Figure 1.7. Schematic representation of hTERC structure. Core domain containing the template 5’-CUAACCCUAAC-
3’ for reverse transcription, conserved domain (CR4,CR5,CR7) and H/ACA box are indicated (Autexier C. and Lue 
N.F. 2006)   
 
TERC possess not only the H/ACA box  but also a CAB box motif such as scaRNAs (Fig. 1.7) that 
mediates TERC accumulatation in cajal bodies in human cancer cells or in primary cells with 
ectopically induced hTERT expression (Petrov A. V. et al. 1998; Zhu Y. et al. 2004; Niu H. et al. 
2000; Lue N. F. and Li Z. 2007; Chang M. et al. 2007). This indicates that Cajal bodies are 
important for the assembly and/or function of human telomerase. 
Moreover, the H/ACA box represent a binding site for dyskerin, an enzyme with RNA-binding 
protein capacity (Meier U.T. 2005). Dyskerin together with three associated proteins (NHP2, 
NOP10,GAR1) binds the H/ACA box to control the stability of TERC in Cajal bodies (Pogacic V. et 
al. 2000; Artandi S.E. and DePinho R. A. 2010). In addition, the cajal body protein TCAB1 has 
been found to bind the CAB box of TERC. Importantly, depletion of TCAB1 reduced telomerase 
RNA localization to Cajal bodies and led to telomere shortening (Venteicher A.S. 2009). 
Together these results, indicate that telomerase holoenzyme requires the contribution of 
associated proteins for its assembly, stability, trafficking and function in human cancer cells. 
Importantly, TERC deleted mice resulted telomere shortening and, as expected, the telomerase 
activity was not detectable. Moreover, cells from the fourth TERC-/- generation showed 
chromosome ends lacking detectable telomere repeats, aneuploidy, and chromosomal 
abnormalities, including end-to-end fusions (Blasco M.A. et al. 1997). These results indicate the 
importance of TERC for telomere length maintenance. 
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Another important evidence  that demonstrates the importance for TERC comes from the 
generation of Terc (hTR) knockout mouse. Terc knockout mice do not show telomerase activity 
and are subjected to telomerase shortening in successive generations. This finally leads to an 
early onset disease such as cardiac arrest, loss of fertility and reduced tissue regeneration. 
Interestingly, Terc -/- mice showed reduced proliferative potential or high levels of apoptosis in 
the affected tissues, correlated with p53 upregulation that confers an improved resistance to 
oncogenic stress (Blasco M.A. et al. 1997; González-Suárez E. et al. 2000; Lee H.W. et al. 1998).  
Importantly, Terc knockout mice presents a clear evidence that stem and progenitor cells are 
depleted and/or functionally compromised through various processes such as increased 
apoptosis, senescence and impaired differentiation. In addition Terc knockout mice show 
pronounced differentiation towards the myeloid lineage, a profile similar to that in aged 
humans (Rossi, D. J. et al 2007; Choudhury, A. R. et al. 2007; Sahin E. and DePinho R.A 2010). 
This demonstrate the importance for TERC and telomerase activity for tissue regeneration and 
the control of organismal aging.  
 
1.3.3 Telomere elongation by telomerase 
The processivity of telomerase has been first shown in Tetrahymena enzyme and was 
subsequent validated in various species including human (Greider C.W. and Blackburn E.H 1989; 
Morin G.B. 1989). The mechanism of action of telomerase can be divided in three steps: binding 
of the RNA template and TERT to telomere single-stranded; addition of telomere repeats at the 
3’-overhang of DNA and successive translocation and repositioning of the 3’-overhang of 
telomere with the 3’ template boundary of TERC,  to start a new round of telomere elongation 
(Fig. 1.8).  
The processivity of telomerase can be influenced by many factors such as temperature, 
substrate concentration, G-quadruplex interacting-agents or proteins that interact with 
telomerase or telomeric DNA (Morin G.B. 1989; Bosoy D. and Lue N.F. 2004; Sun D. et al. 1999; 
Maine I.P. et al. 1999; Hardy C.D. et al. 2001). A large number of telomerase-associated 
proteins has been identified. Proteins that interacts directly with TERT, such as p23 chaperon, 
TEP1, 14-3-3 or Pinx1, play a key role in controlling enzymatic function of telomerase (Holt S.E. 
et al. 1999; Seimiya H. et al. 2000; Harrington L. et al. 1997; Nakayama J-I. et al. 1997; Yan L. 
2014; Yoo J.E. et al. 2014). In vitro experiments revealed that Pinx1 can binds by its small TID 
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domain the telomerase catalytic subunit TERT to inhibit TERT activity (Zhou X.Z. and Lu K.P. 
2001; Banik S.S.R. and Counter C.M. 2004; Yoo J.E. et al. 2014). Importantly, the interaction 
between telomerase and shelterin components can also play a critical role in telomerase 
activity. In particular, it has been shown that interaction of telomerase with TPP1-POT1 
stimulates the processivity of the enzyme (Wang F. et al. 2007; Hwang H et. al. 2012).  
 
 
 
Figure 1.8. Schematic representation of the mechanistic steps of telomere replication by telomerase.a) 
hybridization of the RNA-templating region TERC (hTER) with the telomeric 3’-overhang and positioning of the 3’-
end of the DNA at the active site of TERT for nucleotide addition. b) TERT adds nucleotides to the RNA-templating 
region. c) telomerase complex dissociate from telomeric overhang then 3’-end hybridize with the distal region of 
the RNA-templating region. d) A second round of telomere synthesis is initiated. Reiterative synthesis, dissociation, 
and repositioning of the telomeric overhang leads to repeat addition processivity, a unique feature of telomerases 
(Mason M. et al. 2011). 
 
 
1.3.4 Immortalization of primary human fibroblast by ectopic expression of hTERT 
Telomerase activity confers unlimited proliferation potential. Normal somatic cells undergo 
senescence after a limited number of cell division due to a progressive loss of telomeric DNA. 
This drives cells into a state of cellular senescence that contribute to aging (Meyerson M. et 
al.1997; Bodnar A.G. et al.1998; Vaziri H. and Benchimol S. 1998) (Fig. 1.9). In contrast, in tumor 
cells replicative telomere shortening is balanced by telomere lengthening, mediated by 
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telomerase in 90% of human cancer (Shay J.W. et al. 1991). Importantly ectopic expression of 
hTERT in human fibroblast re-established telomerase activity and extended lifespan by 
rejuvenating telomeres. This demonstrats that TERT is a central factor regulating timing of 
cellular senescence. Importantly, ectopic expression of telomerase in human fibroblasts was 
sufficient for immortalization, but did not impact on cancer formation (Morales C.P. et al. 
1999).  
 
 
 
Figure 1.9. Representative image of proliferating (A) and senescent (B) fibroblast (Martinez-Zubiaurre et al. 2013). 
 
1.3.5 Regulation of telomerase expression 
Initial studies of TERT expression and telomerase activity indicated a strong suppression of 
hTERT in somatic tissue, however high telomerase activity in germ cells and cancer cells 
associated with high expression of TERT.  This is in line with the proliferative potential of these 
cells (Kim N.W. et al. 1994). Importantly, it has been found that telomerase is expressed in 80-
90% in human cancer and its essential for continuing growth of malignant cells (Kim N.W. et al. 
1994; Shay J.W. & Bacchetti S. 1997). Deeper analysis revealed that cells from tissues with high 
renewal potential such as bone marrow, gastrointestinal tract and testis or activated 
lymphocytes, display a modest levels of telomerase activity (Artandi S.E. and DePinho R.A. 
2010), at the same time stem-or progenitor cells present in those tissues have high telomerase 
activity (Yui J. et al. 1998; Liu K. et al. 1999; Forsyth N.R. et al. 2002). In line with this, Terc 
knockout mice showed depleted and/or functionally compromised stem cells through various 
processes such as increased apoptosis, senescence and impaired differentiation triggered by 
telomere dysfunction (Rossi D. J. et al 2007; Choudhury, A. R. et al. 2007; Sahin E. and DePinho 
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R.A 2010). Telomerase expression is reactivated during the reprogramming of human 
fribroblast to induce pluripotent stem cells (Takahashi K. et al. 2007).  
In line with distinct activity levels of telomerase in self-renewing cells and differentiated cells, 
hTERT is subjected to tight regulation by transcription factors, epigenetic regulation and post 
transcriptional regulation.  
Oncogenes such as c-Myc and Sp1 (Kanzawa T. et al. 2003) or suppressor genes as HER2 and 
p53 can bind hTERT promoter sites and act as activators or repressors of hTERT expression, 
respectively (Papanikolaou V. et al. 2009).  
On the epigenetic level, hTERT expression that can be modulated through inhibition of the DNA 
methyltransferase (DNMT) or histone acetyltransferase (HAT) activities. CpG islands at the 
promoter of hTERT mediate the regulation of TERT expression via DNMTs. In fact, treatment of 
cells with 5’-aza-2’-deoxycitidine, a DNA methhylation inhnibitor, showed increased of TERT 
expression (Dessain S.K et al. 2000; Zinn R.L. et al 2007).  
Experiments in normal human somatic cells treated with Histone deacetylase inhibitor (HDACi) 
such as Trichostatin A (TSA) showed a transcriptional regulation of TERT. Remarkably, 
depending on the cell type HDACi treatment can lead to the activation but also repression of 
hTERT. 
In telomerase positive cells, such as activated T lymphocytes, TSA induces hyperacetylation of 
histones at the hTERT proximal promoter and directly transactivates TERT gene.  
Importantly, activation of TERT promoter is abolished by the mutation in binding sites for the 
Sp1 transcription factor, suggesting that TSA regulates hTERT via Sp1 motif. 
In addition  was found  that hTERT promoter is tightly associated with Sp1 which is recruited 
into the hTERT promoter by histone deacetylase (HDAC). Thus, treating cells with an HDACi 
such as TSA increased hTERT expression in normal human somatic cells demonstrating that Sp1 
is involved in the HDAC mediated transcriptional repression of the hTERT gene (Won J. et al. 
2002; Hou M. et al. 2002). On the contrary, TSA treatment suppresses TERT mRNA expression 
and telomerase activity in human prostate cancer without altering the expression factors such 
as c-Myc or p21 (Suenaga M. et al. 2002). 
SAHA (suberoylanilide hydroxamic acid) is another important HDACi that was found to have 
antiproliferative properties by causing the varied cancer cells to undergo cell cycle arrest, 
apoptosis, and differentiation (Munster R.N. et al. 2001; Arnold N.B. et al. 2007; Li C.T. et al. 
2011). Importantly, lung cancer cells treated with SAHA showed the reduction of telomerase 
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activity by decreasing hTERT mRNA (Li C.T. et al. 2011). So, the combination of SAHA with other 
chemotherapeutic agents can be important against human cancer cells. 
The fact that HDACi increase or suppress TERT expression according to the cell type suggest the 
existence of multiple pathways that control hTERT (Suenaga M. et al. 2002).  
TERT was demonstrated to be regulated at post transcriptional or  translational level.  
In fact, was demonstrated that serine/threonine protein kinase Ca (PKCa) can phosphorylate 
hTERT and activate telomerase activity in breast cancer cells (Li H. et al. 1998; Xi P. et al 2013). 
Moreover, the protein kinase Akt is also found to be involved in activation of telomerase 
activity by phosphorylating two potential phosphorylation sites of hTERT (Kang S.S. et al. 1999; 
Xi P. et al 2013). Recently, PP2A the major serine/threonine phosphatase was demonstrated to 
interact with hTERT in vitro and in vivo, regulating hTERT subcellular localization and inhibiting 
telomerase activity (Xi P. et al 2013). 
The post transcriptional regulation of TERT expression includes direct and indirect targeting of 
TERT by microRNAs. In particular, miR-138, miR-498, miR-21 miR-1207-5p and miR-1266 were 
able to reduce cancer cell proliferation, phenocopying the effect of classic RNAi mediated 
knock-down of TERT. It was observed that miR-138 in combination with APG (flavonoid 
apigenin) reduce hTERT expression sensitizing tumor cells to apoptosis, both in vitro and in vivo 
experiments (Chakrabarti M. et al. 2013). Moreover, miR-21 was found to regulate hTERT 
expression by targeting PTEN/PI3K/AKT signaling pathway (Zhu H.Y. et al. 2014). Recently data 
show that miR-1207-5p and miR-1266 decrease TERT expression by specific interaction with the 
3’UTR of hTERT inhibiting  gastric tumor growth in vitro and in vivo (Chen L. et al. 2014).  
Together telomerase activity is modulated on multiple levels, promoting therapeutic targets for 
human cancer.  
 
1.3.6 Extra-telomere roles of telomerase 
Numerous studies demonstrate the role of telomerase in controlling telomere homeostasis in 
stem and cancer cells. However a number of studies anticipate alternative functions of hTERT.  
 In fact, the overexpression of TERT in mice triggers the activation of quiescent bulge stem cells, 
independently of telomere elongation, indicating a direct impact of TERT on stem cell renewal 
(Flores I. et al. 2005; Sarin K.Y. et al. 2005). In addition, TERT binds to promoters responsive to 
Wnt signaling, (Park J.I. et al 2009; Barker N. et al 2001) suggesting  that TERT can work as 
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transcription factor.  On the contrary another work showed that Wnt/β-catenin regulates TERT 
expression through the interaction with Klf4, a core component of the pluripotency 
transcriptional network. In particular β-Catenin binds to the TERT promoter in a mouse 
intestinal tumor model and in human carcinoma cells. This two studies demonstrate that TERT 
can function as transcription factor and that there is a bidirectional activation of TERT and Wnt 
pathway both in embryonic stem (ES) cells and cancer (Hoffmeyer K. et al. 2012; Zhang Y. et al. 
2012).  
Moreover TERT was linked to post-transcriptional gene silencing. In fact, TERT was 
demonstrated to interact with the RNA component of a mitochondrial RNA processing 
endoribonuclease (RMRP). hTERT and RMRP were able to form a ribonucleoprotein complex 
that has RNA-dependent RNA polymerase (RdRP) activity and produces double-stranded RNAs 
which are processed into small interfering RNAs (Maida Y. et al. 2009). 
In line with this, hTERT was localized to mitochondria (mt) during oxidative stress (Ahmed S. et 
al. 2008) where it improves mitochrondrial function and stress resistance, independently of its 
telomeric function (Saretzki G. 2009; Gordon D.M. and Santos J.H. 2010). Moreover, it has been 
demonstrated that TERT co-fractionates with mtDNA  and also interacts with mitochondrial 
tRNAs.  This suggest that TERT works in mitochondria as a TERC-independent reverse 
transcriptase, establishing it as a new player in mtDNA metabolism (Sharma N.K. et al. 2012). 
These studies add new unprecedented roles of telomerase.  
 
1.3.7 Telomerase and cancer 
The contribution of telomerase to tumor development and progression has been studied in 
depth. The activation of telomerase as a mechanism to ensure unlimited cell proliferation, is a 
hallmark for almost all human cancer (Shay J.W. et al. 1997). Several mechanisms have been 
reported to activate telomerase in cancer: the oncogenes Myc and Wnt which transcriptionally 
activate telomerase (Wu K.J. et. al. 1999; Hoffmeyer K. et al. 2012; Greider C.W. 2012), 
epigenetic alterations, mechanisms involving alternative splicing (Kyo S. and Inoue M. 2002) 
and mutations increasing transcriptional activity of TERT promoter (Huang F.W. et al. 2013; 
Horn S. et al. 2013).  
Even though telomerase activation can occur early in tumor development, telomerase activity 
is not necessary for cancer initiation but more importantly it can stimulate tumor progression 
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by allowing telomere maintanance above a critically short length. In fact in telomerase 
deficiency condiction,  telomere shortening and dysfunction alone could fuel chromosomal 
instability and promote carcinogenesis, while subsequent activation  of telomerase may be 
necessary to allow cancer growth and progression (Begus-Nahrmann Y. et al. 2012; Ding Z. et al. 
2012). 
In line with this, telomerase deficient mice (TR-/-) show resistance to tumorigenesis (Gonzalez-
Suarez E. et al. 2000), except  when tumor suppressors or p53 are bypassed (TR-/- crossed with 
p53+/- or p53-/-) as frequently occurring in cancer (Artandi S.E. et al. 2000; Chin L. et al. 1999). 
In this case in fact, the lack of a proper DNA damage response allows genomic instability to give 
rise to cancer. 
Otherwise telomerase over-expression during mouse development (TgTERT mice) results in 
only a slight increase of tumor incidence, suggesting that TERT over-expression alone is not 
sufficient to cancer formation (Tomas-Loba A. et al. 2008). 
Importantly, cancer cells transfected with dominant negative TERT or silenced for TERT with a 
specific RNA interference were more likely to undergo apoptosis compared to the control, this 
highlights the anti-apoptosis effect of hTERT in cancer (Wu P. et. al. 2005; Del Bufalo D. et al. 
2005). 
In addition to its role in telomere maintenance, extra-telomeric roles of telomerase could have 
an impact on cancer growth such as regulation of Wnt targets and metabolism (Sahin E. et al. 
2010; Vera E. et al. 2013; Hoffmeyer K. et al. 2012; Greider C.W. 2012; Park J.I. et al. 2009). 
 
1.4 Alternative lengthening of telomeres 
Telomere maintenance is controlled by hTERT in 90% of human cancers, in contrast, 10% of 
tumors have apply a mechanism named alternative lengthening of telomeres (ALT) or even 
both ALT and telomerase activity (TA) (Shay J.W. and Bacchetti 1997). 
ALT involves homologous recombination (HR)-mediated DNA copying of a telomeric DNA 
template (Dunham M.A. et al. 2000). To date, four different types of  ALT mechanism have been 
reported depending on telomeric DNA template: i) the telomere of a non-homologous 
chromosome (Dunham M.A. et al. 2000), ii) telomeric sequences elsewhere in the same 
telomere, iii) the sister chromatid telomere (Muntoni A. et al. 2009) or iv) extrachromosomal 
telomeric DNA that may act as the copy template (Henson J.D. et al. 2002) (Fig. 1.10).  
26 
 
These different mechanisms generate defined phenotypic characteristics including telomere 
length heterogeneity (Bryan T.M. et al. 1995,1997), abundant extrachromosomal linear and 
circular telomeric DNA (t-circle) and high frequency of telomere-sister chromatid exchange (T-
SCE) events (Conomos D. et al. 2013). The hallmark feature of ALT cells is the presence of 
subnuclear structures APB (ALT-associated promyelocytic leukemia (PML) bodies). In these 
nuclear bodies, telomeric DNA, shelterin proteins (TRF1, TRF2,TIN2 and Rap1), and HR factors 
as Mre11-Rad50-Nbs1 (MRN) and RAD51, have been identified  (Yeager T.R. et al 1999, Bischof 
O. et al. 2001). Importantly, the disruptions of APBs was demonstrated to modulated the 
expression of proteins that play important roles in normal telomere maintenance, such as 
shelterin or proteins of the MRE11/RAD50/ NBS1 (MRN) complex. Moreover, APBs were found 
to play a direct role in telomere recombination, both by bringing together chromosome ends 
and by promoting telomere-telomere interactions between heterologous chromosomes 
(Draskovic I. et al. 2009). 
In addition, epigenetic regulation at telomere was demonstrated to increase T-SCE in 
embryonic stem cells. In fact, mouse embryonic stem (ES) cells deficient for the DNA 
methyltransferases (Dnmt1) or histone methyltransferases (Suv4-20h and Suv29h) showed the 
activation of ALT pathways associated with defective histone methylation at telomeres and 
subtelomeres (Gonzalo S. et al. 2006 ; Benetti R. et al. 2007). 
These APB bodies are identified generally in tumors of mesenchymal origin including 
osteosarcomas (Ulaner G.A. et al. 2003), soft-tissue sarcomas (Montgomery E. et al. 2004), and 
glioblastoma multiforme (Hakin-Smith V. et al. 2003), than in those of epithelial origin (Henson 
J.D. et al. 2002). 
Importantly, telomerase positive tumors were shown induce resistance to telomerase inhibitors 
by activating ALT (Qin X. et al. 2013). Similarly, mouse lymphomas with an inducible telomerase 
reverse transcriptase allele activate ALT mechanism allowing to resume the growth after the 
shut off of ectopic TERT expression  (Hu J. et al. 2012). Recently, ALT mechanisms have been 
observed to be involved in a natural aspect of telomere biology of mice somatic cell (Neumann 
A.A. et al. 2013). Thus, ALT is not limited to cancer, but is also relevant in normal tissue.  
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Figure 1.10. Alternative lengthening of telomeres. The copy template used for alternative lengthening of 
telomeres-mediated telomere lengthening may also be: the same telomere through telomere-loop (t-loop) 
formation (a); the telomere of the sister chromatid (b); linear extrachromosomal telomeric DNA (c); or circular 
extrachromosomal telomeric DNA (d) ( Cesare A.J. and Reddel R.R. 2010). 
 
1.5 Telomere length regulation by the shelterin complex 
Telomere length is maintained in specific range in telomerase positive cell, indicating the 
existence of an equilibrium between telomere shortening and elongation. In addition to classic, 
direct regulators of telomerase or ALT, Shelterin impacts on telomere length regulation in cis.  
Shelterin allows a change in telomere conformation during the cell cycle causing a extendable 
and non-extendable states, as demonstrated in yeast (Blackburn E.H. 2001; Teixeira M.T. et al. 
2004; Hector R.E. et al. 2007; Bianchi A. et al. 2007; Sabourin M. et al. 2007). In vertebrates 
cells Shelterin is critical for the access of telomerase at chromosome ends (Fig. 1.11). In fact, 
more copies of shelterin components per cells are found compared to active telomerase 
(Cohen S.B. et al. 2007; Takai K.K. 2009). This led to the hypothesis that long telomeres 
containing high levels of Shelterin components represent an impediment for telomerase. On 
the contrary, short telomere are preferentially elongate by telomerase (Hemann M.T. et al. 
2001; Ouellette M.M. et al. 2000; Zhu L. et al. 1998). 
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Shelterin components have non-specific steric effects, like the role played by TRF1 and TRF2, or 
specific interactions with telomerase such as the interplay with TPP1. 
In particular, overexpression of TRF1 and TRF2 leads to telomere shortening, suggesting that 
both proteins are required for the length homeostasis of human and mouse telomeres (Munoz 
P. et al. 2005 and 2009). Thus, high expression of shelterin components induce a close 
conformation of telomere preventing the access of telomerase (van Steensel B. and de Lange T. 
1997; Smogorzewska A. et al. 2000).  
Consequently, TRF1 and TRF2 are negative regulators of telomere length in cis by affecting the 
ability of telomerase to extend individual chromosome ends.  
Moreover, POT1 knockout can lead to telomere elongation by limiting the access of telomerase 
to the 3’-overhang (Churikov D. et al. 2008; Lei M. et al. 2005; Veldman T. et al. 2004; Wu L. et 
al. 2006).  
Rap1, unlike TRF1, TRF2 and POT1 does not bind directly to telomeric DNA but is recruited to 
telomeres by TRF2 and plays a negative role in telomere length regulation in human cells. (Li B. 
and de Lange T. 2003; Arat N.O. and Griffith J.D. 2012).  
Shelterin located at telomere can directly interact with telomerase, demonstrated by a specific 
interaction between telomerase and the OB-fold motif of TPP1, that promotes to telomere 
length regulation (Abreu E. et al. 2010). In line with this, mutation of the OB-fold motif of TPP1 
disrupts telomere recruitment. 
 
 
 
Figure 1.11. Model of telomerase regulation by Shelterin complex (Palm w. and de Lange T. 2008) 
 
 
In line with the direct role of TRF1 and TRF2 in telomere length regulation, the proteins that 
control TRF1 and TRF2 turnover or function impact on telomere length.  
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TRF1 ubiquitination by SCF E3 ligase Fbx4 induce proteosomal degradation of TRF1 with 
consequent telomere elongation (Zeng Z. et al. 2010). Moreover, polyADP-ribosilation of TRF1 
by Tankyrase-1 (TNKS1) reduces the ability of TRF1 to bind to telomeric DNA causing loss of it at 
telomere with subsequent telomere elongation (Smith S. et al. 1998; Smith S. and de Lange T. 
2000). Finally the MRN complex (Mre11-RAD50-NBS1) recruits ATM to telomeres, triggering 
TRF1 phosphorylation leading to TRF1 dissociation from telomeres and telomere elongation 
(Wu Y. et al. 2007). 
Moreover, TRF2 was demonstrate to interact with and to be acetylated by p300 that increase 
the stability of TRF2 by the inhibition of its ubiquitin-dependent proteolysis. This mechanism is 
critical to  maintain functional telomeres (Her Y.R. and Chung I.K. 2013).    
 
1.6 The DNA damage response in mammalian cells 
During their lifespan, eukaryotic cells are exposed to intrinsic and extrinsic stress threating 
genome integrity by causing DNA damege. Cells developed a complicated system to overcome 
this problem. Upon DNA damage cells activate a DNA damage response (DDR) leading to cell 
cycle arrest and cell death. This response can be separated in three sections: sensors, 
transducers, and effectors  (Zhou B.B. and  Elledge S.J. 2000). In mammalian cells, the MRN 
complex composed by Mre11-Rad50-Nbs1 represents the main sensor for double-stranded 
breaks (DBSs) which recruits and activates ATM. Instead, the main sensors in ATR pathway that 
involve single or double-stranded breaks are: ATRIP, RPA, Rad17-Rfc2-5 clamp and Rad9-Rad1-
Hus1 (9-1-1). Then these sensors communicate with the transducers. 
There  are three important members of transducer that belong to phosphatidylinositol 3-
kinase-like-protein kinase family (PIKKs). The most upstream PIKKs kinase in DDR are ATM 
(Ataxia telangiectasia mutated), ATR (ATM and Rad3-related protein) and DNA-PKcs (DNA-
dependent protein kinase) (Lempiainen H. and Halazonetis T.D. 2009; Lovejoy C.A. and Cortez 
D. 2009). 
Specifically, the ATM protein was identified in the human genetic disporder ataxia-
telangiectasia where patients are hypersensitive to radiation and show a defective response to 
a specific DNA lesion (Metcalfe J.A. et al. 1996; Pandita T.K. 2002). In contrast to ATM, ATR is 
essential for the cells, its deletion leading to early embryonic lethality in mouse and cell 
lethality in human cells (Brown E.J. and Baltimore D. 2000, 2003; de Klein A. et al. 2000; Cortez 
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D. et al. 2001). ATM is mainly activated by double-stranded DNA breaks (DSBs), while ATR 
respond to a broad spectrum of DNA damage as DSBs or lesions that interfere with replication. 
The third PIKKs called DNA-PK is a DNA strand break (DSB) repair enzyme, composed of a 
catalytic subunit (DNA-PKcs) and a targeting subunit (Ku70-ku80 hetorimer) (Hartley K. et al. 
1995; Smith G.C. and Jackson S.P. 1999; Polo S.E. and Jackson S.P. 2011). The DNA-PK is mainly 
involved in DSBs repair events by nonhomologous end-joining (NHEJ), thus, cells and animals 
deficient in DNA-PK are defective in DSB repair (Smith G.C. and Jackson S.P. 1999; Polo S.E. and 
Jackson S.P. 2011). 
Finally, at the end of DNA damage response pathway there are the effectors that are substrates 
of tranducers (ATM, ATR, DNA-PK). Importantly, the effectors leads to the activation of a broad 
spectrum of cellular process such as DNA damage repair (HR and NHEJ), cell cycle arrest, 
apoptosis and senescence that are important for maintenance of genomic stability of 
organisms.  
 
1.6.1 Sensors and transducers of DNA damage response 
 
At the beginning of the DNA damage response, MRN complex recruits and activates ATM (Uziel 
T. et al. 2003; Lee J.H. and Paull T.T. 2005) (Fig. 1.12). This protein is activated not only by 
double-stranded DNA (dsDNA), but also by dsDNA ends with short single stranded DNA (ssDNA) 
that resembles, “uncapped telomeres” (Shiotani B. and Zou L. 2009; Celli G.B. and de Lange T. 
2005). After the activation of ATM the subsequent events are: the phosphorylation of the 
variant histone H2AX (γH2AX) by ATM (Meier A. et al. 2007; Savic V. et al. 2009), the 
amplification of γH2AX on DNA through interaction with Mdc1 and ATM (Stewart G.S. et al. 
2003; Lee M.S. et al. 2005; Stucki M. et al. 2005; Lou Z. et al. 2006), and the activation of 
effectors as Chk2, Brca1,p53, 53BP1 (Shiloh Y. 2003; Lavin M.F. 2008). These effectors play a 
critical role for cell cycle arrest and activation of DNA damage repair such as homologous 
recomnination (HR) or nonhomologous end-joining (NHEJ), maintaining the genomic stability of 
the cell. 
Unlike ATM, ATR has been shown to interact, through ATRIP, with RPA-coated ssDNA at the site 
of DNA damage and stressed replication forks (Zou L. and Elledge S.J. 2003) (Fig. 1.12). Single 
stranded DNA is generated by three different scenarios: replication stress, resection of DNA 
ends, uncoordinated DNA unwinding and synthesis at replication forks. During these events 
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ssDNA is coated by RPA that is recognized by ATR-ATRIP complex. RPA promotes also the 
loading of the Rad17-Rfc2-5 clamp and the recruitment of Rad9-Rad1-Hus1 (9-1-1) checkpoint 
clamps onto dsDNA (Ellison V. and Stillman B. 2003; Zou L. et al. 2003). In addition, ATR activity 
is stimulated by TOPBP1, an ATR phoshorylation target that can also activate ATR in the 
absence of DNA, and claspin, which is necessary for CHK1 phosforilation. Subsequently, these 
proteins play an important role in engage and stimulate the ATR-ATRIP complex on ssDNA 
(Cotta-Ramusino C. et al. 2011). In this way the full capacity of ATR is activated (Liu S. et al. 
2011). This multistep process ensures that ATR is only activated when both ssDNA and 
ssDNA/dsDNA junctions are present at sites of DNA damage and are recognized by DNA 
damage sensors. 
 
 
 
 
Figure 1.12. DNA damage response. The DDR is activated by DSBs and/or by the single-stranded DNA coated by 
RPA. DSBs are sensed by the MRE11–RAD50–NBS1 (MRN) complex that recruits the protein kinase ATM. ATM 
undergoes autophosphorylation and phosphorylates the histone H2A variant H2AX at the site of DNA damage. 
γH2AX is recognized by MDC1. MDC1 recruitment to γH2AX fuels the additional accumulation of MRN (to which 
MDC1 binds), which leads to amplified local ATM activity and the spreading of H2AX along the chromatin from the 
DSB. Exposure of modified histone residues further boosts the accumulation of the DNA-damage mediator 53BP1 
at the sites of DNA damage, in addition to the ability of 53BP1 to bind to MDC1 directly. Phosphorylation and 
activation of the protein kinase CHK2 by ATM is dependent on MDC1 and 53BP1. RPA-coated single-stranded DNA 
triggers the recruitment of the heterodimeric complex ATR /ATRIP. ATR activity is boosted by additional ATR 
targets, such as the RAD9–HUS1–RAD1 (9–1–1) and RAD17–RFC complexes. In addition, ATR activity is stimulated 
by TOPBP1 and claspin, which is necessary for CHK1 phosphorylation by ATM. Both CHK1 and CHK2 are responsible 
for DDR signalling in distant nuclear regions from the DNA-damage site. Finally, p53 and the CDC25 phosphatases 
are the bottom elements of the DDR signalling cascade that interface this pathway with the core of the cell-cycle 
progression machinery. DDR-mediated arrest can be transient, and if DNA damage is effectively removed cells 
resume normal proliferation. However, if DNA damage is particularly severe, cells may undergo apoptosis or enter 
a protracted DDR-induced cell-cycle arrest that is termed cellular senescence (D’adda di Fagagna F. 2008). 
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Recent studies demonstrate close cooperation between ATM and ATR. Experiments in yeast 
and human cells revealed that ssDNA was generated at DSBs by the action of nuclease. An 
important example of nuclease is represented by MRN complex, even if ATM is required for an 
efficient resection. In fact, it was observed that depletion/ inactivation of ATM or Mre11 led to 
diminished ATR responses to DSBs. These results suggested that ssDNA generated by DSBs 
required the action of both ATM and ATR. These in vitro experiments reveal that resection of 
DNA ends induce ATR activation, and progressively attenuates the ability of dsDNA to activate 
ATM (Shiotani B. and Zou L. 2009). All these data demonstrate that DSB resection not only 
promotes ATR activation, but also coordinates the functions of ATM and ATR at DSBs. 
Importantly, ATR was shown to phosphorylate H2AX in response to DNA replication stress. The  
histone  H2AX  phsophorilated in serine 139 is the principal marker of DNA damage and is able 
to recruit ATM onto the chromatin adjacent to stressed replication forks (Ward I.M. and Chen J. 
2001). In summary these studies confirm the closely relation between ATM and ATR. 
 
1.6.2 Effectors of DNA damage 
 
Activation of ATM and ATR leads to phosphorylation of the effectors in the DNA damage 
response pathway. The main downstream kinases of ATM and ATR are the cell cycle checkpoint 
kinases CHK2 and CHK1, respectively. These two kinases act to reduce cyclin-dependent kinase 
(CDK) activity by various mechanisms, some of which are mediated by activation of the p53 
transcription factor (Bartek J. and Lukas J. 2007; Riley T. et al. 2008; Kastan M. B. and Bartek J. 
2004). Finally, p53 and also the CDC25 phosphatases are the bottom elements of DNA damage 
response signaling cascade that interface these pathways with the core of the cell-cycle 
progression machinery.  
Two important examples of CDC25 activation by CHK1 and CHK2 are: the phosphorylation of 
CDC25A and CDC25C that have a role in driving the cells through the cell cycle (Bartek J. and 
Lucas J. 2003; Kastan M.B. and Bartek J. 2004; Thanasoula M. et al. 2012). These two 
phosphatase enzymes, CDC25A and CDC25C, remove crucial inhibitory phosphorylations on 
CDK/cyclin suche as CDC2/cyclin B, playing a critical role in cell cycle progression (Reinhardt 
H.C. and Yaffe M.B. 2009; Thanasoula M. et al. 2012). 
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Remarkably, the main tumor suppressor p53 acts also as transcriptional activator of a CDK 
inhibitor called p21, which binds the complex Cyclin E/CDK2 to establish cell cycle checkpoint 
arrest (Stein G.H. et al. 1999; Fang L. et al. 1999).  
p53 is a fundamental effector of the DNA damage response pathway that can transcriptionally 
activate or repress many target genes to initiate diverse cellular responses, including G1/S 
boundary cell-cycle arrest, cellular senescence, apoptotic cell death (Valente L.J. et al. 2013). 
 
 
1.6.3 DNA damage control at telomeres 
 
Shelterin complex plays an important role in blocking the activation of DNA damage signaling at 
chromosome ends. In fact, inhibition or depletion of shelterin components is linked to the 
activation of ATM/ATR and initiation of DNA damage response at telomeres (Fig. 1.13). DNA 
damage signaling at dysfunctional telomere can be visualized by immunofluorescence staining. 
In particular DNA damage proteins such as 53BP1, MDC1, or γH2AX are recruited to 
dysfunctional telomeres, forming so called “TIFs” (Telomere damage induced foci) (Takai H. et 
al. 2003; d’Adda di Fagagna F. et al. 2003; Dimitrova N. de Lange T. 2006) (Fig. 1.13 left panel).  
Firstly, shelterin allows t-loop formation that prevents telomeres from being recognized as 
double-stranded breaks by DNA damage signalling (Griffith J.D. et al. 1999); however, loss of 
function mouse models systems have shown the specific contribution of the different shelterin 
components in eliciting DNA damage response at telomere. 
Amongst shelterin components, TRF2 is crucial to suppress the ATM-dependent DNA damage 
response (DDR) pathway (Lazzerini Denchi E. and de Lange T. 2007; van Steensel B. et al. 1998). 
In fact, deletion of TRF2 in mouse cells or its inhibition with dominant negative allele in human 
cells, results in a DDR mediated by ATM (Celli G.B. and de Lange T. 2005; Karlseder J. et al. 
1999) (Fig. 1.13 right panel). Recent data support a two-step mechanism for TRF2-mediated 
end protection (Okamoto K. et al. 2013). The initial step requires the dimerization domain of 
TRF2 that inhibits ATM activation. Next, TRF2 independently modulates the propagation of DNA 
damage signaling downstream of ATM activation, inhibiting the E3 ubiquitin ligase RNF168 at 
telomeres and consequently, preventing 53BP1 localization and chromosome fusions (Okamoto 
K. et al. 2013). 
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Figure 1.13. DNA damage response at telomere. Representative images of TIFs in TRF1-deleted mouse embryonic 
fibroblasts. Co-localizzation of 53BP1 and telomeric probe at telomere indicate an activation of DNA damage 
response (left panel) (Martinez P. et al. 2009). Representative model of telomere damage response regulated by 
Shelterin complex. TRF2 deletion induces the activation of ATM pathway due to the unprotected dsDNA at 
chromosome end; in contrast POT1 deletion leads to RPA recruitment at 3’-overhang triggering the activation of 
ATR pathway (Palm W. and de Lange L. 2008).  
 
 
 
On the other hand, to prevent ATR activation, telomeres deploy the single-stranded DNA 
binding activity of POT1 (Fig. 1.13 right panel). Specifically, TPP1/POT1a blocks the binding of 
RPA to telomeres, suggesting that ATR is repressed through RPA exclusion (Takai K.K. et al. 
2011). To allow effective exclusion of RPA and repression of ATR signaling, TIN2 is necessary to 
stabilize TPP1/POT1a on the single stranded telomeric DNA. In line with this, Pot1a knockout 
mouse cells show increase of TIFs at telomeres (Palm W. et al. 2009 ). 
Importantly, the conditional TRF1-deleted mouse embryonic fibroblasts (MEFs) also results in 
the activation of DNA damage response showed by abundant telomere γH2AX foci and 
ATM/ATR activation at chromosome ends (Martìnez P. et al. 2009; Sfeir A. et al. 2009). 
Interestingly, recent reports introduced a role of TRF1 in mediating replication stress-induced 
ATR signaling by a mechanism that involves TIN2-dependent recruitment of the TPP1/POT1 
heterodimers to exclude RPA from the lagging strand template (Zimmermann M. et al. 2014).  
Together these data highlight the role of TIFs as the hallmark of DNA damage events at 
chromosome ends and demonstrate that deregulation of even one shelterin components leads 
to the activation of DNA damage response. 
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1.7 Telomeric DNA damage repair 
Telomeric DNA damage signaling leads to a cell cycle arrest to start DNA damage rapair, thus 
avoiding senescence or apoptosis. Two main mechanism act at dysfunctional telomeres: the 
nonhomologous end-joining (NHEJ) and the homologous recombination (HR). NHEJ is the 
predominant repair mechanism in mammalian cells which acts quickly sealing the breaks with 
consequent formation of a microdelitions. In contrast HR is a complex high-fidelity repair 
mechanism based on homologous recombination between sister chromatids that can lead to 
aberrant telomere length and recombination (Shiloh Y. 2003). 
 
1.7.1 Non homologous end joining (NHEJ) at dysfunctional telomeres  
NHEJ at dysfunctional telomeres lead to a covalent chromosome ends fusion between the C-
strand of one telomere and the G-strand of another telomere (Smogorzewska A. et al. 2002). It 
has been observed that fusion on damaged telomeres  occur when telomeres are critically short 
or when TRF2 is inhibited (Smogorzewska A et al. 2002; Celli G.B. and de Lange T. 2005) (Fig. 
1.14). Unprotected telomeres are recognized by Ku70-Ku80 heterodimer that serves as a scaffold 
for the assembly of the other NHEJ factors including DNA-dependent proteins kinase (DNA-PKcs) 
and XRCC4/DNA ligase IV which in turn recruits other proteins such as Mre11, PARP1, PARP3, 
BRCA1, XRCC4 (Beck C. et al. 2014). First, the endonuclease ERCC1/XPF remove the 3’overhang 
and then XRCC4-Ligase IV seal the break promoting the fusion between two chromosome ends. 
The DNA ligase IV or Ku70 have a key role in NHEJ, as demonstrated by reduced telomere 
fusions in the absence of Ku70 or XRCC4 (Corneo B. et al. 2007; Yan C.T. et al 2007) (Fig.1.14).   
TRF2 has a key role in suppressing NHEJ. However also POT1 and TPP1 have a significant role in 
suppressing NHEJ. This was demonstrated in knockdown experiments for human POT1 or in 
POT1 knockout mouse cells that result in chromosome end-to-end fusions. Remarkably,  the 
phenotype is aggravated in the context of TRF2 depletion (Hockemeyer D. et al. 2005, 2006; 
Veldman T. et al. 2004). In addition, telomere fusions have been observed in cells depleted of 
TPP1, presumably due to its role in POT1 recruitment and TRF2 stabilization at telomeres 
(Hockemeyer D. et al. 2007; O’Connor M.S. et al. 2006). This data indicates that shelterin 
protects chromosome ends from NHEJ by the maintenance of t-loop structure. The models 
proposed are two: in the first model the t-loop can block the loading of Ku70/80  at telomere 
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(Celli G.B. et al. 2006) while in the second model the binding of TRF2-Rap1 can block the access 
of NHEJ machinery at chromosome ends (Bae N.S. and Baumann P. 2007).  
 
 
 
Figure 1.14. DNA damage repair NHEJ at dysfunctional telomere. Schematic representation of NHEJ pathway at 
telomere. Loss of TRF2 is a main Shelterin components involved in NHEJ activation (Palm W. and de Lange T. 2008). 
 
 
1.7.2 Homologous recombination mechanism at telomere 
Dysfunction of Shelterin components was demonstrated to induce DNA damage activation and 
subsequent DNA damage repair. In fact was demonstrated that ku70/80-deficient mouse cells 
lacking either Rap1 or both Pot1a and Pot1b activate a HR mechanism. Consequently, the 
combination of Rap1 and POT1 is important to repress HR (Sfeir A. et al. 2010). 
Different DDR proteins such as RAD51 family, BRCA1 and BRCA2 are critically involved in HR. 
Specifically RAD51 recombinase with its paralogs (RAD51B, RAD51C, RAD51D, XRCC2, and 
XRCC3) assembles nucleoprotein filaments at break sites to initiate the search for a 
homologous recombination target sequence (Badie S. et al. 2010). In addition, RAD51 and 
XRCC3 are involved in branch migration and Holliday junction resolution activities (Liu Y. et al. 
2004, 2007).  
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It was demonstrated that assembly of RAD51 at DNA breaks depends on BRCA2 while RAD51C 
have an early function in DDR leading to CHK2 activation (Badie S. et al. 2009; 2010).  
HR posses high-fidelity repair activity and can be subdivided into 3 subtypes of HR at telomere: 
i) “t-loop HR”, ii) “T-SCEs”, iii) “Recombination with interstitial sites” (Fig. 1.15). 
 
 
 
 
Figure 1.15. Homologous recombination repair at dysfunctional telomeres. a) Excision of the telomeric loop 
through t-loop HR. b) recombination between sister telomeres. c) recombination between a telomere and 
chromosome internal telomere-related sequences (Palm W. and de Lange T. 2008). 
 
 
1.7.2.1 T-loop homologous recombination  
The “t-loop HR” has been observed using  a TRF2 allele lacking the N-terminal GAR domain 
(Wang R.C. et al. 2004). The cells with this construct showed telomere deletion and 
accumulation of circular telomeric DNA due to the formation of a Holliday junction (HJ) at the 
strand invasion point of the t-loop. This mechanism is dependent on XRCC3 and WRN, the first 
protein own a resolvase activity while the helicase WRN is responsible for branch migration in 
“t-loop HR” (Liu Y. et al. 2004; Li B. et al. 2008; Nora G.J. et al. 2010). This demonstrate that 
Shelterin components and in particular the GAR domain of TRF2 is important to repress HR 
event at telomeres (Fig. 1.15 a). 
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1.7.2.2 Telomere sister chromatid exchange mechanism 
In the second type of HR,“ Telomere Sister Chromatid Exchange”, telomeres located at sister 
chromatids can initiate recombination events (Fig. 1.15 b). 
This event constitute a threat to telomere function because unequal exchanges can lead to 
elongate one sister telomere at the expense of another.  
Interestingly, ALT cells display high presence of telomeric circles and elevate levels of T-SCEs 
suggesting that these cells lost repression of HR (Londono-Vallejo J.A. et al. 2004; Cesare A.J. 
and Griffith J.D. 2004; Wang R.C. et al 2004; Sapir E. et al 2011). 
T-SCEs phenotype has been observed in cells lacking both TRF2 and Ku70, but the lack of TRF2 
or Ku70 alone was not sufficient to induce T-SCEs (Celli G.B. et al. 2006). In addition to TRF2-
Ku70, the helicase WRN or RTEL1 can repress T-SCEs. In fact, mouse cells showed short 
telomere and high levels of T-SCEs in the absence of WRN and telomerase. In addition RTEL1 
deficient mouse cells also showed high levels of T-SCEs (Laud P.R. et al. 2005; Sarek G. et al. 
2015). RAP1 loss affects also telomere function. it has been demonstrated an increase of T-SCE 
in mouse cells lacking a functional Rap1 gene or with a TRF2 mutant incapable of binding RAP1. 
This data demonstrated that RAP1 functions as repressor of HR at telomeres (Sfeir A. et al. 
2010; Martinez P. et al. 2010).  
In this type of HR mechanism, TRF2 together with other proteins ensure the repression of this 
DNA damage repair at telomere. 
 
1.7.2.3 Homologous recombination with interstitial sites 
Finally, “Recombination with interstitial sites” leads to terminal deletions of all sequence distal 
to the interstitial TTAGGG repeat array producing an extrachromosomal element called Double-
Minute chromosomes (TDMs) (Fig. 1.15 c). This includes telomeric sequences and the 
intrachromosomal telomeric repeats, the sizes expected are variable due to the location of the 
interstitial sequences (Zhu X.D. et al. 2003; Laud P.R. et al. 2005). These TDMs have been 
observed in immortalized mouse embryo fibroblast lacking of the subunit ERCC1, an 
endonuclease (ERCC1/XRF) recruited to telomere by TRF2 (Zhu X.D. et al. 2003). However this 
mechanism is not frequent due to the low content of chromosome internal telomeric DNA 
repeats. The last contribution of TDMs formation is that of WRN in presence of short telomere 
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or in immortalized mouse cells deleted of POT1a and POT1b (Laud P.R. et al. 2005; He H. et al. 
2006, Wu L. et al. 2006).  
 
1.8 Replication stress and genomic instability    
In eukaryotes, DNA replication originates at thousands of individual replication origins of DNA. 
(Woodward A.M. et al. 2006; Ge X.Q. et al. 2007; McIntosh D. and Blow J.J. 2012 ).  
DNA replication represents a major biochemical reaction and physical barriers originating from 
template of DNA synthesis, such as DNA nicks, gaps and stretches of ssDNA can cause the 
slowing or stalling of replication fork progression and/or DNA synthesis. Important external 
mediators of replication stress are: products of cellular metabolism, ultraviolet light, or 
chemical mutagens such as cisplatinum or mitomicyn C which can cause DNA inter-strand 
crosslinks or DNA secondary structures (Kim H. and D’Andrea  A.D. 2012) (Fig. 1.16).  
DNA secondary structures mainly found in repeat rich regions of the genome represent an 
important barrier to DNA replication. 
These structures lead to contraction or expansion of repeat sequences in the DNA leading to 
structural alteration that can induce replication stress (McMurray C.T. 2010; Kim J.C. and Mirkin 
S.M. 2013). An example of secondary structures formed in GC-rich DNA are referred to as G-
quadruplex (G4) structures. Chemical stabilization or loss of helicases that unwind structural 
DNA elements, cause slowed DNA replication speed and an increase of DSBs (Paeschke K. et. al. 
2013; Bochman M. et al. 2012).  
In fact, mutations in human DNA helicases such as RecQ, WRN, BLM, FANCJ can unwind G4 
structures in vitro (Helmrich A. et al. 2013; Bermejo R. et al. 2012; Barlow J. et al. 2013; 
Bermejo R. et al. 2011; Huertas P. and Aguilera A.) and are associated with human diseases that 
cause genomic instability such as fanconia anemia and breast cancer (Wu Y. et al. 2008). 
In addition to G4 structures, two other important structures can be considered as source of 
replication stress, the “early replicating fragile sites” and the  “common fragile site” which are 
detailed in the paragraph 1.8.1.  
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Figure 1.16. Schematic representation of replication stress. A) In the presence of inhibitors of replicative DNA 
polymerases or DNA distorting lesions (red stars) cause the stalling of polymerase while the helicase continues to 
unwind DNA; this produces an excess of unreplicated ssDNA that induce the activation of DNA damage response. 
B) Other DNA lesions, such as interstrand crosslinks produced by mitomycin C, block the progression of the 
helicase and stall DNA polymerases without the production of ssDNA. This can resemble DSBs inducing a DNA 
damage response. Polymerases (yellow circles), helicase (in green), fork protection complex (in blue) (Recolin B. et 
al. 2014). 
 
 
Replication stress can be chemically induced by treating cells with hydrohyurea (HU) or with 
aphidicolin. 
The first compound depletes the cellular pool of deoxyribonucleotides by the inhibition of 
ribonucleotide reductase, while aphidicolin is a DNA polymerase activity inhibitor. In particular 
aphidicolin, inhibits the DNA polymerases but not the helicases resulting in an excess of ssDNA 
causing the so called “replication fork uncoupling” (Fig.1.16 A)(Walter J. et al. 2000; Byun T.S et 
al. 2005). In contrast, other types of DNA damage such as interstrand cross-links (mytomicin C) 
physically block the progression of helicases and consequently the activity of the DNA 
polymerase without production of ssDNA. The consequent stalled replication fork resembles a 
DSB and is targeted of resection by nucleases activity (MRN complex) that generate ssDNA (Fig. 
1.16 B) (Lambert S. and Carr A.M. 2005). In both cases, DNA polymerase or helicase block or the 
generated ssDNA trigger ATR signaling activation (Gobbini E. et al. 2013; D’Amours D. and 
Jackson S.P. 2002). The model proposed is that the ATR/ATRIP complex interacts directly with 
RPA that is bound on ssDNA damage (Costanzo V. et al. 2003; Zou L. et al. 2003; Ball H.L. et al. 
2005; Cortez D. et al. 2001). In line with this, RPA depletion by RNA interference showed a 
reduced formation of DNA damage foci highlighting the importance of RPA in ssDNA damage 
response (Zou L. et al. 2003; Dart D.A. et al. 2004). In fact, heterozygous RPA mutant mouse 
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embryonic fibroblast showed defects in DSB repair and chromosomal instability (Wang Y. et al. 
2005). 
 
Together this highlights the important role of replication stress sources in inducing replication 
stalled forks and consequent activation of ATR. Remarkably, genomic fragile sites represent the 
major source of replication stress that lead to chromosomal breaks and consequently to 
genomic instability and cancer formation (See 1.8.1).  
 
1.8.1 Causes of replication stress and chromosome fragility 
Recent studies revealed that genomic regions that are prone to fragility during replication 
stress, or oncogenic stress condition, are characterized by specific features. Two different types 
of sequences were demonstrated to be prone to replication stress: Common fragile sites (CFSs) 
and “early replication fragile sites” (ERFSs) that show different characteristics (Fig. 1.17).   
Chromosome fragile sites were first observed in methaphase from cells subjected to replication 
stress conditions and result gaps and breaks. The corresponding genomic loci were named 
“common fragile sites”, large genomic regions spanning hundreds to thousands of kilobases. 
Common fragile sites have common features but appear at different chromosome localization 
according to the cell or tissue type (Debatisse M. et al. 2011).  
The main feature of CFSs is a high context in AT-rich sequences that show high flexibility and 
are prone to fold into secondary structures. These structures can create a barrier to replication 
fork progression leading to fork stalling and breaks in these sites. Moreover, Common fragile 
sites are sequences that initiate replication late in S phase or are slow in replication (Drusco A. 
et al. 2011). 
CFS can be achieved using low concentration of aphidicolin that causes a stalled DNA 
replication converting CFSs into hotspots for sister chromatid exchange (Cheng C.H. and Kuchta 
R.D. 1993; Ikegami S. et al 1978; Arlt M.F. et al. 2006). At current about 120 CFSs are listed in 
the genome database, but the exact number varies greatly among individuals. 
Consistent with the formation of secondary structures of CFS, DNA helicases such as WRN and 
BLM antagonize fragility by opening secondary structure at CFS (Pichierri P. et al. 2011). 
A recent study identified the second group of fragile sites referred to as ERFSs. These regions 
undergoes to fork collapse under replication stress and have been localized in proximity of early 
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firing origins of replication. Nussenzweig and co-workers observed that ERFSs are G-C rich, 
accumulate in repetitive elements such as LINEs and SINEs and are associate with highly 
transcriptional active genes (Barlow J.H. et al. 2013). Consequently, ERFSs and CFSs show 
different features however have the activation of ATR and the presence of homologous 
recombination proteins (ex. BRCA1, SMC5, RAD51) as common feature. Importantly, CFS and 
ERFS are involved in genomic instability during tumorigenesis (Franchitto A. and Pichierri P. 
2011). 
 
 
 
Figure 1.17. Summary of principal characteristics of CFSs and ERFs. Oncogene-induced replication stress causes 
replication fork stalling and collapse at both CFS and ERFS while ATR kinase and homologous recombination 
prevent collapse and mediate fork restart and repair. The main characteristics  of CFS and ERFS are shown 
(Mortusewicz O. et al. 2013) 
 
1.8.2 Genomic instability and telomere fragility 
Several studies have linked telomere with chromosome fragility. 
Similar to CFSs, telomeres are late replicating regions, prone to form secondary structure and 
condensed chromatin structure, on the other hand telomere repeats have high G/C content 
similar ERFSs. 
Telomeres can fold up to form a G-quadruplex structure that represents an obstacle to DNA 
replication leading to fragility and telomere sister chromatid exchange. 
The regulators identified to be involved in telomere fragility include shelterin components 
(TRF1, Rap1, TTP1), DNA damage response or repair proteins (ATR, BRCA2, RAD51, Nth1, SLX4), 
helicases (RECQL4,RTEL1, BLM), CST complex (STN1) and the zinc finger protein (ZNF365) 
(McNee C.J et al. 2010; Barefield C. et al. 2012; Badie S. et al. 2010; Vallabhaneni H. et al. 2013; 
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Martinez P. et al. 2010; Ghosh A.K. et al. 2012; Deng Z. et al. 2013; Vannier J.B. et al. 2013; 
Wilson J.S. et al. 2013; Huang C. et al. 2012; Tejera A.M. et al. 2010). 
Specifically, it was demonstrated that Conditional Brca2 deletion and Rad51 inhibition in mouse 
embryonic fibroblasts (MEFs), led to telomere shortening and increased telomere fragility 
associated with replication defects. This highlights the important role of HR proteins involved in 
the restart and repair of stalled or broken replication forks ensuring telomere length 
maintenance by facilitating telomere replication (McNees C.J. et al. 2010; Badie S. et al. 2010). 
In addition, helicases RECQL4, RTEL1, BLM  were shown to be implicated in the resolution of 
telomeric secondary structures, as demonstrated by telomere defects during telomere 
replication in loss of function experiments (Zirmmerman M. et al. 2014; Ghosh A.K. et al. 2012; 
Vannier J.B. et al. 2013; Deng Z. et al. 2013) .   
Recently, the zinc finger protein ZNF365 has been associated with an increase of telomere 
dysfunction and cancer risk. ZNF365 locus, regulated by p53, was shown to suppress the 
expression of a subset of common fragile sites including telomeres (Zhang Y. et al. 2013). 
Importantly, the shelterin components TRF1, TRF2, and Rap1  have a central role in suppression 
of telomere fragility.  
Specifically, Rap1-deleted mouse model showed increased frequencies of chromosome ends 
with multitelomeric signals demonstrating a fragile-telomere phenotype (Martinez P. et al. 
2010). 
Knockout of TRF1 impairs efficient replication of telomere and drives fork stalling leading to a 
strong increase of a fragile telomere phenotype. Moreover, It was demonstrated that TRF1 and 
TRF2 interacting with BLM and RTEL1 helicases respectively, repress fragile-telomere 
phenotype (Sfeir A. et al. 2009; Vannier J.B. et al. 2012; Zimmermann M. et al. 2014). This 
indicates that TRF1 and TRF2 collaborating with BLM and RTEL1 suppress fragility at telomeres. 
In particular, TRF1 conditionally deleted mice showed induction of γ-H2AX foci at telomere and 
DNA damage activation (ATM/ATR). Importantly, abrogation of p53 and RB pathways led to 
telomere fragility and chromosomal instability including sister chromatid fusions. In these mice, 
dysfunction of TRF1 is sufficient to induce telomere instability and tumorigenesis (Martinez P. 
et al. 2009). 
The role of TRF1 in suppressing fragility was also demonstrated at chromosome internal site 
that contains two stretches of TTAGGG repeats in telomerase-immortalized human BJ 
fibroblasts (Bosco N. and de Lange T. 2012). All together, these data demonstrate that shelterin 
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components, DNA damage response or repair proteins and helicases have a central role in 
preventing telomere fragility to maintain genomic stability and suppress cancer formation. 
 
1.9 microRNA and gene regulation 
 
1.9.1 Biogenesis of miRNAs 
microRNAs (miRNAs) are 20-23 nucleotides RNA molecules that act as powerful regulators of 
gene expression. miRNAs are evolutionarily conserved and  have been indentified in plants, 
animals and viruses. miRNAs derive from the metabolic processing of long RNA transcripts 
encoded by miRNA genes and are involved in controlling gene expression in processes such as 
proliferation, apoptosis, differentiation and metabolism (Bartel D.P. 2004). 
The biogenesis of miRNAs is a multi-step process that starts in the nucleus and translocates to 
the cytoplasm. microRNAs are transcribed by RNA polymerase II from independent genes or 
introns of protein-coding genes giving rise to so called a pri-miRNAs (Fig. 1.18) (Lee Y. et al. 
2004). This transcript fold into hairpin that acts as substrate for the RNase III, Drosha. This 
enzyme is a highly conserved protein that forms a large  complex referred to as the 
Microprocessor. Drosha cleave the single-strands of pri-miRNAs producing a ~70 nucleotide 
small RNA called pre-miRNA (Lee Y. et al. 2004).  
The pre-miRNA is exported to the cytoplasm by an Exportin 5-mediated mechanism (Yi R. et al. 
2003). Subsequentily another RNAse III, Dicer, processes the pre-miRNAs to an ~20-bp 
miRNA/miRNA* duplex. Only one strand, considered as the mature miRNA, is incorporated into 
the miRNA-induced silencing complex (RISC). This complex contains Argonaute proteins, 
GW182 and others and mediate miRNAs base pairing to the target mRNA, inducing 
translational repression or deadenylation and degradation. 
For a long time, the complementary strand of mature miRNA, indicated as miRNA*, was 
considered without a relevant function, instead recent studies demonstrated that miRNA* 
plays also a biological role as the guide strand (miRNA) (Bhayani M.K. et al 2012).  
The mature miRNAs prevalently binds the 3’-untranslated region (UTRs) of target mRNA using 
its seed region formed by 6-8, even if the binding is not perfect and contains mismatches. 
Various computer software can be used to predict miRNAs able to target the 3’-UTR  of specific 
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mRNAs. Recent studies have demonstrated that also the 5’-UTR or the coding region can be 
target of mature miRNAs (Lytle J.R. et al. 2007, Moretti F. et al. 2010, Qin W. et al. 2010). 
 
 
Figure 1.18. Schematic model of microRNA biogenesis. RNA polymerase II (Pol II) produces the pri-miRNA, then a 
multi-protein complex that includes DROSHA cuts the tails of pri-miRNA producing the pre-miRNA. This double-
stranded hairpin structure is exported from the nucleus by RAN GTPase and exportin 5 (XPO5). Finally, the pre-
miRNA is cleaved by DICER1 to produce two miRNA strands. One of the two strands, the mature miRNA sequence, 
is incorporated into RISC complex which then targets the specific 3′ untranslated region mRNA sequence inducing 
translation repression or mRNA cleavage (Ryan B.M. et al. 2010). 
 
 
1.9.2 miRNAs in human diseases 
miRNAs have been demonstrated to play a central role in controlling a wide range of processes 
such as cell metabolism, development, cell proliferation or apoptosis (Mattick J.S. and Makunin 
I.V. 2005; Berezikov E. and Plasterk R.H. 2005; Bartel B. 2005; Zamore P.D. and Haley B. 2005; 
Croce C.M. and Calin G.A. 2005; Sayed D. and Abdellatif M. 2011). Lack or excess of miRNAs has 
been observed to be link to a number of important disease ranging from myocardial infarction 
to autoimmune disease, including cancer (Li Y. et al. 2012; Sayed D. and Abdellatif M. 2011; van 
Rooij E. and Eric N. Olson E.N. 2012). 
Consequently, miRNA have a central role in pathologies of diverse origins including cancer. In 
the past years major advancements were achieved in understanding the role of miRNAs in 
human cancer. 
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Interestingly, it has been found that more than 50% of miR genes are located at fragile sites or 
at chromosomal regions showing amplification, deletion or translocation in cancer (Calin G.A. et 
al. 2004) and deregulated miRNA expression has been associated with many tumor types (Lu J. 
et al. 2005; Volinia S. et al. 2006). 
The first example of miRNAs involved in tumor formation and progression was characterized by 
studies on miR-15a and miR-16. These two miRNAs are located on a chromosome region that is 
frequently deleted in Chronic Lymphocytic Leukemia (CLL) determining down-regulation of both 
miRNAs (Calin G.A. et al. 2002). 
In general, miRNAs are downregulated in the context of cancer, however a limited number of 
miRNAs, such as miR-155 or miR-21 appear upregulated in cancer and act as tumor promoting 
oncomiRs. In fact, overexpression of miR-155 or miR-21 in mice caused a B cell malignancy 
(Costinean S. et al. 2006; Hatley M. E. et al. 2010; Medina P. P. et al. 2010).  
 
1.9.3 miRNAs deregulation in cancer 
microRNAs appear altered in many human diseases especially in cancer and have an important 
contribution to pathology.  
The deregulation of miRNAs expression occur at different levels: the gene level, transcriptional 
and post transcriptional gene regulation or miRNA biogenesis. 
The first type of alterations is represented by miRNAs located in regions involved in 
chromosomal aberrations (Calin G.A. et al. 2002; Tagawa H. and Seto M. 2005; Zhang L. et al. 
2006). Alterations such as deletions, amplifications or mutations can lead to altered miRNA 
expression. The main example of deletion is demonstrated by miR-15a and miR-16-1 in B-cell 
chronic lymphocytic leukemia (CLL) (Raveche E.S et al. 2007).  
Dysfunction of the components involved on the maturation of miRNA leads to the modulation 
of miRNAs levels or miRNA composition in the RISC complex. Altered Drosha or Dicer represent 
examples of altereted miRNA biogenesis in human cancer (Merritt W.M. et al. 2008; Nakamura 
T. et al. 2007; Thomson J.M. et al, 2006). Another important mechanism by which miRNAs 
expression can be deregulated is through tumor suppressors or oncoproteins.  
Importantly, the tumor suppressor p53 can alter miRNA expression as observed for miR-34 
family that promotes apoptosis in colon cancer cell line (Chang T.C. et al. 2007; He L. et al. 
2007). On the contrary, the oncoprotein MYC has been demonstrated to induce expression of 
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the oncogenic miR-17-92 cluster and negatively regulates the transcription of tumor suppressor 
miRNAs, such as let-7 and miR-29 family members (Chang T.C. et al. 2009; Mott J.L. et al. 2010).  
Finally, epigenetic alterations such as modulation of DNA methylation or histone acetylation 
lead to  deregulation of miRNA expression.  
From all the miRNAs gene known, the 50% is located in vicinity to CpG island, suggesting that 
DNA methylation plays a major role in controlling miRNA expression (Weber B. et al. 2007). In 
fact, treating T24 bladder cancer cells or human fibroblasts with the DNA methyltransferase 
inhibitor 5’-aza-2'-deoxycytidine (DNMT) and the histone deacetylase (HDAC) inhibitor 4-
phenylbutyric acid (PBA), caused a strong upregulation of several miRNAs. In particular, miR-
127 showed a strong upregulation and the corresponding gene was found to be embedded in a 
CpG island (Saito Y. et al. 2006). 
Hypometylation has been shown to lead an upregulation of oncogenic miRNAs as let7a-3 in 
lung adenocarcinoma (Brueckner B et al. 2007) or miR-21 in epithelial ovarian cancer (Iorio 
M.V. et al. 2007). On the contrary, hypermetylation has been linked to down regulation of miR-
9-1 in breast cancer (Lehmann U. et al. 2008).  
Along with DNA methylation, the acetylation of histones critically impact on miRNA expression. 
Scott and coworkers showed that inhibition of the histone deacetylase (LAQ824) in SKBR3 
breast carcinoma cells causes a strong alteration of miRNA expression (Scott G.K. et al. 2006). 
To date several drugs are aviable to inhibit HDACs, such as TSA or SAHA, that can be used to 
modulate the miRNAs expression in cancer cell. The efficiency of SAHA was shown by the use of 
this drug in cutaneous T-cell lymphoma. Specifically, SAHA caused the selective induction of 
malignant T-cell apoptosis and modulation of acetylated histones, p21waf1, Bax, Stat6 and 
caspase 3 (Marks P.A. and Breslow R. 2007). Moreover, miRNA expression profiles in lung 
cancer cells using a miRNA microarray, has shown that SAHA treatment was also responsible of 
miRNA alteration (Lee E.M. et al. 2009).   
1.9.4 Application of miRNAs in cancer: diagnosis, prognosis and therapy 
Many clinical cancer studies focus their attention on miRNA as biomarker, because the small 
size of miRNAs confers higher stability compared to long mRNA; especially in fixed tissued or 
other biological material such as blood (Mitchell P.S. et al. 2008; Schwarzenbach H. et al. 2011), 
circulating exosomes (Taylor D. D. and Gercel-Taylor C. 2008), urine (Hanke M. et al. 2010), and 
saliva (Michael A. et al. 2010; Park N.J. et al. 2009). Moreover, the microRNAs expression 
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profiles allow to discriminate different types of cancer with higher accurancy then mRNA 
profiles (Lu J. et al 2005; Volinia S. et al. 2006).  
Importantly, miRNA can be used as prognostic markers to predict cancer outcome. 
Overexpression of miR-155 and downregulation of let-7a can predict a poor disease outcome in 
CLL and lung cancer (Yanaihara N. et al 2006). 
miRNAs in cancer have been used also to discriminate the different cancer subtype. For 
example, expression of miR-200 family of miRNAs allows to distinguish between basal and 
luminal breast cancer subtype.  
A very interesting application for miRNAs in a disease in a relevant setting represents the 
potential to predict the physiological changes that lead to cancer formation. 
Overexpression of miR-205 and miR-21 in ductal adenocarcinoma were demonstrated to 
precede phenotypic changes in the ducts, thus these two miRNAs are considered an early 
marker of this neoplastic disease (du Rieu M.C et al. 2010). In addition, a study on plasma 
sample of lung cancer patients collected 1-2 years before the onset of disease, has identify a 
miRNAs signature with predictive and prognostic potential (Boeri M. et al. 2011).  
Currently, large efforts are invested in developing strategies that allow the alteration of miRNA 
expression in human cancer. The approaches used are diverse, ranging from viruses to 
synthetic molecules (Almeida M.I. et al.  2011) .  
The stability and delivery of these molecules is the major hurdle for their use in therapy.In fact, 
major problems such as elimination of introduced synthetic miRNAs by the kidney or 
degradation by immune system need to be overcome. An example how to deliver miRNA 
represents the use of LPH (liposome-polycation-hyaluronic acid) to transport miR-34a to lung 
metastasis of murine melanoma cells (Chen F. et al. 2010). Alternatively, intranasal 
administration of an adenovirus expressing let-7a hairpin reduced tumor formation in lung 
cancer mouse model (Esquela-Kerscher A. et al. 2008). To avoid the loss of miRNAs, through 
filtration by the kidney, chemically modified anti-miR oligonucleotides (AMOs) have been 
developed (Weiler J. et al. 2006). 
An example for the high potential of miRNAs in therapy represents miR-122 LNA molecules 
targeting miR-122 in HCV infections have reached clinical trials (Gebert L.F.R. et al. 2014). 
Together this demonstrates that treating cancer through the use of synthetic miRNAs is getting 
closer. 
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Aim of the project 
 
The expression of telomerase and shelterin has been reported to be tightly regulated at 
transcriptional and post-transcriptional level. Alterations in the expression of shelterin 
components or telomerase cause telomere dysfunction and have been linked to cancer and 
aging. miRNAs have been demonstrated to control a wide range of biological process and have 
an important contribution to the pathology of human cancer. However, miRNAs that impact on 
telomere  homeostasis have not yet been described. 
The aim of my PhD thesis project is to identify miRNAs that control the expression of shelterin 
and telomerase complex components thereby impacting on telomere function during cancer 
formation and progression. 
Our work is expected to introduce “telo-miRNAs” as new level of telomere regulation that is 
expected to impact on telomere related maladies such as cancer and aging. 
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2. Materials and Methods 
 
2.1 Cell lines and culture 
Cell lines used were obtained from ATCC and have not been cultured for longer than 6 months. 
In this project MCF-7 (Michigan Cancer Foundation-7, breast adenocarcinoma), SK-BR-3 (breast 
adenocarcinoma derived), T-47D (ductal carcinoma), and HCT-116 (colorectal carcinoma) cells 
were cultured in RPMI-1640, with the addition of 10% heat-inactivated FBS (Gibco). Instead, 
MDA-MB-231 (breast adenocarcinoma), MDA-MB-468 (breast adenocarcinoma), MDA-MB-157 
(medulallary carcinoma), HeLa (cervix adenocarcinoma), U-2 OS (osteosarcoma), and H1299 
(carcinoma; non–small cell lung cancer) cells were cultured in DMEM with the addition of 10% 
heat-inactivated FBS.  
Stable cell lines MCF-7 and SK-BR-3 overexpressing miR-155 were selected with blasticidin 
(5mg/mL). Instead, MDA-MB-231 infected with retroviral vectors overexpressing miR-296 and 
miR-512 were selected with blasticidin (8mg/mL) while MDA-MB-231 infected with retroviral 
vectors shControl and shTERT were selected with puromycin (2ug/mL). MDA-MB-231 infected 
with pBabe empty were selected with puromycin (2ug/mL) while pBabe-TERT were selecelted 
with hygromicin (100ug/mL) 
SK-BR-3 was treated with Aphidicolin (Sigma) for 20 hours at a concentration of  0.4 mmol/L; 
while the proteasome inhibitor MG-132 (Millipore) was used for 8 hours at a concentration of 
12.5 mmol/L. 
Instead, MDA-MB-231 was treated with 5’-Aza-2’-deoxycytidine (Sigma) at a concentration of 1, 
3 o 10 µmol/L for 5 days and the compound was added fresh each day. Moreover, MDA-MB-
231 was treated with Trichostatin A (Sigma) for 24h at a concentration of 1 µmol/L while 
Suberoylanilide hydroxamic acid (SAHA) (Sigma) was used for 48h at a concentration of 5 
µmol/L.  
 
2.2  Cloning of specific 3’-UTR into psiCHECK-2 expression vector 
The 3’-UTR of  TRF1, hTERT and TRF2, was amplified by PCR from genomic DNA of HeLa cells. 
The PCR reaction was performed in a total of 50 ul in which has been used:  2,5 ul of  DMSO 
(Dimethyl sulfoxide),  1,75 ul dNTPs (10 nM), 5 ul of Buffer 1 (10X),  0.75 ul of Taq DNA 
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polimerasi (Expand long template PCR mix Roche), 1 ul (100 ng/ul) of  genomic DNA and 10 
pmol of the following primers:  
 
TRF1 Fw:   5’ GCCGCGGCCGCTTGTGTTTGTAAAAGCTTG 3’ 
TRF1 Rev:  5’ GCCGCGGCCGCGTATATGGTACTCATCCATG 3’                      
 
TRF2 Fw:   5’ GCCGCGGCCGCAACAGGCTTTCATTTCCAC 3’ 
TRF2 Rev:  5’ GCCGCGGCCGCAAAAAAAGATTACAGAAAACACTTTACTG  3'      
 
TERT Fw:   5’ GCCGCGGCCGCTGGCCACCCGCCCACAGCCAG 3’  
TERT Rev:  5’ GCCGCGGCCGCCAAAACTGAAAAAC 3’ 
                                                    
At the end of the primers was added the sequence of restriction enzyme NotI to allow the 
cloning of PCR fragment on to luciferase reporter vector (psiCHECK-2). First, the PCR product 
has been cloned in to pCR2.1-TOPO vector using TOPO TA-cloning kit (Invitrogen). The 3’-UTR 
was sequenced to avoid the presence of mutation, then, the sequence were cut with NotI (New 
England BioLabs). Next the psiCHECK-2 vector was cut with the same restriction enzyme and 
treated with phosphatase alkaline to avoid the re-ligation of the vector (1ul of AP for 30 minute 
at 37°C, New England BioLabs). After that, the PCR product and psiCHECK-2 was legated using 
1ul of DNA ligase T4 (ROCHE), 2 ul di Buffer (10X) at 16°C over night. The product of ligation was 
used to  transform competent bacteria HIT DH5α (UBI). At the end , the psiCHECK-2 vector with 
the specific 3’-UTR was sequenced to verify the correct orientation of the insert in to the 
vector. 
Moreover, psiCHECK2-mPax9 and an expression vector for mmu-miR-206 was used as positive 
control vector for miRNA dependent targeting in Renilla luciferase reporter assays (Cacchiarelli 
D. et al. 2010). 
 
2.3 Generation of mutant 3’-UTR of TRF1 and TERT 
The psiCHECK-2 ∆-miR-155 TRF1-3’-UTR was generated by PCR- amplifying 3’-UTR sequences 
upstream and downstream of the miR-155 target site. The PCR oligonucleotides used are:  
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PCR amplicon 1: TRF1-3’-UTR-Fw: GCCGCGGCCGCTTGTGTTTGTAAAAGCTTG, 155mutsite1- Rv 5’-
CGCGGATCCTTAAACAAAAGTTTTAAATTAC-3’;  
PCR amplicon 2: 155mutsite2-Fw 5’- CGCGGATCCCAGTATTTTTCTGTGACC – 3’, TRF1-3’-UTR-Rv: 
GCCGCGGCCGCGTATATGGTACTCATCCATG).  
Then the PCR fragments were ligated and cloned into psiCHECK-2,then, the loss of seed 
sequence was verified by the sequencing. 
The mutant of TERT-3’-UTR was generated using specific oligonucleotides with the QuikChange 
II XL Site-Directed Mutagenesis Kit (agilent). The protocol was performed according to the 
manufacturer’s suggestions and the specific primers are listed below: 
 
TERT-∆479-481 Fw: CCTGCACCTGGAGAAGGGTCCCTGTGGGTCAAATTG 
TERT-∆479-481 Rev: CAATTTGACCCACAGGGACCCTTCTCCAGGTGCAGG 
TERT-∆83-85 FW: AGGGAGGGAGGGGCAAACCACACCCAGGCCC 
TERT-∆83-85 Rev: GGGCCTGGGTGTGGTTTGCCCCTCCCTCCCT 
TERT-∆164-166 FW: CCTGCATGTCCGGCTGAAGGCTTGTTGTCCGGCTGAG 
TERT-∆164-166 Rev: CTCAGCCGGACAACAAGCCTTCAGCCGGACATGCAGG 
 
2.4 miRNA library vectors  
The library contains 439 expression vectors which was kindly provided by the group of R. 
Agami, Division of Gene Regulation, The Netherlands Cancer Institute, Amsterdam. Each vector 
(derived from Mouse Embryonic Stem Cell Virus )(Voorhoeve P.M. et al 2006) contains the 
genomic sequence of ~500 nt that encoded a specific miRNAs, cloned downstream to the viral 
promoter CMV. The vectors contain the gene for the resistance to Ampicillin to select the 
positive clones in bacterial cells, while the gene for the resistance to Blasticidin was used to 
select the positive clones in eukaryotic cells. 
The DNA of all vectors of the library used in this study were transformed into bacterial cells HIT 
competent DH5α (UBI) and plasmid DNA was obtained using miniprep kit (Qiagen). The 
sequence of the plasmid DNA obtained was verified prior to using them in the screening. 
 
 
53 
 
2.5 Luciferase reporter screening 
HeLa cells were cotransfected with 18ng of 3’-UTR luciferase reporter plasmids (TRF1, TRF2, 
TERT) and 80ng of miRNA expression vectors. The cells were transfected in a 48 well plate using  
Lipofectamine 2000  (Life Technologies). Seventy-two hours posttransfection the cells was lysed 
in LBL lysis Buffer 5x and the lysates were loaded in a GloMax  Microplate Luminometer 
(Promega) to analyzed the Renilla/Firefly luciferase reporter activity by the Dual Luciferase 
Reporter Assay System (Promega). The reagents LAR II e Stop & Glo were diluted as described 
by the manufacturer. The value of Renilla luciferase has been normalized to Firefly luciferase so 
the reporter activity was expressed as the ratio Renilla/Firefly luciferase. 
A Student t test was used to calculate the statistical significance. 
 
2.6 Transfection of siRNA and RNA-oligonucleotides 
The siRNA or RNA-oligonucleotides used to transiently transfect the cells are the following:  
ON-TARGETplus smartpool TRF1 siRNAs (Dharmacon) Human, ON-TARGETplus non-targeting 
siRNA#1 (Dharmacon), ON-TARGETplus smartpool TERT siRNAs (Dharmacon)   Human, 
hsa-miR-155-5p mimic siRNAs (Dharmacon), miRIDIAN microRNA hsa-miR-155-5p hairpin 
inhibitor (Dharmacon), miRIDIAN microRNA mimic negative control siRNA (Dharmacon), hsa-
miR-296-5p mimic siRNAs (Dharmacon), miRIDIAN microRNA hsa-miR-296-5p hairpin inhibitor 
(Dharmacon), hsa-miR-512-5p mimic siRNAs (Dharmacon), miRIDIAN microRNA hsa-miR-512-5p 
hairpin inhibitor (Dharmacon). The cells were seeded the day before the transfection and the 
number of cells depended on the cell type. The following day, the cells were transfected using 
the RNAiMAX Lipofectamine (Invitrogen) and the siRNA or RNA-oligonucleotides at a final 
concentration of 30nM according to the manufacturer’s suggestions. Western blotting, 
immunocytochemistry or RNA analysis was performed 3 days post-transfection. 
 
2.7 Protein extracts and Western blotting 
The whole-cell lysates for Western blot analysis were prepared using  a modified RIPA buffer 
(20 mmol/L Tris-HCl (pH 7.5) 350 mmol/L NaCl, 1 mmol/L Na2EDTA, 1 mmol/L EGTA, 1% NP-40, 
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1% sodium deoxycholate, 2.5 mmol/L sodium pyrophosphate, 1 mmol/L b-glycerophosphate, 1 
mmol/L Na3VO4, 1 mg/mL leupeptin). 
Instead, for the preparation of nuclear extracts, cells were resuspended in Buffer 1 [20 mmol/L 
Hepes-KOH (pH 7.9), 10 mmol/L KCl, 1.5 mmol/L MgCl2, 1 mmol/L EDTA, 1 mmol/L EGTA, 0.2% 
NP40] and incubated for 10 minutes on ice. Nuclei were pelleted and lysed in Buffer 2 [20 
mmol/L Hepes-KOH (pH7.9), 350 mmol/L NaCl, 1.5 mmol/L MgCl2, 10 mmol/L KCl, 10% glycerol, 
1 mmol/L dithiothreitol). To all samples were added the complete protease inhibitor (Roche) 
and were sonicated followed by centrifugation. Supernatants were recovered and used for 
Western blotting according to standard procedures. 
The primary antibodies used are listed below:  
mouse anti –actin (Sigma A2228), mouse anti TRF1 (TRF-78, abcam 10579); mouse anti-TRF1 
(N-19, Santa Cruz, sc-6165-R); mouse anti-TRF2 (clone 4A794, Millipore, 05-521); rabbit anti-
POT1 (Epitomics 5334-1); mouse anti-ATM (clone 5C2, Santa Cruz sc-23922); mouse anti-P-ATM 
(S1981) (clone 10H11.E12, Santa Cruz sc-23922); rabbit anti-ATR (Cell Signalling, 2790); rabbit 
anti-P-ATR (S428) (Cell Signalling 2853); rabbit anti-Chk1 (Cell Signalling 2345); rabbit anti-P-
Chk1 (S345) (Cell Signalling 2341); rabbit anti P-Chk2 (T68) (Cell Signalling 2661); mouse anti-
Chk2 (Cell Signalling 3440); goat anti-Lamin A/C (clone N-18, Santa Cruz sc-6215); mouse anti-
γH2AX (ser139) (clone JBW301, Millipore, 06-570), anti P-p53 (ser15) (Cell Signalling, 9284), 
Cyclin B1 (GNS1, Santa Cruz-245), Cyclin A (H-432, Santa Cruz-751), Cyclin E (M-20, Santa Cruz-
481), Cleaved caspase-3 (Asp 175) (Cell Signalling, 9661), Anti-PARP-1 (Calbiochem AM30). 
 
The membranes were incubated with the specific secondary antibodies  bound to the HRP 
enzyme (horseradish peroxidase-conjugated antibody) (GE Healthcare) and the levels of 
proteins expression were detected by chemiluminescence using the ECL system (GE Healthcare) 
with subsequent exposure on autoradiography film (GE Healthcare). 
The quantification of the densitometric analysis of Western blot was performed using the 
software Image-J. 
 
2.8 Vectors and vector construct 
Vectors purchased are: pLPC-NFLAG-TRF1 (Adgene 16058), p-Babe-hygro-hTERT (Addgene), 
pMKO.1-puro hTERT shRNA (Addgene).miR-512 and miR-296 vector were included in the 
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miRNA library kindly provided by the group of R. Agami while miR-512 vector was cloned in our 
laboratory using the following primes: (BamHI) GC-GGATCC-  CCAAAGTGCTGGGATTACAG ; 
(ECORI) GC-GAATTC- AAGAGGCAACCAATCCAGAC .  
 
2.9 RNA extraction and RT-PCR 
Total RNA was extracted by lysing the cells in TRIzol reagent (Gibco/BRL) and subsequent 
precipitation with chloroform. After addition of 20% of chloroform, the samples were shaken 
vigorously for 10 seconds and then vortexed for 15 seconds. After incubation for 5 minutes at 
room temperature, the samples were centrifuged at 13000 rpm for 10 minutes at 4°. The 
transparent upper phase which contains RNA was transferred into a clean tube. An equal 
volume of isopropanol was added and then, the tubes were left for 30 minutes at -20°C. In 
order to precipitate the RNA, the samples were centrifuged at  13000 rpm for 30 minutes at 
4°C. The pellet was washed with 70% ethanol and, after 5 minutes of centrifugation, the pellet 
was resuspended in water. The RNA concentrations were quantified at Nanodrop. 
For quantitative mRNA expression analysis 500 ug of RNA was subjected to reverse 
transcription using QuantiTect Reverse Transcription Kit according to the manufacturer’s 
suggestions. 
Quantitative PCR was performed using the SYBR Green Master Mix (Applied Biosystem) and 
analyzed with a StepOnePlusTM real time PCR machine (Applied Biosystem). mRNA levels were 
normalized to actin and specific PCR primers (10pmol) used for quantitative real-time PCR are: 
  
TRF1 Fw: 5’ CCGCTGCCTTCATTAGAAAG 3’; 
TRF1 Rev: 5’ GCTGTTTGTATGGAAAATGGC 3’; 
 
TERT Fw: 5’ AACAAGCTGTTTGCGGGGAT 3’; 
TERT Rw: 5’ CCAGGGTCCTGAGGAAGGTTT 3’; 
 
TRF2 Fw: 5’ CATGCAGGCTTTGCTTGTCA 3’;  
TRF2 Rev: 5’ CTGCATAACCCGCAGCAATC 3’; 
  
β-ACTIN Fw: 5’ AGCACTGTGTTGGCGTACAG 3’;  
β-ACTIN Rev: 5’ TCCCTGGAGAAGAGCTACGA 3’; 
 
To detect miRNAs expression,  the total RNA extraction was the same as described above. To 
reverse transcribed the specific miRNAs was used the hsa-miR-155, has-miR-296-5p, has-miR-
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512-5p and RNU46 TaqMan™ MicroRNA Assay system (Applied Biosystems). The human 
snoRNA RNU46 was used as a reference. RNA used to performed the reverse transcription was 
10 ng and the stem loop real-time PCR was performed using a Taqman Fast PCR Master mix 
(Life Technologies) according to conditions as suggested by the manufacturer.  
The Quantitative miRNA expression data was analyzed using a StepOnePlus™ Sequence 
Detection System (Applied Biosystems).  
 
2.10 Immunofluorescence  
SK-BR-3 cells were seeded on slides and the day after the cells were transfected with siRNA or 
RNA-oligonucleotides. Three days after, the cells were washed with 1x PBS and, fixed in 4% 
paraformaldehyde (PFA) for 20 minutes. Subsequently the cells were washed with 1x PBS and 
treated with citrate buffer [0.1% (w/v), 0.05% Triton X-100] for 10 minutes at room 
temperature. Cells were blocked for 30 minutes in 3% BSA (1_ PBS) and incubated with mouse 
anti-TRF1 [Santa Cruz (N-19) sc-6165-R], mouse anti-TRF2 [Millipore (4A794) 05-521], or rabbit 
anti-POT1 (Epitomics 5334-1) antibodies in 3% BSA (1x PBS), 0.1% Tween-20 for two hours at 
room temperature in a wet chamber. Cells were washed three times in 0.3% BSA (1xPBS), 0.1% 
Tween-20 for 5 minutes and incubated with secondary antibodies for 45 minutes in a wet 
chamber. After the incubation three washes were performed in 1x PBS with 0.1% Tween-20 for 
5 minutes. In particular, in the second wash was added the 20 DAPI (Vector Laboratories) to 
stain the nuclei. The slides were mounted with Vectashield. Then, the cells were analyzed using 
a Zeiss Axiovert 200 M microscope, equipped with a Zeiss AxioCam MRm digital camera. Images 
were captured using AxioVision Rel. 4.8 imaging software. Nuclei were analyzed with TFL-TELO 
Software and a Student t test was used to calculate the statistical significance. 
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2.11 Telomere Q-FISH 
Day 1: SK-BR-3 cells previously trasfected with the specific siRNA or RNA-oligonucleotides were 
blocked in methaphase by treatment with colcemid at a final concentration of 1ug/ml for 3 
hours at 37°C.  
The cells were washed and treated with trypsin. Then, the cells with the medium were 
centrifuged at 900 rpm for 5 minutes.  The cells were resuspended in 1 ml of medium using a 
vortex and 9 ml of hypotonic solution (0.03 M Na-Citrate) previously heated at 37°C was added.  
The cells were incubated for 25 minutes at  37°C and then centrifuged for 5 minutes at 900 
rpm. The hypotonic solution was removed leaving only 1 ml and then 2 ml of fix solution 
(Methanol: acetic acid 3:1)  were added drop by drop using a vortex. Subsequently, 9 ml of fix 
solution were added. In this step it is possible to store the samples at -20 °C or continue 
repeating the step with the fix solution. 
The slides were washed with methanol and dried with paper, then were washed with 45% 
acetic acid. 200ul of each sample were dropped from a distance of 1 meter on the slide, 
inclined at 45 ° to prepare metaphases. The slides were left to dry overnight in the dark at room 
temperature (RT). 
 
Day 2: The cells were washed for 15 minutes at RT by adding 500uL of 1X PBS to each slide and 
then fixed with 4% formaldehyde for 2 minutes at RT. After three washes for 5 minutes with 1X 
PBS with agitation, the slides were incubated in pepsin solution (200mg of pepsin, 168ul of HCl, 
200 ml of H2O) ,previously heated, for 10 minutes at 37 ° C in the bath.  
The fixing and washing steps were repeated a second time and then the slides were dehydrated 
with three successive washes, respectively, in 70%, 90%, and 100% ethanol for 5 minutes each 
and left to dry for 20 minutes. The probe PNA telomere (TTAGGG) 4 was prepared by 
resuspending the 5 ng of lyophilised probe in 200 ul of water and then incubated at 37 ° C for 5 
min, 70 ° C for 3 min, and again at 37 ° C for 5 min (Table 1). 15 ul of probe were added to each 
slide and cover with a coverslip, so the slides were denaturated at 80 ° C for 3 minutes exactly. 
The Slides were then incubated for 2 h at RT in the dark in a humid chamber. To remove the 
coverslip two washes were performed of 15 minutes with FISH solution (Table 2) at RT, 
followed by 3 washes of 5 minutes in 1XTBS with 0,01% of Tween 20 at RT and one wash in 1X 
TBS with DAPI for 5 minutes. The slides were then dehydrated with 3 washes, respectively in 
70%, 90%, 100% of ethanol, then mounted in Vectashield and stored at 4 ° C. 
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At last the metaphases were analyzed to study the chromosome aberrations using a Zeiss 
Axiovert 200 M microscope, equipped with a Zeiss AxioCam MRm digital camera. Images were 
captured using AxioVision Rel. 4.8 imaging software. 
For quantitative telomere DNA FISH analysis we used the same protocol without blocking the 
cells in colcemid. We analyzed interphase nuclei using spot IODanalysis (TFL-TELO) software. 
The Student t test was used to calculate the statistical significance. 
 
 
 
Table 1: probe 
 
Stock to 250 ul (10 slides) Final concetration 
1M Tris pH 7.2 2.5 ul 10mM 
Buffer MgCl pH 7.0  
(25 mM MgCl, 9 mM citric acid, 82 mM Na2HPO4) 
21.4 ul  
Deionized Formamide 175.0 ul 70% 
probe 25ug/ml 5.0 ul 0.5 ug/ml 
BM 10% (blocking reagent) 12.5 ul 0.25% 
H2O  33.6 ul  
 
Table 2: FISH solution 
Stock To 400 
ml  
Final concetration 
Formamide 280 ml 70% 
1M Tris pH 
7.2  
4ml 10mM 
BSA 10% 4ml 0.1% 
H2O  112  
 
 
2.12 Immunofluorescence combined with telomere FISH  
MCF-7 and SK-BR-3 cell lines were seeded in coverslips and three days after transfection, with 
siRNA or RNA-oligonucleotides the stable cells, were washed in 1X PBS and fixed in 4% 
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paraformaldehyde (1X PBS) for 20 minutes. The cells were washed in 1X PBS and treated with 
Triton X-100 0.1% in 1X PBS for 7 minutes at RT. Then, the cells were washed two times with 1X 
PBS and were blocked with the 3% of BSA (1X PBS) for 20 minutes at 37°C . Subsequently, the 
slides were incubated with the primary antibody (1:200) in 3% of BSA (1X PBS) 0,1% Tween-20 
(anti-γH2AX ser139 clone JBW301, Millipore, 06-570) at 4° C over night or 1h at RT.  The 
following day, the cells were washed two times in 1X PBS for 5 minutes with 0.05% Triton X-100 
(PBS 1X) and then incubated with the secondary antibody (1:300) for 1 hour at RT. 
The slides were washed two times in 1X PBS for 15 minutes and  were fixed in 4% formaldehyde 
for 2 minutes exactly, then washed again 3 times in 1X PBS for 5 minute. This step was 
repeated, the slides were dehydrated with three successive washes, respectively, in 70% 
ethanol, 90%, and 100% from 5 minutes each and left to dry for 20 minutes. 
The hybridization with the probe is the same explain in the paragraph 2.11. 
15ul of probe were used and the slides were incubated at 80°C for exactly 3 minutes, then the 
slides were incubated in a humid chamber for 2  hours at RT. After two wash with 50% of 
formamide,10mM Tris pH 7.2, 0.1% BSA for 15 minutes the slides were washed 3 times with 
TBS 1%, 0.08% Tween-20. In the second wash was added the DAPI to stain the nuclei. 
The slides were dehydrated with three successive washes, respectively, in 70% ethanol, 90%, 
and 100% from 5 minutes each and left to dry before mounting with Vectashield. 
The Student t test was used to calculate the statistical significance. 
 
2.13 Retrovirus infection 
The transduction was performed using HEK 293GP (Gag and Pol)  
The solution DNA-CaCl2 (2,5 M CaCl2 sterilized by filtration) for a 10cm dish was prepared 
adding sequentially: to 450 ul with H2O, 50ul CaCl2 and 5-10 ug of specific plasmid DNA, then 
mixed carefully. In an other tube was added 500ul of 2X HBS (Table 1) and the DNA solution 
was transferred drop by drop to the 2X HBS. The solution was mixed introducing air bubbles 
and incubated for 20-30 minutes to allow efficient formation of DNA-Ca-PO4 precipitates. Then, 
the solution was added dropwise to the cells that were previously covered with 10 ml of  fresh 
medium and incubated at 37 C°. The day after the medium was changed and the cells were 
incubated for 48 hours. 
Subsequently, the supernatant that contains the virus was collected and filtered  in a tube with 
1ml of serum (FBS) and 8ug/ml of polybrene. Then the solution was added to the cells to infect 
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and the day after, the medium was changed  with the fresh one. After 24 hours the specific 
antibiotic to select the transfected cells was added. 
 
 
2X Hepes-buffer saline (HBS) For 50ml/ stock solution 
50mM Hepes pH7 10ml        (250 mM) 
280 mM NaCl 5 ml         (2,8 M) 
1.5 mM Na2HPO4 0,5 ml      (150 mM) 
 To 50 ml with H2O 
 
 
2.14 TRAP assay 
Telomerase activity was measured in MCF-7 cells using TRAPeze Telomerase Detection Kit  
(Millipore S7700). 
Cells were transiently transfected with specific siRNA or RNA-oligonucleotides and three days 
after were washed with 1X PBS and lysed with 1X CHAPS buffer (100ul for well of a six well 
plate) for 30 minutes on ice. The samples were centrifuged at 12,000 g for 20 minute at 4 °C 
and the supernatant was transfer into a fresh tube and the protein concentration was 
determined. 
The kit used present two option: detection of radiolabeled product or staining of products 
either by SYBR Green or Ethidium Bromide. We used the last option with SYBR Gold nucleic acid 
gel (Life Technologies). 
The non-radioactive method does not provide the labeling of TS primer, so we prepared the 
reaction as shown below: 
 
10X TRAP Reaction Buffer 5ul 
50X dNTP Mix 1ul 
TS primer Mix 1ul 
TRAP primer mix 1ul 
Taq Polymerase (5 units/ uL) 0,4ul 
dH2O 39,6ul 
Cell extract  
(total of 100, 50 and 25 ng for 
sample) 
2ul 
Total volume 50ul 
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The controls used in this experiment are: Heat-inactivated control that was performed 
incubating the 4-5ul of cell extract at 85 °C for 10 minutes, then we used only 2ul for the 
reaction. 
Primer-dimer/PCR  contamination control was performed using 2ul of 1X CHAPS lysis buffer 
instead of cell extract. The last control was the quantitative control where we added 1ul of 
control template TSR8 and 1ul of dH2O. The samples were incubated at 30 °C for 30 minutes 
and then 3-step of PCR was performed at 94 °C for 30 seconds, 59 °C for 30 seconds and 72 °C 
for 1 minute, for 30 cycles in a thermocycler.  
After that, the samples were loaded in a 10% non-denaturing polyacrylamide gel (mono/bis 
=19:1) in 0,5 X TBE buffer for 1,5 hours at 400 volts. 
5X TBE buffer (54 g Tris base, 27,5 g Boric Acid, 20ml of 0,5 M EDTA ph 8)  
To make 50mL: 
49,5 mL 10% non-denaturing polyacrylamide gel in 0,5X TBE, 0,5 mL 10% Ammonium 
persulfate, 0,05 mL TEMED. 
After electrophoresis the gel was stained with SYBR green according to the manufactures 
instruction and was used gel DOC XR system (BIO-RAD) for imaging. 
 
2.15 Bisulfite assay  
MDA-MB-231 cells were treated or not with 5’-Aza-Cytidine at a concentration of 3 uM for 5 
days before extracting the genomic DNA.  
Cells was resuspended in protein K buffer (Ambion) and then genomic DNA was extracted using 
phenol/Chloroform/isoamyl alcohol (Fischer scientific). A total of 500 ng of genomic DNA was 
converted with Qiagen EpiTect Bisulphite kit following the manufacturer’s instructions and 
amplified by PCR with primer set designed using MethPrimer software (Li & Dahiya, 2002). 
Primers used for the CpG island predict to miR-296 are: GTGTTAGGAGTGGAGATAGGATAGT; 
TCAATAAAAATAAAAAAAACCTCC. Primers used for the first CpG island of miR-512 are: left 
primer TTGTAATTTTAGTATTTTGGGAGGT; right primer AAAACAATCTCACTCTATTACCCAAAC; 
while in the second CpG island were used: left primer TGGTTTATGTTTGTAATTTTAGTGTTT; right 
primer CAAATAATTCTCCTACCTCAACCTC. 
The PCR products were isolated from 2% agarose gels using  gel extraction kit (Qiagen). 
Subsequently, they were ligated into pCR2.1 using TA cloning kit (Invitrogen). Individual clones 
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were sequenced with M13 Fw and M13 Rw primers. Sequencing reactions were analyzed using 
QUMA software (Quantification tool for Methylation Analysis).  
 
2.16 Senescence-associated-β-galactosidase (SA-β-gal) assay 
MCF7 or MDA-MB-231 cell lines were transfected with mimic-miR-control or mimic-miR-296-5p 
and mimic-miR-512-5p. Positive control for senescent cells was generated by treating cells with 
100 nM Adriamycin (Sigma Aldrich). After 6 days, cells were washed in PBS, fixed in 2% 
formaldehyde/0.2% glutaraldehyde for 15 minutes at room temperature. Cells were then 
washed and incubated with fresh SA-β-gal staining solution containing 1mg/ml X-gal, 40 mM 
citric acid/sodium phosphate (pH 6.0), 5 mM potassium ferrocyanide, 5 mM potassium 
ferricyanide, 150 mM NaCl and 2 mM MgCl2 for 16-18 h at 37 °C. Blue-stained senescent cells 
were counted using a light microscopy (Olympus IX71, Olympus America, PA, USA) and the 
images were captured by digital camera (Olympus-Camedia C-5060). 
 
2.17 Facs analysis 
MCF-7 and MDA-MB-231 cells were transiently transfected with specific miRNA-
oligonucleotides and three days after the supernatant and the cells were recovered  and 
centrifuged for 5 minutes at 1000 rpm. The supernatant  was removed,then cells were washed 
with 500ul of 1X PBS and centrifuged for 5 minutes at 1000 rpm. PBS was removed and was 
added 300ul of 1X PBS with 700ul of cold 100% ethanol and left for 30 minutes at -20 °C. 
Subsequently, the samples were centrifuged for 5 minutes at 4000 rpm, the supernatant was 
eliminated and the cells were washed with 1X PBS. The  samples were centrifuged again and for 
each sample was added a following solution:  100 ul of 1X PBS with 0,1% NP40  and  2ul of 
RNase A (10mg/ml). 
Then the samples was carefully mixed and left for 10 minutes at RT.  
After that, was added 300 ul of PI solution to a final volume of 400ul for sample. 
Propidium iodide (Sigma) was prepared using  the stock solution (1mg/ml) diluited 1:20 in 
water to arrive at final concentration of 50ug/ml. 
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The suspension was then analyzed using BD FACSCalibur flow cytometer. All flow cytometry 
data were analysed using the FlowJo software (Tree Star, Ashland, OR, USA). 
 
2.18 Growth curve 
MDA-MB-231 and MCF-7 cells were seeded the day before the first transient transfection with 
RNA-oligonucleotides and, at day 3 the transfection was repeated. The cells were counted at 
day 0, 1, 3 and 6 for MDA-MB-231 while only at day 6 for MCF-7. Stable MDA-231 cells 
overexpressing hTERT were transiently transfected with the specific RNA-oligonucleotides at 
day 0 and 3, then the cells were counted at day 6. The Student t test was used to calculate the 
statistical significance. 
 
2.19 Breast cancer specimen collection and immunohistochemistry 
TRF1 expression was analyzed by immunohistochemistry (IHC) on formalin-fixed paraffin 
embedded tissues using the monoclonal antibody (TRF-78, #ab10579, Abcam). Two 
micron–thick sections were stained with a streptavidin enhanced immunoperoxidase technique 
(Supersensitive Multilink, Menarini) using a pH 6 citrate buffer antigen retrieval protocol. TRF1 
was considered positive when at least 20% of the neoplastic cells showed nuclear 
immunoreactivity. Staining was classified as negative, score 0; low, score 1+; medium,score 2+, 
and high, score 3+. 
 
2.20 Bioinformatics on clinical data from breast cancer patients 
Raw data were retrieved from the gene expression omnibus (GEO) public gene expression 
database (GSE7390, GSE3494, GSE1456, GSE2034, GSE2603, GSE6532, GSE4922, GSE12093, 
GSE5327, GSE11121, and Chin dataset). To validate the correlation of TRF1 expression and the 
miR-155 target gene expression signature and breast cancer clinical data, a Mantel–Haenszel 
test was applied to the meta-dataset. Then, Kaplan–Meier survival curve of distant metastasis-
free survival and relapse-free survival (DMFS_mixed) was obtained using the GOBO tool. 
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Regarding miR-296-5p and miR-512-5p raw data for miRNA expression (Agilent ncRNA 60k 
platform) was obtained from the EGA portal (https://www.ebi.ac.uk/ega/home), study 
EGAS00000000122. Data was normalized using standard procedures (Limma).  
Then we performed Kaplan-Meier survival analysis considering distant metastasis free survival 
(DMFS), relapse free survival (RFS) and overall survival (OS) time of breast cancer patients. 
Samples were classified according to the expression of the gene signatures using Kaplan-Meier 
plotter and Outcome for Breast Cancer web tool in order to evaluate the correspondence 
between the expression levels and breast cancer clinical data. 
Statistical analysis was performed in R software environment for statistical computing and 
graphics (http://www.r-project.org). Data were analyzed by a two-tailed Student’s t test, and 
results were considered significant at a p-value < 0.05. 
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3. Results 
 
3.1 miRNAs involved in the regulation of Shelterin and telomerase components 
Shelterin and telomerase components are reported to be finely regulated at post-translational 
level. Shelterin components TRF1 and TRF2 are regulated through different mechanisms  such 
as phosphorylation, ubiquitylation, SUMOylation, poly (ADP-ribosy)lation (Walker J.R. and Zhu 
X-D 2012). At the start of our study a possible role of miRNAs in the post-transcriptional 
regulation of Shelterin or telomerase complex was not known.  
In this study we wished to explore a post-transcriptional regulation of two main telomere 
regulators, TRF1 and TERT, by miRNAs. Identification of “telo-miRNAs” that control telomere 
homeostasis introduces a new level of telomere regulation that impacts on major maladies 
such as cancer and aging. 
In the first part of the project we focused the attention on miR-155 as regulator of the protein 
expression of TRF1; instead, the second part of the thesis is focused on miR-296-5p and miR-
512-5p that regulate TERT expression. 
 
3.1.1 Observations that underline a potential involvement of miRNAs in telomere 
regulation 
To understand whether post-transcriptional gene regulation can impact on the expression of 
telomere regulators, we analyzed whether protein and mRNA expression of TRF1 and TRF2 
show correlation in a panel of human cancer cell lines.  
We performed western blotting and RT-PCR analysis in MDA-MB-468 (basal), SK-BR-3 (Her2+), 
MCF-7 (Luminal A) breast cancer cells, U-2 OS osteosarcoma cells, H1299 non-small cell lung 
cancer cells, HCT-116 and HCT-116 p53 -/- colorectal carcinoma cells (Fig. 3.1.1). 
We found that TRF2 mRNA and protein levels show good correlation. In contrast, TRF1 protein 
levels do not correlate with mRNA expression (Fig. 3.1.1). 
 This is in agreement with the demonstration of a complex post-transcriptional regulation of 
TRF1 by different mechanisms such as phosphorylation, poly ADP-ribosylation, ubiquitylation 
and SUMOylation (Walker J.R. and Zhu X-D 2012). However, to date there are only scarce 
insights into the role of miRNAs in the regulation of  telomere proteins. 
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Figure 3.1.1:  Protein and mRNA expression of TRF1 and TRF2. A) Western blotting for TRF1 (left) and 
quantification (right) in a panel of human cancer cell lines. B) quantitative real-time PCR for TRF1. C) Western 
blotting for TRF2 (left) and quantification (right) in a panel of human cancer cell lines. D) quantitative real-time PCR 
for TRF2, normalized to actin. Arrowheads, specific band for TRF1. L.E., long exposure.  
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3.2 A high throughput approach to identify telo-miRNAs 
To identify miRNAs that control telomere function in cancer by altering the expression of 
telomere regulators, we set up a telo-miRNAs screening protocol. We first performed a 
computational prediction analysis to identify candidate miRNAs with predicted target specificity 
for TRF1, TRF2, POT1, DKC and TERT. Then we tested the target specificity by using high 
throughput luciferase reporter assays. 
 
3.2.1 Computational prediction analysis 
 To find miRNAs with target specificity for the 3’-UTRs of Shelterin TRF1, TRF2, POT1 and 
telomerase complex components DKC and TERT, we performed target prediction analysis in 
silico. Three online programs comprising PITA (Kertesz M. et al. 2007), TargetScan (Lewis B.P 
2005; Friedman R.C. 2009; Grimson A. 2007; García D.M. 2011) and micro-RNA.org (Betel D. et 
al. 2008) that use different algorithm, have been chosen for computational prediction analysis. 
For each prediction program the threshold value has been set as suggested by the respective 
guidelines .  
We then have filtered the computational prediction data to a list of  miRNA candidates 
predicted to target the 3’UTR of TRF1, TRF2, POT1, DKC or TERT (TRF2, POT1 and DKC data not 
show) (Table 1) that was subjected to target validation analysis. 
To validate candidate miRNAs we develop a dual luciferase reporter assay. 
We used a dual-luciferase reporter vector (psicheck-2) that contains the 3’-UTR of  shelterin or 
telomerase components inserted downstream of the stop codon of the Renilla luciferase gene. 
Consequently transcribed Renilla luciferase transcript contains the specific 3’-UTR that can acts 
as target to candidate miRNAs. In addition, the vector contains a firefly luciferase gene that is 
constitutively transcribed and is used to normalize the luciferase activity. Hela cells were co-
transfected with the dual luciferase reporter construct and specific candidate miRNA 
expression vectors (Voorhoeve P.M. et al. 2006) or mimic-miRNA siRNA (Fig. 3.2.1). Three days 
post-transfection the luciferase activity was analyzed using a luminometer. Low Renilla/Firefly 
ratio of luciferase activity indicate targets specificity of miRNA for the respective reporter 
construct. 
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Table 1: Computational prediction analysis from three software (PITA, TargetScan and micro-RNA.org) was used to 
find best miRNA candidates targeting 3’-UTR of TRF1 and TERT (left table). Mimic-miRNAs siRNA used in the high 
throughput screening with the 3’-UTR-TRF1 or 3’-UTR-TERT luciferase reporter (right table). Candidate for TRF2, 
POT1, DKC1 are not shown.  
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Figure 3.2.1: Dual luciferase reporter screening. psiCHECK-2 luciferase reporter vector containing the 3’-UTR of 
shelterin and telomerase components was co-transfected with a library of miRNA mini gene expression vectors or 
mimic-miRNAs siRNA in HeLa cells. Three days post-transfection Renilla/firefly luciferase activity was measured by 
luminometry.  
 
3.2.2 Multiple miRNAs target TRF1 and TERT in high throughput screenings 
We found that expression of miR-155, miR-125b1, miR-296 and miR-330 from miRNA 
expression vectors significantly reduced TRF1 luciferase reporter activity suggesting target 
specificity for 3’-UTR of TRF1 (Fig. 3.2.2 A). 
Parallel screenings using luciferase reporter with 3’-UTR of TRF1 and individual mimic-miRNAs 
siRNA confirmed miR-155, miR-296-3p and miR-330 target specificity to 3’-UTR of TRF1 but also 
found other putative telo-miRNAs (Fig. 3.2.2 B). 
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Figure 3.2.2: Luciferase reporter screening identified miRNAs targeting the 3’-UTR of TRF1. A) luciferase reporter 
assay after co-transfecting the TRF1 luciferase reporter vector with miRNA mini gene expression vector in HeLa 
cells. Three days post-transfection Renilla/firefly luciferase activity was measured using a dual luminometer. 
Renilla:Firefly ratios <100 indicate miRNA-dependent targeting of the TRF1 reporter. Mouse Pax9 3’UTR and miR-
206 were used as positive controls. n= number of independent experiments. A Student t test was used to calculate 
statistical significance (*, P < 0.05; **, P < 0.01; ***, P < 0.001). B) High throughput luciferase reporter screening 
after co-transfecting the TRF1 luciferase reporter vector with mimic-miRNAs siRNA. Three days post-transfection 
Renilla/firefly luciferase activity was measured by luminometer.  Renilla:Firefly ratios <1 indicate miRNA-
dependent targeting of the TRF1 reporter. miRNAs with high targeting efficiency of 3’-UTR-TRF1 (Luciferase 
reporter activity <0,5) are indicate with black bars. n= independent experiments; a Student t test was used to 
calculate standard deviation. 
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Next we identified miRNAs targeting the 3’-UTR of hTERT. We transiently transfected HeLa cells 
with the specific luciferase reporter and candidate miRNA expression vector or individual 
mimic-miRNAs siRNA. Three days post-transfection, luciferase activity was measured by dual 
luminometer. We found 8 mimic-miRNA candidates to target the 3’-UTR of TERT (Fig. 3.2.3). 
Luciferase reporter experiments involving miRNA expression vectors did not result in the 
identification of candidate miRNAs that target the 3’UTR of hTERT. 
High throughput luciferase screening data of TRF2, POT1 and DKC are not shown and are 
subject of investigation in other studies. 
 
 
 
Figure 3.2.3: High throughput luciferase screening identified miRNAs targeting specifically the 3’-UTR of TERT. 
mimic-miRNA siRNA was used in combination with the 3’-UTR-TERT luciferase reporter vector. Three days post-
transfection Renilla/firefly luciferase activity was measured by luminometer. Ratios Renilla:Firefly <1 indicate 
miRNA-dependent targeting of the TERT reporter. miRNAs with high targeting efficiency of 3’-UTR-TERT (Luciferase 
reporter activity <0,5) are indicate with black bars. 3 independent experiments was performed and a Student t test 
was used to calculate standard deviation. 
 
A set of miRNAs identified in the TRF1 reporter screening are reported players in human cancer. 
Some of these miRNAs are known to be involved in different mechanisms such as DNA damage 
repair factors (miR-1245, miR-155), Epithelial to Mesenchymal transition (EMT) (miR-200c, miR-
200b, miR-429, let-7e, miR-155), apoptosis (miR-15a, miR-1285) and proliferation (miR-155). 
Remarkably, miR-155 is a “oncomir” involved in many cancer relevant pathways such as cell 
proliferation by targeting SOCX1 or EMT by targeting RhoA (Song L.et al. 2012; Gasparini P. et 
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al. 2014; Korpal M. and Kang Y. 2008; Zhang G-J et al. 2013; Cimmino A. et al. 2005; Tian S. et al. 
2010; Jiang S. et al. 2010; Kong W. 2008).  
Given the role of miR-155 as oncomiR we focused our attention on miR-155 for its critical role 
in controlling TRF1 expression using breast cancer as a model system.  
TERT high throughput reporter screens revealed miRNAs that are up-regulated (miR-637) or 
down-regulated (miR-608,miR-1207-5p, miR-296-5p, miR-512-5p) in cancer (Zhang J.F. et al 
2011; Zhang Y. et al. 2014; Chen L. et al. 2014; Vaira V. et al. 2012; Wei J-J et al. 2011; Robson 
J.E. et al. 2012; Saito Y et al. 2009; Adi Harel S. et al. 2015). In the second part of my work we 
focused our attention on miR-296-5p and miR-512-5p, for their important role in cell 
proliferation and cancer progression (see 3.4.2).  
 
 
3.3 miR-155 drives telomere fragility in human breast cancer by targeting TRF1 
 
3.3.1 miR-155 targets a conserved sequence motif in the 3’UTR of TRF1 
miR-155 is transcribed from the B-cell integration cluster (BIC) and shows sequence homology  
between human, mouse and chicken. miR-155 is upregulated in different types of lymphoma 
such as Hodgking’ Lymphoma and Burkitt’s Lymphoma but,  is also over-expressed in several 
solid tumors such as breast, colon, lung and cervical cancer (Kluiver J. et al. 2005; Eis P.S. et al. 
2005; Volinia S. et al. 2006; Iorio M.V. et al. 2005; Yan L.X et al. 2008; Wang X. 2008; Yanaihara 
N. et al. 2006). 
Importantly, experiments in mouse model highlight on oncogenic role of miR-155 in cancer 
formation and progression (Sandhu S.K. et al. 2012; Costinean S. et al. 2006). 
The predicted miR-155 target site is located at position 93-115 in the 3’-UTR of human TRF1 
(Fig. 3.3.1 A). We found that this region is conserved in chimpanzee, cow and rabbit, while 
mouse and rat do not maintain this target sequence (Fig. 3.3.1 A). This raises the possibility that 
post-transcriptional regulation of TRF1 through miR-155, could contribute to species specific 
aspects of telomere regulation (Fig. 3.3.1 A). 
To demonstrate target specificity of miR-155 for the 3’UTR of TRF1, we generated a luciferase 
reporter construct carrying a 3 nucleotides deletion of miR-155 target site (∆miR-155-TRF1-
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3’UTR) (Fig. 3.3.1 B). HeLa cells were transiently  transfected with miR-155 mimic-miRNAs siRNA 
and wild-type or ∆miR-155-TRF1-3’UTR luciferase reporter vector. Three days post-transfection, 
luciferase activity was measured by dual luminometry. We found that mimic-miR-155 siRNAs in 
combination with wild type 3’UTR of TRF1 induces a reduction of luciferase activity, thus 
confirming the data from high throughput luciferase reporter assay. In contrast, ectopic miR-
155 has no effect on ∆miR-155-TRF1-3’UTR demonstrating target specificity of miR-155 for the 
3’UTR of TRF1 (Fig. 3.3.1 B). 
To understand if the reduction of endogenous miR-155 levels in cancer cells could have an 
impact on the TRF1 expression, we transiently co-transfected HeLa cells with mimic-control or 
antago-miR-155 siRNAs and the luciferase reporter construct (wt-TRF1-3’UTR). Three days post-
transfection, we measured luciferase activity. Introduction of antago-miR-155 that targets 
endogenous miR-155, caused an increase in TRF1 3’-UTR luciferase reporter activity as 
compared to control mimic-miRNA. As expected, mimic-miR-155 reduced the luciferase activity 
(Fig. 3.3.1 C). 
To further confirm target specificity of miR-155 for the 3’-UTR of TRF1 we co-transfected HeLa 
cells with luciferase reporter constructs, containing the human 3’UTR of TRF2 or TERT, in 
combination with miR-155 mini gene expression vector. miR-155 does not induce a reduction of 
luciferase activity of 3’-UTR of TRF2 and TERT reporter construct. As expected, ectopic miR-155 
reduced the luciferase activity of 3’-UTR of TRF1 (Fig. 3.3.2). 
Together, these data indicates that miR-155 specifically targets the 3’-UTR of TRF1 in human 
cells. 
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Figure 3.3.1: miR-155 targets a partially conserved sequence motif in the TRF1 3’-UTR. A) the target site for the seed 
region of miR-155 is conserved in the TRF1 3’UTR of human, chimpanzee, cow and rabbit. B) mimic-miR-155 siRNA and 
wt-3’-UTR-TRF1 or ∆miR-155-3’-UTR-TRF1 luciferase reporter vector were co-transfected in HeLa cells. wt= wild Type 
luciferase reporter; ∆miR-155= mutant of 3’UTR-TRF1 luciferase reporter.  C) 3’-UTR-TRF1 luciferase reporter vector 
and mimic-miR-155 or antago-miR-155 siRNA were co-transfected in HeLa cells. Three days post-transfection 
Renilla/firefly luciferase activity was measured by luminometry. Renilla:Firefly ratios <100 indicate miRNA-dependent 
targeting of the TRF1 reporter. n= number of independent experiments; a Student t-test was used to calculate 
statistical significance. P-values are shown. 
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Figure 3.3.2: miR-155 target specifically the 3’UTR of TRF1. Co-transfection of 3’-UTR of TRF1, TRF2 and TERT in 
combination with miR-155 mini gene expression vector in HeLa cells. Three days post-transfection Renilla/firefly 
luciferase activity was measured by luminometry. Renilla:Firefly ratios <100 indicate miRNA-dependent targeting 
of the TRF1 reporter. n= number of independent experiments; a Student t-test was used to calculate statistical 
significance. p-values are shown. 
 
 
3.3.2 miR-155 induces translational repression of TRF1  
To test whether miR-155 levels impact on TRF1 protein expression in human cell we transfected 
H1299 human non–small lung cancer cells and U-2 OS osteosarcoma cells with mimic-control, 
mimic-miR-155 or antago-miR-155 siRNAs. Three days post-transfection we performed western 
blotting experiments using a TRF1 specific antibody. We found decreased TRF1 protein levels in  
H1299 and U2-OS cancer cells trasfected with mimic-miR-155 siRNAs. In contrast, ectopic 
introduction of antago-miR-155 siRNAs increase the protein expression in both cell lines when 
compared to the mimic-control (Fig. 3.3.3 A,B right and top panel).  
Importantly, miR-155 has no impact on the expression of other shelterin components such as 
TRF2 and POT1 (Fig. 3.3.3 A,B bottom panel).  
We conclude that TRF1 expression is miR-155 dosage sensitive in human cancer cells. 
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Figure 3.3.3: Regulation of TRF1 expression by miR-155 overexpression. (A) H1299 and (B) U-2 OS cells were 
transiently transfected with mimic-miR-155 or antago-miR155 siRNA. Three days post-transfection western 
blotting for TRF1, TRF2, and POT1 expression in miR-155 in gain and loss-of-function experiments was performed. 
Quantification of TRF1 levels (Right). n= number of independent experiments; a Student t-test was used to 
calculate statistical significance; p-values are shown. 
 
miRNAs can induce RNA degradation of target mRNAs or induce translation repression thereby 
lowering the expression of respective targets genes (Acunzo M. et al. 2014). 
To understand if TRF1 is regulated at the RNA or translational level, we transfected SK-BR-3 
breast cancer cells with mimic-miR-155, antago-miR-155 siRNAs or TRF1 specific siRNA. As 
expected siTRF1 reduced mRNA levels of TRF1 compared to control RNAi; in contrast, mimic- or 
antago-miR-155 did not have a significant impact on TRF1 mRNA levels (Fig. 3.3.4). 
Together, this demonstrate that miR-155 induces translational repression of TRF1 by targeting 
its 3’-UTR. 
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Figure 3.3.4: miR-155 does not induce mRNA degradation of TRF1. Ectopic introduction of mimic-miR-155 or 
antago-miR-155 in SK-BR-3 cells does not affect TRF1 mRNA expression levels, as determined by real-time PCR. 
Expression levels were normalized to actin. TRF1 RNAi reduce TRF1 mRNA levels. con= control; n=number of 
independent experiments; a student t-test was used to calculate statistical significance; p-values are shown. 
 
3.3.3 miR-155 has a direct effect on TRF1 
Several studies demonstrate that TRF1 is subjected to different post-translational modifications 
that contribute to its stability, binding activity and localization. The main mechanism by which 
TRF1 levels are modulated are phosphorylation, SUMOylation, PARsylation and ubiquitynation 
(reviewed Walker J.R and Zhu X-D 2012). Ubiquitynation is a major post-translational pathway 
that is used by cells to target proteins for degradation by proteasome. Importantly, TRF1 
binding to telomeric DNA is dynamic and there is a exchange rate between bound TRF1 and 
free TRF1. E3 ligases such as SCFFbx4 and RLIM polyubiquitynate TRF1 when is not bound to 
telomeres (Her Y.R. and Chung I.K. 2009; Lee T.H. et al. 2006). The process of 
polyubiquitynation of TRF1 leads to protein degradation by proteasome (reviewed Walker J.R 
and Zhu X-D 2012).   
To exclude that miR-155 reduces TRF1 levels through the promotion of ubiquitin-proteasome 
pathway we tested whether miR-155 can reduce TRF1 expression under conditions of 
proteasome inhibition. We cotransfected SK-BR-3 with mimic-control or mimic-miR-155 siRNAs 
and flag tagged TRF1 lacking the corresponding 3’UTR.  
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Two days post-transfection, cells were treated with proteasome inhibitor MG-132 for 8 hours, 
and western blotting was performed with a specific TRF1 antibody. Flag-tagged TRF1 appears as 
a slower migrating band respect to the endogenous TRF1 (Fig. 3.3.5 A high exposure, B low 
exposure).  
MG-132 treatment increased both endogenous TRF1 and flag-tagged TRF1 in cells transfected 
with control miRNAs. mimic-miR-155 siRNAs reduced endogenous TRF1 but did not interfere 
with the stabilization of flag-tagged TRF1, indicating that miR-155 does not modify proteasome-
dependent degradation of TRF1. 
 
 
Moreover, to exclude that miR-155 targets putative positive regulators of TRF1, a target 
prediction program (TargetScan) was used. In this analysis we considered the following genes: 
AKT, ATXN7L3, CK2, Gcn5, GNL3L, TIN2 and USP22 (Chen Y-C et al. 2009; Atanassov B.S. et al. 
2009; Kim M.K. et al. 2008; Zhu Q. et al. 2009; Zeng Z. et al. 2010). AKT overexpression is 
demonstrated to increase TRF1 while CK2 inhibition shortens TRF1 half-life. Moreover, the 
depletion of Gcn5 or USP22 increase TRF1 ubiquitination, instead, ATXN7L3, GNL3L and TIN2 
protect TRF1 from ubiquitination.  
Importantly, this analysis revealed that miR-155 is not predicted to target any positive 
regulators of TRF1 stability (Fig. 3.3.5 C).  
Altogether, these data demonstrate that miR-155 specifically target partially conserved region 
in the human 3’-UTR of TRF1 and does not impact on the turnover of TRF1 protein. 
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Figure 3.3.5: miR-155 does not induce proteasome-dependent degradation of TRF1. A) SK-BR-3 co-transfected 
with Flag-tagged TRF1 lacking the TRF1 3’-UTR and mimic-control or mimic-miR-155 siRNAs. 2 days post-
transfection, cells were treated with MG132 and extracts (20µg) were subjected to western blotting using an anti-
TRF1 antibody. Flag-tagged TRF1 appears as a slower migrating band. Extracts of TRF1 knock-down cells were used 
to identify endogenous TRF1. Asterisk indicates a non-specific band. Actin was used as a loading control. Ratio 
between endogenous TRF1 and actin are indicated; Ratio of untreated cells transfected with control miRNAs and 
Flag-tagged TRF1 was set “1”. Stabilization of endogenous TRF1 by MG132 does not depend on miR-155. B) 
Extracts from (A). (2 µg) were subjected to western blotting using an anti-TRF1 antibody to detect Flag-tagged 
TRF1. Ratio of MG132 untreated cells transfected with control miRNAs and Flag-tagged TRF1 was set “1”. miR-155 
does not target Flag-tagged TRF1. miR-155 does not impair stabilization of Flag-tagged TRF1 by MG132. C) Positive 
regulators of TRF1 protein expression levels do not contain miR-155 target sites, as predicted by Targetscan target 
prediction analysis. Mode of action is indicated. Top 1000 predicted miR-155 target genes were considered for the 
analysis; target site conservation was not considered in the in silico analysis.   
 
 
 
C 
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3.3.4 Clinical relevance of miR-155 and TRF1 in breast cancer 
Recent studies show that miR-155 is upregulated in breast cancer and that high levels of miR-
155 are associated with clinical-pathological markers, tumor subtype and poor survival rates 
(Kong W. et al. 2010; Iorio M.V. et al. 2005; Yan L.X. et al. 2008).  
After demonstrating specific targeting of TRF1 by miR-155, we wished to test the clinical 
relevance of this mechanism in human breast cancer. 
To investigate miR-155 dependent regulation of TRF1 is relevant in breast cancer, we started to 
test the expression of miR-155  and TRF1 by miRNA expression array analysis (Biagioni F. et al. 
2012) and immunohistochemistry (IHC) in tissue derived from Luminal, triple negative and 
HER2+ breast cancer. We found that all breast cancer subtypes showed a significant 
upregulation of miR-155 expression in tumoral tissues compared to the respective peritumoral 
tissues (Fig. 3.3.6 A). 
To test whether miR-155 levels coincide with low TRF1 expression, we used  normal breast and 
37 ER+ luminal cancer samples, that were previously assayed for miR-155 expression to 
measure TRF1 protein level by immunohistochemistry (IHC).  
Fixed cancer tissues were used to perform IHC using a specific anti-TRF1 antibody (Fig. 3.3.6 B). 
According to TRF1 staining intensity cancer samples were separated into three categories: high, 
Medium-low and Low-negative of TRF1 expression. 
We found that 28% of breast cancer samples have been classified as TRF1 high, while the 72% 
of cancer samples  have been classified as medium-low or low-negative for TRF1 (33% and 39% 
respectively) (Fig. 3.3.6 C). These data suggest that downregulation of TRF1 is a frequent event 
in luminal ER+ breast cancer. Importantly, 83% of samples with a reduced protein expression of 
TRF1  show significant correlation with miR-155 upregulation (p=0,034) (Fig. 3.3.6 D).  
These experiments demonstrate that miR-155 and TRF1 show reverse correlation in breast 
cancer, suggesting a functional link in vivo. 
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Figure 3.3.6: Clinical relevance of miR-155 and TRF1 expression in human breast cancer. A) box plot diagrams showing 
miR-155 upregulation in breast cancer compared with peritumoral tissues, as determined by miRNA expression array 
analysis described in Biagioni F. et al 2012. P-values were calculated using the Fisher method. B) Representative image 
of Immunohistochemistry for TRF1 is shown; samples used were the same of miRNA expression studies in (A). Scale 
bar= 30 mm. B) proportion of TRF1 staining intensities in samples analyzed in (B). C) Luminal cancer samples with 
significantly increased miR-155 expression show reduced TRF1 staining in IHC performed in (B). A Pearson χ
2
 test was 
used to calculate statistical significance. n= number of patients. 
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Next we wished to obtain insights into the clinical relevance of miR-155-dependent regulation 
of TRF1 expression in breast cancer. We showed that miR-155 induces translational repression 
of TRF1, without impacting on TRF1 mRNA expression. However large data sets containing TRF1 
and miRNAs expression data were not available to us. Consequently we generated Kaplan-
Meier curves based on the expression of TRF1 or reported miR-155 target genes. 
We used breast cancer gene expression data sets (GOBO) obtained from a total of 1881 breast 
cancer patients (Ringner M. et al. 2011) to performed a Kaplan-Meier survival analysis of mixed 
distant metastasis-free survival (DMSF) and relapse-free survival (RFS).  
DMSF is a temporal measure that describes the time period between the appearance of a 
primary tumor to the formation of metastasis in distant organs or lymphonodes. RFS is referred 
as to length of time after original (primary) tumor and the reappearance of a new tumor. 
We found that low TRF1 mRNA expression are linked to reduced DMSF and relapse free survival 
in luminal ER+ breast cancer (Fig. 3.3.7 A). But we did not find the same correlation in other 
breast cancer subtypes. Furthermore, multivariate analysis using TRF1 expression data showed 
that clinical outcome of luminal ER+ breast cancer patients is independent from the standard 
clinical parameters, such as lymph node status, tumor size or age (Fig. 3.3.7 B).  
These data demonstrate that low mRNA TRF1 levels are linked with poor clinical outcome in 
luminal ER+ breast cancer. 
At the time of the study we did not have access to large miRNA expression data that would 
allow to generate patient survival curves. Consequently, we decided to use mRNA expression 
data of a panel of validated miR-155 target genes as surrogate marker for the activity of miR-
155 in luminal ER+ breast cancer tissues. More precisely, miR-155 upregulation has clinical 
relevance in luminal breast cancer, patients with low levels of miR-155 target genes are 
expected to show poor clinical outcome. 
Consequently we performed Kaplan-Meier survival analysis using expression data from 20 
validated miR-155 target genes in ER+ breast cancer. We found that patients with a low miR-
155 signature expression recapitulate results from TRF1 survival curves and showed a poor 
prognosis, indicating that miR-155 is clinically relevant (Fig. 3.3.7 C,D). This suggests that TRF1 is 
part of miR-155 signature that contribute to poor survival in ER+ breast cancer.  
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Figure 3.3.7: Clinical relevance of TRF1 and miR-155 signature genes in human breast cancer. A) Kaplan–Meier survival 
curve of time considering both distant metastasis-free survival and relapse-free survival (DMSF_mixed) of patients 
with ER+ breast cancer. Red line= high TRF1 mRNA expression; gray line= low expression of TRF1. n= number of 
patients. B) multivariate analysis showing that low TRF1 expression behaves as independent predictor of poor clinical 
outcome compared to standard clinical parameters. In the panel for each clinical variable and TRF1 expression, Hazard 
Ratio (HRs) and corresponding p-values calculated by Cox regression analysis are shown. C) Validated miR-155 target 
genes (Mattiske S. et al. 2012) that form a miR-155 signature with poor survival in ER positive breast cancer. n= 
number of patients; p-values are shown. D) Panel of 20 miR-155 target genes signatures used for the Kaplan-Meier 
analysis in (C). 
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3.3.5 Mechanism of TRF1 regulation by miR-155 in cancer cell lines 
After demonstrating the clinical relevance of miR-155 and TRF1 in ER+ breast cancer, we wished 
to understand the mechanism of miR-155 dependent regulation of TRF1 in human breast 
cancer cell lines. 
 
To evaluate the effects of miR-155 on TRF1 expression, we analyzed TRF1 protein levels in three 
breast cancer cell lines. We transiently transfected the cells with mimic- or antago-miR-155 
siRNAs and western blotting analysis was performed. The results show that antago-miR-155 
increase the basal levels of TRF1 expression when compared to mimic-control in all breast 
cancer cell lines. In contrast, ectopic introduction of mimic-miR-155 reduces the expression of 
TRF1 (Fig. 3.3.8).  
This validates that miR-155 controls TRF1 expression in luminal breast cancer cell lines. 
 
 
 
Figure 3.3.8: TRF1 regulation by miR-155 in human breast cancer cell lines. MDA-MB-468, SK-BR-3 and MCF-7 were 
transiently transfected with mimic-miR-155 or antago-miR-155. Three days post-transfection western blotting was 
performed. Actin was used as loading control. TRF1 expression is miR-155–dosage sensitive in all breast cancer cell 
lines. 
 
 
To understand if miR-155 dependent regulation of TRF1 expression has an impact on telomere 
function, we investigated the impact of miR-155 on telomere homeostasis using SK-BR-3 and 
MCF-7 cells as model system for luminal ER+ breast cancer. 
 
First, we wanted to evaluate if miR-155 impacts only on global TRF1 level or does also alter 
TRF1 abundance at telomeres. To test this, we transiently transfected SK-BR-3 (luminal breast 
cancer cells) with mimic-miR-155, antago-miR-155 siRNAs, or TRF1-specific siRNAs. 
Substantially we performed a quantitative immunofluorescence analysis to measure TRF1 
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abundance at telomeres (Fig. 3.3.9 A). The program telo-TFL was used to quantify fluorescence 
intensity for each signal and an arbitrary fluorescence value was assigned for each nuclear TRF1 
signal.  
We found that ectopic introduction of miR-155 or TRF1-specific siRNA, significantly reduce TRF1 
fluorescence intensity when compared to mimic-control (Fig. 3.3.9 A, left panel). Most 
importantly, the introduction of antago-miR-155 siRNAs increase the signal intensity of TRF1 at 
telomeres. These results were reproduced when TRF1 signals were divided into three 
categories base on TRF1 fluorescence intensity.  The category “A” indicates low signals of TRF1 
at telomere while “B” and “C” indicate medium and high signal, respectively.  
As expected we found increased numbers of low intensity TRF1 signals in mimic-miR-155 
transfected cells and higher numbers of high TRF1 signals in antago-miR-155 transfected cells 
(Fig. 3.3.9 A, right panel).  
The result was recapitulated in H1299 non–small lung carcinoma cells, that showed high 
endogenous levels of TRF1 and also high levels of endogenous miR-155 (Fig. 3.3.9 B,C). 
Importantly, miR-155 does not have an effect on the abundance  of TRF2 or POT1 at telomeres 
(Fig. 3.3.10 A,B).  
Together these results indicate that miR-155 dependent regulation of TRF1 expression does not 
alter global TRF1 levels but also directly controls the abundance of TRF1 at telomeres. This data 
is also indicative for an altered composition/structure of the shelterin complex, anticipating 
alterations in telomere homeostasis. 
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Figure 3.3.9: Regulation of TRF1 mediated by miR-155 at telomere. A) Quantitative immunofluorescence for TRF1 on 
SK-BR-3 cells transfected with the indicated mimic-miRNAs or siRNAs; representative images (Top panel). TRF1 
fluorescence intensity analyzed for each telomere (Bottom left). Individual telomere signal intensities were 
categorized in three subgroups (Bottom right). N=number of independent experiments; n=total signals analyzed; at 
least 20 nuclei were analyzed. a.f.u.= arbitrary fluorescence units. B) Quantitative immunofluorescence for TRF1 on 
H1299 cells transfected with the indicated mimic-miRNAs or siRNAs. p-values and SDs are indicated. 3 independent 
experiments was performed; n=total signals analyzed; N= number of nuclei were analyzed. a.f.u.= arbitrary 
fluorescence units. C) miR-155 expression in different cancer cell lines was performed by RT-PCR; miR-155 expression 
was normalized against RNU46.  
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Figure 3.3.10: miR-155 does not affect TRF2 and POT1 at telomere. Quantitative immunofluorescence for TRF2 (A)  or 
POT1 (B) on SK-BR-3 cells transfected with the indicated mimic-miRNAs siRNAs. Top panels: quantification of TRF2 (A)  
or POT1 (B) for each individual telomere signal; bottom panels: representative images. Arbitrary fluorescence units 
(a.f.u.) for TRF2 or POT1 abundance are shown. 3 experimental replicas were analyzed; N= number of nuclei; n=total 
signals analyzed; medium values and standard deviation are indicated; a student t-test was used to calculate statistical 
significance; p-values are shown. 
 
3.3.6 miR-155 dependent regulation of TRF1 impacts on telomere length regulation and 
DNA damage  response. 
TRF1 was the first component of Shelterin identified in mammals (Zhong Z. et al. 1992, Chong L. 
et al. 1995). Long-term overexpression of TRF1 in telomerase positive tumor cells showed a 
progressive telomere shortening. Conversely, telomere elongation was induced by expression 
of a dominant-negative TRF1 (van Steensel B. and de Lange T. 1997). Moreover, mice with 
transgenic TRF1 expression caused a gradual decrease in telomere length (Munoz P. et al. 
2009). Together this indicates that TRF1 acts as a negative regulator of telomere length.  
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TRF1 plays also a protective role on telomere preventing the recognition of chromosome ends 
by DNA damage factors. In line with this, loss of TRF1 in mouse model showed activation of 
DNA damage pathway and increase of telomere fragility (Munoz P. et al. 2009). 
Consequently we wished to investigate whether miR-155-dependent regulation of TRF1 
expression has an impact on telomere length and telomere function. We transiently transfect 
telomerase expressing SK-BR-3 breast cancer cells with mimic-miR-155 or with a TRF1-specific 
siRNA pool. After 2 consecutive rounds of transfection a quantitative telomere-FISH was 
performed on interphase cells. Fluorescence intensity from telomeres has been analyzed with 
telo-TFL program to obtain a length distribution in experimental cells.  
We found that mimic-miR-155 significantly increased a telomere length respect to mimic-
control. In agreement with this data we found same effect in TRF1-specific siRNA cells (Fig. 
3.3.11 left panel). These results were reproduced when telomeric signals were divided into 
three categories base on telomeric fluorescence intensity.  The category “A” indicates low 
telomere signals while “B” and “C” indicate medium and high signal, respectively.  
As expected we found increased numbers of high intensity telomere signals in mimic-miR-155 
transfected cells that is similar to the positive control (siTRF1) transfected cells (Fig. 3.3.11 right 
panel).  
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Figure 3.3.11: miR-155 induce telomere elongation by targeting TRF1.Telomere length measurements were 
performed by quantitative telomere DNA FISH on interphase cells, after repeated transfection of SK-BR-3 cells with 
the indicated mimic miRNA siRNAs. Representative images (Top panel). Telomere fluorescence intensity analyzed 
for each telomere (Bottom left). Individual telomere signal intensities were categorized in three subgroups 
(Bottom right). p-values and SDs are indicated. N=number of independent experiments; n= total signals analyzed; 
at least 20 nuclei were analyzed. Arbitrary fluorescence units (a.f.u.). 
 
 
To validate this data in long term experiments we generated SK-BR-3 cells ectopically 
expressing miR-155 from a miR-155 minigene. 
SK-BR-3 cells over-expressing miR-155 show 70x upregulation of mature miR-155 compared to 
control vector cells (Fig. 3.3.12 A). As expected, miR-155 over-expressing cells show a 50% 
reduction of TRF1 protein levels (Fig. 3.3.12 B) without impacting on TRF1 and TRF2 mRNA 
levels (Fig. 3.3.12 C,D). 
Subsequently, we performed quantitative telomere DNA FISH using SK-BR-3 over-expressing 
miR-155.  
As demonstrated in transient experiments, telomere length regulation mediated by miR-155-
dependent regulation of TRF1 was recapitulated using SK-BR-3 stably over-expressing miR-155 
from miR-155 mini gene (Fig. 3.3.12 E, left panel). These results were reproduced when 
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telomeric signals were divided into three categories base on telomeric fluorescence intensity.  
The category “A” indicates low telomere signals while “B” and “C” indicate medium and high 
signal, respectively.  
As expected we found increased numbers of high intensity telomere signals in stably over-
expressing miR-155 compared to the control miR-vector (Fig. 3.3.12 E, rigth panel).   
 
The Shelterin component TRF1 has a role in protecting chromosome ends from exonuclease 
activity and DNA damage repair factors. In fact, loss of TRF1 is liked with impaired telomere 
function leading to the activation of DNA damage response (Sfeir A. et al. 2009; Martinez P. et 
al. 2009). TRF1-deleted mouse cells display increase number of DNA damage foci at telomere. 
DNA damage foci that mark short or dysfunctional telomeres, are known as TIFs (Telomere 
damage induced foci) (d’Adda di Fagagna F. et al. 2003; Takai H. et al. 2003), Further, loss of 
TRF1 led to the phosphorylation of upstream factors such as ATM, ATR and downstream 
checkpoint kinases Chk1 and Chk2 (Martinez P. et al. 2009). Together this, demonstrates that 
TRF1 protects telomeres from eliciting a DNA damage response. 
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Figure 3.3.12: SK-BR-3 stably overexpressing miR-155 from a mini gene. A) Expression of miR-155 was  determined by 
quantitative Taqman real-time PCR. miR-155 levels were quantified versus RNU46. B) Ectopic miR-155 reduces TRF1 
protein expression; actin was used as loading control. TRF1 protein levels were normalized versus actin. Top panel: 
quantification of TRF1 down-regulation. Bottom panel: representative western blotting of cell lines described in (A). C-
D) Ectopic miR-155 in cells described in (A) does not alter TRF1 (C) or TRF2 (D) mRNA levels, as determined by 
quantitative real-time PCR. Expression levels were normalized versus actin. E) Ectopic miR-155 mediates telomere 
elongation in SK-BR-3  described in (A); as determined by quantitative telomere DNA-FISH on interphase cells. Left 
panel: telomere fluorescence intensity for each telomere is indicated, red lines indicate media, medium values and 
standard deviations are indicated. Right panel: individual telomere signal intensities were categorized in 3 subgroups 
according to a.f.u. (A, 0-1500; B, 1500-4000; C, >4000).  A-D) n= number of independent stable cell lines. E) N= number 
of nuclei analyzed; n= total number of signals analyzed; 4 experimental replicas were analyzed, a.f.u=arbitrary 
fluorescence units. A-E) A student t-test was used to calculate statistical significance; p-values are shown. 
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Given the role of TRF1 in protecting chromosome end we wished to investigate whether miR-
155 dependent regulation of TRF1 expression could alter telomere function. To demonstrate 
this hypothesis we transiently transfected luminal MCF-7 and SK-BR-3 breast cancer cell lines 
with mimic- or antago-miR-155 and performed western blotting to analyzed major markers of 
the DNA damage response. We found that in both cell lines γH2AX protein levels appears 
increased upon transfection with mimic-miR-155 (Fig. 3.3.13 A,B left panel). This suggest that 
miR-155 induces the activation of DNA damage response.  
Moreover, other important factors such as ATM/ATR, CHK1/CHK2 and phospho-p53 (Ser15) are 
linked  with DNA damage response and other genomic aberration to trigger DNA damage 
repair.  
Importantly, we found that ectopic introduction of miR-155 induced activation and 
phosphorylation of ATM and ATR in both MCF-7 and SK-BR-3 breast cancer cell lines. As 
expected, the downstream DNA damage checkpoint kinases Chk1 and Chk2 were hyper 
phosphorylated in miR-155 transfected cells (Fig. 3.3.13 A,B left panel).   
In line with the activation of DNA damage response, MCF-7 that express wild-type p53 show a 
strong activation of p53 (ser15) in ectopic mimic-miR-155 condition (Fig. 3.3.13 A left panel). 
SK-BR-3 that express mutant p53 do not show a significant increase of this marker, probably 
due to the already high basal level of phospho-p53 (ser15) in this cell line (Fig. 3.3.13 B left 
panel). 
This experiment show that miR-155 plays a key role in controlling the DNA damage response 
pathway in luminal breast cancer cell. 
To understand if the increased of DNA damage is fueled by an accumulation of dysfunctioned 
telomeres, we performed γH2AX immunofluorescence combined with telomere DNA FISH on 
MCF-7 and SK-BR-3 cells, transfected with mimic- or antago-miR-155. Successively, we analyzed  
the frequency of localization levels of γH2AX with telomeres. We found that ectopic 
introduction of miR-155 increased the percentage of TIFs in both cancer cell lines when 
compared to control cells (Fig. 3.3.13 C,D right panel). Importantly, antago-miR-155 significantly 
reduce TIF frequency in both MCF-7 and SK-BR-3 cell lines (Fig. 3.3.13 C,D right panel).  
As expected, specific TRF1 siRNA induce an increase of TIFs compared to control cells (Fig. 
3.3.14 A)  
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Figure 3.3.13: miR-155 dependent regulation of TRF1 induce DNA damage response at telomere. A-B) Ectopic 
introduction of miR-155 induces DNA damage signaling in MCF-7 (A)  and SK-BR-3 (B) cells. Representative images 
are shown; actin and/or lamin A/C was used as loading control. Arrowheads= specific bands. C-D) Ectopic 
introduction of miR-155 in MCF-7 (C) and SK-BR-3 (D) cells induces DNA damage at telomere as demonstrated by 
co-localization of H2AX with telomeres in immunotelomere FISH experiments. N= number of independent 
experiments; n= number of nuclei analyzed; C–D) a Student t test was used to calculate statistical significance; p-
values are shown. 
 
 
To validate our results we determined TIF frequency in MCF-7 ectopically expressing miR-155 
from an introduced miR-155 mini gene. 
MCF-7 over-expressing miR-155 show more than 100x upregulation of mature miRNA when 
compared to control vector cells (Fig. 3.3.14 B). As expected, miR-155 over-expressing cells 
show a reduction of TRF1 protein levels (Fig. 3.3.14 C). We further found that ectopically over-
expression of miR-155 significantly increases co-localization events of γH2AX with telomere 
signals (Fig. 3.3.14 D).  
This indicates that miR-155 dependent regulation of TRF1 modulates telomere function in 
luminal breast cancer cells. 
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Together our data show that miR-155 modulates Shelterin composition at telomere by 
controlling TRF1 expression. A modulation of TRF1 levels leads to telomere length alterations 
and impacts on telomere function. This identify miR-155 as novel telomere regulator. 
 
 
 
 
Figure 3.3.14: Reduction of TRF1 protein levels induces telomere dysfunction. A) Transfection of SK-BR-3 cells with 
a TRF1 specific siRNA pool results in an increased abundance of dysfunctional telomeres. H2AX immunostaining 
combined with telomere DNA FISH was used (Telomere Dysfunction-Induced Focus  (TIF) frequency). B) Stable 
MCF-7 overexpressing a miR-155 mini-gene display increased levels of mature miR-155, as determined by Taqman 
real-time PCR. miR-155 expression levels were normalized to RNU-46. C) Stable cells described in (B) show reduced 
TRF1 protein expression, as determined by western blotting. Actin was used as a loading control. D) Increased 
telomere dysfunction in MCF-7 described in (B). H2AX immunostaining combined with telomere DNA FISH was 
used (Telomere Dysfunction-Induced Focus  (TIF) frequency). n= number of nuclei analyzed; N= number of 
experimental replicas. A student t-test was used to calculate statistical significance; p-values are shown. 
 
 
3.3.7 miR-155 drives telomere fragility and chromosome instability 
Several studies demonstrated that TA-rich or GC-rich sequences can lead to the formation of 
secondary structure during the replication (Barlow J.H. et al 2013). Telomere TTAGGG tandem 
repeats are GC-rich regions prone to form secondary structures (Wang Q. et al. 2011). Thus, the 
uncoupled action of DNA polymerase and helicases during DNA replication can lead to telomere 
fragility. Replication stress or oncogenic stress are the main causes of this phenotype that can 
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finally lead to chromosome breakage generating amplification or deletion events that promote 
cancer formation and progression (Barlow J.H. et al. 2013). 
Tandem telomeric TTAGGG repeats have been demonstrated to form G-quadruplex structures 
(G4) or form the so called T-loop structure at the end of telomere (Wang Q. et al. 2011; Doksani 
Y. 2013). These structures can impede DNA polymerase  and induce DNA replication stress and 
telomere fragility. At telomeres TRF1 promotes telomere replication and suppresses telomere 
fragility in mouse (Sfeir A. et al. 2009; Martinez P. et al. 2009). Thus we ask whether miR-155 
can impact on telomere replication by altering TRF1 abundance at telomeres.  
Fragile telomeres can be indentify by telomere DNA FISH and are characterized by an abnormal 
telomere shape or multitelomeric signals. This phenotype is also observed in ATR-deficient cells 
or as a consequence of treatment with aphidicolin, a DNA polymerase inhibitor.  
 
To demonstrate a role of miR-155 in controlling telomere fragility, we transiently transfected 
SK-BR-3 with mimic- or antago-miR-155. Cells were blocked in metaphase 3 days post 
transfection and were subjected to telomeric DNA FISH. Telomeres with an abnormal shape of 
multitelomeric signal were considered as fragile telomere (Fig. 3.3.15 A). We found that ectopic 
miR-155 significantly increases telomere fragility. In contrast, antago-miR-155 suppress the 
fragility compared to control cells (Fig. 3.3.15 B). In line with this TRF1-specific siRNA pool 
recapitulated the effect of ectopic miR-155 (Fig. 3.3.15 C).  
Importantly, data from acute miRNAs transfection experiments were reproduced in SK-BR-3 
cells stably expressing miR-155 (Fig. 3.3.15 D).  
All together these data suggest that telomere fragility is miR-155 dosage sensitive. 
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Figure 3.3.15: miR-155 drives telomere fragility in breast cancer cell line. A) Representative images of fragile 
telomeres characterized by multiple telomere signals. B-C) frequency of telomere fragility in SK-BR-3 cells 
transfected with mimic-miR-155 or antago-miR-155 siRNAs. TRF1 specific siRNA pool was used as positive control.  
For analysis telomere DNA FISH was used. D) Frequency of telomere fragility in SK-BR-3 cell line stably over-
expressing miR-155. N= number of metaphases spreads analyzed; n= number of analyzed chromosomes. At least 
three experimental replicas were analyzed. A Student t-test was used to calculate statistical significance; p-values 
are shown. 
 
 
We next wished to exclude that the effect of miR-155 on telomere fragility is caused by non-
specific interaction of miR-155 with proteins involved in the suppression of telomere fragility.  
We consequently asked whether combined transfection of miR-155 and siTRF1 causes 
aggravation of telomere fragility. We transiently transfected SK-BR-3 with a combination of 
mimic-miR-155 and TRF1-specific siRNA. Assessing of telomere fragility by DNA FISH, we found 
that the combination of ectopic miR-155 with siTRF1 did not augment the telomere fragility 
respect to single siTRF1 or miR-155 siRNA transfection. miR-155 driven reduction of TRF1 
protein expression has been verified by western blotting (Fig. 3.3.16 A).  
This suggests that mimic-miR-155 and TRF1-specific siRNA act on the same pathway controlling 
telomere fragility.  
 
 
 
 
97 
 
 
 
Figure 3.3.16: miR-155 drives telomere fragility by targeting of 3’-UTR-TRF1. A) Percentage of fragile telomeres in 
SK-BR-3 cells after transient transfection of mimic-miR-155 in combination with TRF1 siRNAs. Bottom: TRF1 levels 
in experimental samples. Actin was used as a loading control. B) Percentage of fragile telomeres in SK-BR-3 cells 
co-transfected with Flag-tagged TRF1 and mimic-miR-155. Telomere fragility induced by miR-155 is rescued by co-
introduction of Flag-tagged TRF1. Bottom panel: anti-TRF1 Western blotting of samples in (B). C) Reported 
suppressors of telomere fragility do not contain miR-155 target sites, as determined by Targetscan target 
prediction analysis (http://www.targetscan.org/). Top 1000 predicted miR-155 target genes were considered for 
the analysis; target site conservation was not considered in the in silico analysis. 
 
 
Moreover, co-transfection of SK-BR-3 cell lines with mimic-miR-155 siRNAs and an expression 
vector encoding flag-tagged TRF1 lacking the respective 3’-UTR rescued telomere fragility 
driven by miR-155 (Fig. 3.3.16 B).  
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Finally, we wished to exclude that telomere fragility is triggered by miR-155 targeting of 
alternative regulators of fragility. We performed a miR-155 prediction analysis using TargetScan 
software of the following genes: ATR, BLM, BRCA2, NTH1, RAD51, RAP1, RECQL4, RTEL1, SLX4, 
STN1 and TPP1 which play an important role in suppression of fragility (McNees C.J. et al. 2010; 
Barefield C. et al.2012; Badies S. et al. 2010; Vallabhaneni H. et al. 2013; Martinez P. et al. 2010; 
Ghosh A.K. et al. 2012; Deng Z. et al. 2013; Vannier J-B. et al. 2013; Wilson J.S. et al. 2013; 
Huang C. et al.2012; Tejera A.M et al. 2010).  
We found that all reported suppressors of telomere fragility lacked target sites for miR-155 (Fig. 
3.3.16 C).  
Altogether, these experiments demonstrate that miR-155 drive telomere fragility by specifically 
targeting TRF1. 
We next wished to test wheter miR-155 modulates telomere fragility caused by inhibition of 
DNA polymerase by the drug aphidicolin. 
To link miR-155 with a role in controlling telomere replication, we modulated miR-155 levels in 
the contest of DNA aphidicolin. 
Aphidicolin is a DNA polymerase inhibitor that binds at or near the nucleotide-binding site of 
enzyme blocking its activity (Baranovskiy A.G. et al. 2014). 
 
Cells treated with aphidicolin show aberrant structures in metaphase chromosomes that 
resemble CFSs and are called fragile telomeres (Sfeir A. et al. 2009; Martinez P. et al. 2009).  
In particular we were interested in investigating if antagonizing endogenous miR-155 levels  
could modulate fragile telomere phenotype in the contest of aphidicolin. To test this we 
transiently transfected SK-BR-3 with mimic-control or antago-miR155, and subjected cells to an 
aphidicolin treatment. Subsequently, the fragility of telomeres was analyzed by telomere DNA 
FISH. As expected we found that aphidicolin increase telomere fragility in cells transfected with 
mimic-control (Fig. 3.3.17 A). Importantly, telomere fragility is significantly reduced by antago-
miR-155  (Fig. 3.3.17 B) . Moreover, antago-miR-155 in combination with aphidicolin reduced 
telomere fragility to levels observed in untreated, control miRNA-transfected cells  (Fig. 3.3.17 
B).  
Together this indicates that the introduction of antago-miR-155 protects aphidicolin-induced 
telomere fragility by increasing the expression of TRF1. This highlights the role of miR-155 in 
the control of telomere fragility by regulating TRF1 expression. 
99 
 
 
 
 
 
Figure 3.3.17:  Inhibition of endogenous miR-155 rescue telomere fragility. A) Frequency of telomere fragility in SK-
BR-3 cells transfected with mimic-miR-control and treated or untreated with Aphidicolin. B) Telomere fragility in 
SK-BR-3 cells transfected with miR-155 inhibitor and treated or untreated with Aphidicolin. N= number of 
metaphases spreads analyzed; n= number of analyzed chromosomes. At least three experimental replicas were 
analyzed. A Student t-test was used to calculate statistical significance. p-values are shown. 
 
 
During analysis of methaphase spreads we observed an increase frequency of sister telomere 
fusion in SK-BR-3 cells while other alteration (Fusion with or without telomeric signal, breaks 
and complex fusions) were not altered (Fig. 3.3.18 A). Importantly, the combination of 
transfection of miR-155 and vector encoding Flag-tagged TRF1 rescued the telomere sister 
chromatid fusion phenotype (Fig. 3.3.18 A). This excludes that miR-155 off target effects 
mediate telomere sister chromatid fusions. Remarbably, we found that aphidicolin treatment 
increases telomere sister chromatid fusions.  
Consequently we wished to test whether telomere sister chromatid fusion mediated by 
aphidicolin treatment can be rescued by increasing TRF1 using antago-miR-155. Transient 
transfection of antago-miR-155 reduced telomere sister chromatid fusions and also protects 
telomere from telomeric sister chromatids driven by Aphidicolin (Fig. 3.3.18 B, C). 
This result indicates that miR-155 drive telomere sister chromatid fusion by targeting TRF1.  
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Figure 3.3.18: miR-155 induce genomic instability by targeting of 3’-UTR-TRF1. A) Increased frequency of telomeric 
sister chromatid fusions induced by miR-155 is rescued by cointroduction of Flag-tagged TRF1 lacking the 
corresponding 3’-UTR in SK-BR-3 cells. Representative images are shown. B) Frequency of telomeric sister 
chromatid fusions in SK-BR-3 cells transfected with mimic-miR-control and treated or untreated with Aphidicolin. 
C) Frequency of telomeric sister chromatid fusions is reduced in SK-BR-3 cells transfected with antago-miR-155 and 
treated with Aphidicolin. N= number of metaphases spreads analyzed; n= number of analyzed chromosomes. At 
least three experimental replicas were analyzed. A Student t-test was used to calculate statistical significance. p-
values are shown. 
 
 
Altogether, we show that miR-155-dependent regulation of TRF1 is an efficient mechanism to 
control telomere fragility and genomic instability in human breast cancer cells. 
The consistent upregulation of miR-155 in breast cancer suggests that impaired telomere 
function is a central aspect of the oncogenic function of miR-155 that promotes genomic 
instability in human breast cancer and contributes to reduced distant metastasis-free survival 
and relapse-free survival in ER+ breast cancer. 
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3.4 Tumor-suppressor microRNAs by miR-296-5p and miR-512-5p repress 
telomerase in human breast cancer 
Upregulation of telomerase represents a key step in cancer formation. Consequently targeting 
telomerase is a promising strategy to fight human cancer. In line with this several clinical 
compunds such as GRN163L (Imetelstat), GV1001, BIBR1532, RHPS4, have been studied in pre-
clinical experiments and in clinical trials such as in pancreatic cancer. Currently GRN163L 
(Imetelstat) and GV1001 have been tested in clinical trials (Burchett K.M. et al. 2014; Middleton 
G. et al. 2014; Bashash D. et al. 2013). 
The aims of this project is to identify miRNAs that target telomerase in human breast cancer. 
Identifying endogenous miRNA dependent pathway of telomerase regulation is expected to 
provide insight into the regulation of telomerase expression that can offer new inroads in 
identifying  novel telomerase based anti-cancer strategies.  
We wished to indentify miRNAs with target specificity to 3’UTR of hTERT telomerase 
component, understand their cellular mechanism of action, investigate the clinical relevance 
and control of expression.  
 
3.4.1 Candidate miRNAs miR-296-5p and miR-512-5p are downregulated in human breast 
cancer 
The high throughput luciferase screening using the 3’UTR-TERT luciferase reporter reveled 8 
miRNAs (miR-541, miR-637, miR-1207-5p, miR-16-1*, miR-661, miR-608, miR-296-5p, miR-512-
5p) candidates that passed the selection criteria of our luciferase reporter screen (Fig. 3.1.4). All 
candidate miRNAs were found dysregulated in cancer; remarkably the majority of miRNAs 
represented by miR-1207-5p, miR-661,  miR-608, miR-296-5p, miR-512-5p are commonly 
downregulated in cancer promoting tumor formation and  progression (Zhang J.F. et al 2011; 
Zhang Y. et al. 2014; Chen L. et al. 2014; Vaira V. et al. 2012; Wei J-J et al. 2011; Robson J.E. et 
al. 2012; Saito Y et al. 2009; Adi Harel S. et al. 2015). 
Given that reactivation of telomerase expression is a hallmark of human cancer (Shay J.W. and 
Bacchetti S. 1997), we focused our attention on miRNAs that are downregulated in human 
cancer and thus allow improved telomere maintenance and protection from apoptosis by 
increased telomerase expression. 
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Focusing on breast cancer as model system in our study we found that miR-296 and miR-512 
were significantly downregulated in breast cancer tissue compared to peritumoral tissue (data 
not shown). 
To obtain better insights into a possible clinical relevance of these miRNAs we studied 
candidate miR-296-5p and miR-512-5p expression using the METABRIC dataset, that links 
mRNA and miRNA expression with clinical data of 995 primary breast tumor (Curtis C. et al. 
2012).  
In line with our small data set, we found that miR-296-5p and miR-512-5p showed significant 
downregulation across various subtypes of human breast cancer in the METABRIC data set(Fig. 
3.4.1 A,B).  
Remarkably absolute miR-296-5p expression levels are higher than miR-512-5p levels. 
 
 
Figure 3.4.1: Expression levels of miR-296-5p and miR-512-5p in human breast cancer. A-B) METABRIC datasets 
were used to analyze the expression of miR-296-5p (A) and miR-512-5p (B)  in human breast cancer subtypes and 
normal breast tissue. p-values are shown. 
 
3.4.2 miR-296-5p and miR-512-5p have a role in human cancer 
miR-296-5p is encoded by the the lincRNA Nespas that is transcribed from parental allele of the 
imprinted GNAS cluster located at chromosome 20q13.3 (Robson J.E. et al. 2012). Various 
biological functions have been attributed to miR-296-5p such as cancer progression, metastasis, 
neo-vascularization, the control of stem cell self-renewal, hepatocyte lipoapoptosis but also the 
repression of enterovirus replication (Vaira V et al. 2012, 2013; Tay Y. et al. 2008; Würdinger T. 
et al. 2008; Cazanave S.C. et al. 2011; Wei J-J et al. 2011). In human cancer,  miR-296-5p 
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expression has been observed to be reduced during tumor progression. In particular miR-296-
5p downregulation has been observed in different types of primary and metastatic lesions  such 
as colorectal, breast, lung,  parathyroid, liver and bile ducts cancers (Vaira V. et al. 2012, 2013; 
Tay Y. et al. 2008; Würdinger T. et al. 2008; Cazanave S.C. et al. 2011; Robson J.E. et al. 2012; 
Wei J-J. 2011). Good insight into the molecular function of miR-296-5p comes from breast 
cancer cell models. In particular, miR-296-5p impairs the expression of Scrib that controls cell 
mobility and polarity-cell plasticity thereby limiting cell migration and tumor cell invasiveness 
(Vaira V. et al. 2012). In line with this miR-296-5p downregulation was linked to breast cancer 
progression and metastasis (Savi F. et al. 2014). 
In addition, miR-296 and its targets, the oncogenic protein HMGA1, show inverse correlation of 
expression in prostate cancer. HMGA1 is overexpressed in prostate cancer and represents a 
main cause of chromosomal instability. Ectopic miR-296 expression down-regulates HMGA1 
leading to a significant reduction of prostate cancer cell proliferation and invasion (Wei J-J. et 
al. 2011). 
The other validated target genes of miR-296-5p include different types of proteins such as 
IKBKE, a member of the IKK family, that has a known role in innate immunity, or HWNK4 a 
protein involved in ion transport (Mao J. et al. 2010; Robson J.E. et al. 2012). Moreover, HGS 
(hepatocyte growth factor-regulated tyrosine kinase substrate) was found to be regulated by 
miR-296. Importantly, HGS is involved in the regulation of growth factors receptors, such as 
PDGFR-β and VEGFR2 (Ewan L.C. et al. 2006; Würdinger T. et al. 2008; Takata H. et al. 2000). In 
addition, the interstitial collagenase Matrix metalloproteinase-1 (MMP1), MAP2K3, a 
participant of the MPA kinase signaling cascade, and the proapoptotic protein PUMA are 
validated targets of miR-296-5p (Cazanave C.S. et al. 2011). 
Together miR-296-5p is a pluripotent miRNA that has as tumor suppressive function in human 
cancer. 
Two intergenic miRNA genes, miR-512-1 and miR-512-2, that are localized in a distance of 2395 
nt from each other on chromosome 19, encode for mature miR-512-5p.  
miR-512-1 and miR-512-2 are localized in vicinity to the Alu repeats and are subjected to 
epigenetic silencing in gastric cancer cells. Treatments of cells with inhibitors of DNA 
demethylation or HDACs result in the activation of miR-512-5p expression (Saito Y. et al. 2009). 
 Similar to miR-296, miR-512-5p has been observed to be downregulated in lung cancer. 
Treatment of lung cancer cells with inhibitors of DNMTs or HDAC increased the expression of 
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miR-512-5p increasing sensitivity to cisplatin (Adi Harel S. et al. 2015). Moreover, gastric cancer 
cells showed augmented apoptosis rates and inhibition of cell migration upon reactivation of 
miR-512-5p expression. Together, this indicates a tumor suppressive role after treatment with 
DNMT inhibitor (Adi Harel S. et al. 2015). 
Validated target genes of miR-512-5p represent Mcl-1 and TEAD4. MCL-1 is an important 
oncoprotein with a anti-apoptotic function while TEAD4 mediates the activity of the 
transcriptional co-activator YAP (Saito Y. et al. 2009; Adi Harel S. et al. 2015). 
Thus, the epigenetic regulation results essential to reactivate silenced miR-512-5p impairing 
cancer progression.   
Summarizing, epigenetic silencing of miR-512-1 and miR-512-2 promotes human cancer 
progression by reducing susceptibility to apoptosis and chemotherapeutic agents. 
 
 
3.4.3 miR-296-5p and miR-512-5p target the 3’-UTR of TERT to induce mRNA degradation 
Sequence analysis of the 3’UTR of TERT revealed  three predicted target region for miR-296-5p,   
located at nucleotides 59-94, 457-495 and 456-494; a single target site for miR-512-5p was 
localized at nucleotides 141-177 (Fig. 3.4.2 A). Given the large sequence variability in the TERT 
3’UTR between different species, target sites for miR-296-5p and miR-512-5p are exclusively 
found in human and chimpanzee.   
 
To directly demonstrate the interactions between miR-296-5p or miR-512-5p and their 
predicted target sites, we generated a human TERT 3’UTR reporter constructs carrying 
deletions for individual miR-296-5p or miR-512-5p target sites. We generated three mutants for 
miR-296-5p target sites: the first mutant is located at position ∆83-85, the second includes the 
two target sites located at ∆479-481 and the last mutant represents a combination of the 
previous two deletions and is referred to as ∆83-85, 479-481.  
To validate targeting of hTERT by miR-512-5p we generated a deletion in the hTERT 3’UTR 
covering the miR-512-5p target site at position 168-170 (∆168-170). 
To demonstrate target specificity, we transiently transfected HeLa cells with wild-type (wt) or 
individual TERT 3’UTR mutants in combination with either mimic-control or respective mimic-
miRNA siRNAs. Three days post-transfection, luciferase reporter activity was measured. We 
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found that mimic-miR-296-5p siRNAs efficiently reduced wt TERT 3’UTR luciferase reporter 
activity (Fig. 3.4.2 B). In contrast, deletions of miR-296-5p target sites (∆83-85; or ∆479-481) 
increase the luciferase reporter activity compared to the wild-type reporter construct. 
Importanly, deleting both miR-296-5p target sites further increase luciferase activity, rendering 
the reporter resistant to targeting by miR-296-5p (Fig. 3.4.2 B). 
In analogous experiments involving miR-512-5p, we found that luciferase reporter activity is 
significantly increased upon deletion of the miR-512-5p target site (3’-UTR-TERT ∆168-170) (Fig. 
3.4.2 C). 
Together, this demonstrate the target specificity of miR-296-5p and miR-512-5p for the human 
3’-UTR of TERT. 
 
 
Figure 3.4.2: Specific target sites for miR-296-5p and miR-512-5p in the 3’-UTR of TERT. A) Alignment of miR-296-
5p and miR-512-5p with respective target sites in the 3’UTR of hTERT, positions are shown. B) Co-transfection of 
mimic-miR-296-5p and wt 3’UTR of TERT or specific delition (∆83-85; ∆479-481; ∆83-85, 479-481) of 3’UTR of TERT 
in HeLa cells. Three days post-transfection luciferase activity was measured by dual luminometry. Ratios of 
Renilla/firefly luciferase activity <100 indicates target specificity. C) Co-transfection of mimic-miR-512-5p and wt 
3’UTR of TERT or specific a mutant (∆168-170) of 3’UTR of TERT in HeLa cells. Three days post-transfection 
luciferase activity was measured by dual luminometry. Ratios of Renilla/firefly luciferase activity <100 indicates 
target specificity. n= number of independent experiments. A student t-test was used to calculate statistical 
significance; p-values are shown. 
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3.4.4 miR-296-5p and miR-512-5p downregulate telomerase activity 
After testing the effect of miR-296-5p and miR-512-5p on 3’-UTR of TERT in luciferase reporter 
assays, we wanted to evaluate the effect of miR-296-5p and miR-512-5p on telomerase activity 
in cancer cells.  Telomerase positive MCF-7 breast cancer cells were transiently transfected with 
mimic-control,mimic-miR-296-5p or mimic-miR-512-5p siRNAs and telomerase activity was 
determined by applying the telomere repeat amplification (TRAP) protocol three days post-
transfection. As control MCF-7 cells were transfected with siRNAs that specifically target hTERT.  
Three different dilutions (100 ng, 50 ng, 25 ng)  of protein extract have been subjected to TRAP 
in order to better appreciate difference in telomerase activity between the replicas (Fig. 3.4.3 
A). Importantly, we found that ectopic miR-296-5p and miR-512-5p significantly reduced 
telomerase activity. 
To understand whether miR-296-5p and miR-512-5p target hTERT expression on the 
transcriptional or post-trasncriptional level, we transiently transfected MCF-7 with mimic-miR-
296-5p, mimic-miR-512-5p siRNAs or the respective antago-miRNAs and measured hTERT 
expression 3 days post-transfection by quatitative RT-PCR. In line with the TRAP experiment  we 
found that mimic-miRNAs causes a significantly reduction of TERT mRNA while the treatmet 
with antago-mimic-miRNAs increases TERT mRNA expression with respect to the control (Fig. 
3.4.3 B,C). 
Together, these results demonstrate that miR-296-5p and miR-512-5p act as novel regulators of 
telomerase activity that target the 3’-UTR of hTERT to induce mRNA degradation. 
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Figure 3.4.3: miR-296-5p and miR-512-5p regulate telomerase activity. A) MCF-7 were transiently transfected with 
mimic-miR-296-5p, mimic-miR-512-5p  or TERT specific siRNAs. TRAP (telomere repeat amplification protocol) assay 
was performed three days post transfection. Representative image of TRAP assay in MCF-7 cell line (A, left panel); 
protein concentration (100 ng, 50 ng, 25 ng) used are shown; h.i.= heat inactivated; TRS8= positive control. Mimic-
miRNAs or siRNAs are shown (A, left panel). Telomerase activity quantification of MCF-7 cells transfected with the 
indicated mimic-miRNAs or siRNAs. miR-296-5p and miR-512-5p reduce telomerase activity (right panel).  B-C) hTERT 
expression in MCF-7 cells transfected with mimic-miRNAs or siRNAs (C) and with antago-miRNAs (D) as described. 
miR-296-5p and miR-512-5p induce TERT mRNA degradation. n= number of independent experiments. A student t-
test was used to calculate statistical significance; p-values are shown.  
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3.4.5 Relevance of TERT, miR-296-5p and miR-512-5p  in human breast cancer 
Telomerase has high relevance in human cancer. In fact, almost  90% of human cancers present 
a reactivation of telomerase activity (Shay J.W. and Bacchetti S. 1997). Reactivation of 
telomerase expression protects from critical telomere shortening, thus protecting cells from 
entering into a telomere loss of function situation  that is linked with cellular senescence or 
apoptosis. Consequently, hTERT has high relevance in ensuring unlimited proliferation of tumor 
cells (Bernardes de jesus B. and Blasco M.A. 2013).  
Moreover telomerase component hTERT has a general role in antagonizing apoptosis. In fact, 
downregulation of endogenous hTERT protein by RNAi increased apoptosis induced by  Bcl-
2/Bcl-xL antisense oligonucleotide or by the Bcl-2 inhibitor (HA14-1) in breast cancer cells (Del 
Bufalo D. et al. 2005). In addition, cervical cancer cells treated with HDACi (TSA or SAHA) 
showed a brief hTERT upregulation followed by down-regulation of hTERT with consequent 
induction of apoptosis and cell growth arrest (Wu P. et al. 2005). Importantly, the over-
expression of a dominant negative of  hTERT in cancer cells strongly increased apoptosis 
induced by HDAC inhibitors, demonstrating an anti-apoptotic role of hTERT in a 
chemotherapeutic setting (Wu P. et al. 2005). 
Before performing functional experiments we wished to find evidence that miR-296-5p/miR-
512-5p dependent regulation of TERT has clinical relevance in human breast cancer. 
 
3.4.5.1 Clinical relevance of miR-512-5p and miR-296-5p mediated regulation of TERT in 
breast cancer 
First we analyzed data set (KM plotter) of TERT mRNA expression in all breast cancer using a 
meta-data set comprising 1809 cancer patients (Gyorffy B. et al. 2010). 
We found that high TERT expression is linked with a significant reduction of distant metastasis 
free survival (DMSF) and relapse free survival (RFS) (DMSF_mixed) (p=0.0015) considering all 
breast cancer types (Fig. 3.4.4 A). DMSF is a temporal measure that describes the time period 
between the appearance of a primary tumor to the formation of metastasis in distant organs or 
lymphonodes. RFS is referred as to length of time after original (primary) tumor and the 
reappearance of a new tumor. 
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Interestingly, when studying the clinical relevance of hTERT for DMSF_mixed in breast cancer 
sub-types such as luminal A, luminal B and HER2+, we found that the link between high TERT 
expression and poor DMSF_mixed is limited to basal-type breast cancer (p=0.005) (Fig. 3.4.4 B). 
Basal breast cancer is the most aggressive breast cancer subtype, that contains p53 mutation 
and in most cases is classified as triple negative (ER-, PR-, HER2-) (Carey L.A. et al. 2006; 
Potemski P. et al. 2005; Koboldt D.C. et al. 2012).  In other principal breast cancer subtypes 
such as Luminal A, Luminal B, HER2+ and normal-like, hTERT does not impact on DMSF_mixed 
(data not shown). Importantly, these results were reproduced using the GOBO tools data set 
(Ringner M. et al. 2011), underlining the relevance of hTERT for basal-type human breast cancer 
(data not shown). In line with poor DMSF_mixed, hTERT expression is high in basal breast 
cancer (Fig. 3.4.4 C).   
Finally, multivariate analysis indicates that TERT acts as independent predictor of clinical 
outcome respect to standard clinical parameters such as lymph node status, tumor size or age 
in basal type of breast cancer. (Fig. 3.4.4 D). 
Together, this indicates that hTERT has a particular relevance for basal type breast cancer. 
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Figure 3.4.4: Clinical relevance of TERT expression in human breast cancer. A) Kaplan–Meier survival curve of time 
considering both distant metastasis-free survival and relapse-free survival (DMSF_mixed) of patients with different 
types of breast cancer. B) Kaplan–Meier survival curve of (DMSF_mixed) of patients with basal breast cancer. Red 
line= high TERT mRNA expression; gray line= low expression of TERT. Number of patients are indicated for each 
time point (A-B). C) mRNA data of TERT expression in different types of breast cancer. Number of patients for each 
subtypes is shown. D) Multivariate analysis showing that low TERT expression behaves as independent predictor of 
poor clinical outcome compared to standard clinical parameters. In the panel for each clinical variable and TERT 
expression, HRs (Hazard Ratio) and corresponding p- values calculated by Cox regression analysis are shown. HR= 
Hazard Ratio; p-values are shown. 
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3.4.5.2 miR-296-5p and miR-512-p target genes signature in human breast cancer 
miR-296-5p has been observed to interfere with several relevant cancer pathways such as 
epithelial to mesenchymal transition (EMT), cell mobility and apoptosis . We were consequently 
interested in testing the clinical relevance of alteration of miR-296-5p target gene expression in 
basal breast cancer. 
In order to test whether biological consequences caused by miR-296-5p up-regulation can 
mediate a benefit for breast cancer patients, we investigated the effect of high expression of 
predicted miR-296-5p target genes in basal breast cancer. 
For this analysis we chose a panel of validated miR-296-5p target genes that have a reported 
role in human cancer, comprising HMGA1, MMP1, MAP2K3, SCRIB, PUMA, IKBKE, HWNK4, and 
HGS (Vaira V. et al. 2012, 2013; Würdinger T. et al. 2008; Cazanave S.C. et al. 2011; Robson J.E. 
et al. 2012; Wei J-J. 2011; Mao J. et al. 2010).  Remarkably, we found that the expression of the 
miR-296-5p target gene signature is highest in basal type breast cancer and was liked with a 
significantly reduced DMSF_mixed across all tumors and basal breast cancer, using the breast 
cancer Meta-data set KM plotter (Fig. 3.4.5 A-C) (Gyorffy B. et al. 2010). Validating this result 
using the GOBO tool we again found that high expression of the miR-296-5p target genes 
signature is linked with a significantly reduction of distant metastasis free survival and relapse 
free survival (p=0.00001) across all breast cancer types (Ringner M. et al. 2011). This trend is 
also found in basal breast cancer (Fig. 3.4.5 D,E). However due to low sample number this 
correlation was slightly below the threshold of statistical significance (P=0,07) (low and high 
miR-296-5p target gene signature n= 40 patients and n=242 patients, respectively) (Fig. 3.4.5 E). 
An identical analysis was carried out for miR-512-5p. To date MCL1 is the only validated miR-
512-5p target gene. We thus included a panel of putative target genes with impact on human 
cancer in our miR-512-5p target gene signature. This panel of genes was generated using 
miRNA target prediction programs (miR-walk; miRanda; PITA; RNA hybrid) and consists of CD44, 
COPZ1, DBF4, LZTR1, MAPKAPK3, MN1. miR-512-5p target gene expression low across all 
cancers and is not significantly altered between different breast cancer subtypes (GOBO data 
set), suggesting a common mechanisms that ensures repression of miR-512-1 and miR-512-2 in 
breast cancer (Fig. 3.4.6 A) (Ringner M. et al. 2011). This is in line with a general downregulation 
of this miRNA in human cancer. 
We did not find correlation between expression of the miR-512-5p target gene signature (TERT, 
MCL1, CD44, COPZ1, DBF4, LZTR1, MAPKAPK3, MN1) and DMSF_mixed across all tumor 
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samples  (P=0,07) (Fig. 3.4.6 B) (KM plotter data set). In contrast, high miR-512-5p target gene 
expression that served as surrogate marker for miR-512-5p function resulted in a significant 
reduction of DMSF_mixed in basal type breast cancer (P=0,01)(KM plotter data set) (Fig. 3.4.6 
C) (Gyorffy B. et al. 2010). This suggests that miR-512-5p is functionally related to aggressive 
basal breast cancer. 
Gene expression analysis using the GOBO tool validated the trend from the  KM plotter data. 
Again, miR-512-5p did not correlate between expression of the miR-512-5p target gene 
signature and DMSF_mixed across all tumor samples (Fig. 3.4.6 D) (Ringner M. et al. 2011) but, 
high expression of miR-512-5p target genes signature is linked with a tendential reduction of 
distant metastasis free survival and relapse free survival in basal breast cancer (P=0,163) (Fig. 
3.4.6 E) (low and high miR-512-5p target gene signature n= 151 patients and n=131 patients, 
respectively). This is presumably due to the limited sample number. 
 
Together, data from miR-296-5p, miR-512-5p and related target gene signatures suggest that 
down-regulation of miR-296 and miR-512  is linked with poor prognosis in human breast 
cancer. Importantly, upregulation of miR-296-5p or miR-512-5p target gene expression 
signature, recapitulates reduced DMSF of basal breast cancer patients expressing high hTERT 
levels. This suggests that targeting of TERT by miR-296-5p is an integral component of a miR-
296-5p target genes signature that mediates poor prognosis in breast cancer by targeting TERT. 
We consequently focused functional experiments on basal breast cancer derived cell lines. 
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Figure 3.4.5: miR-296-5p signature in human breast cancer. A) mRNA expression of miR-296-5p  target genes 
signature in different types of breast cancer. Number of patients for each subtypes is shown. B-C) Validated miR-
296-5p target genes that form a miR-296-5p  signature with poor survival in all breast cancer (B) or in basal breast 
cancer subtype (C). Number of patients are indicate for each time point. D-E) Kaplan–Meier survival curve of miR-
296-5p target genes signature considering both distant metastasis-free survival and relapse-free survival 
(DMSF_mixed) of patients in human breast cancer (D) or basal breast cancer (E). Red line= high miR-296-5p target 
genes signature; gray line= low miR-296-5p target genes signature n= number of patients; HR= Hazard Ratio; p-
values are shown.  
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Figure 3.4.6: miR-512-5p signature in human breast cancer. A) mRNA expression of miR-296-5p target genes 
signature in different types of breast cancer. Number of patients for each subtypes is shown. B-C) predicted miR-
512-5p target genes that form a miR-512-5p signature in all breast cancer (B) or in basal breast cancer subtype (C). 
Number of patients are indicate for each time point. D-E) Kaplan–Meier survival curve of miR-512-5p target genes 
signature considering both distant metastasis-free survival and relapse-free survival (DMSF_mixed) of patients in 
human breast cancer (D) or basal breast cancer (E). Red line= high miR-512-5p target genes signature; gray line= 
low miR-512-5p  target genes signature.n= number of patients; p-values are shown.  
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3.4.6 miR-512-5p and miR-296-5p expression is low in basal breast cancer cell lines 
We  first wished to obtain insights into the expression of miR-296-5p and miR-512-5p in breast 
cancer cell lines derived from different subtypes of human breast cancer. Based on breast 
cancer gene expression data that anticipate a role for miR-296-5p and miR-512-5p 
preferentially in basal but not luminal breast cancer, we evaluated miR-296-5p, miR-512-5p or 
hTERT in basal (MDA-MB-231, MDA-MB-468, MDA-MB-157) or luminal (MCF-7, SK-BR-3, T47D) 
breast cancer cell lines by quantitative real-time PCR. We found that miR-296-5p was efficiently 
down-regulated in basal type cells  (∆CT: 7 in MDA-MB-231; 7,7 in MDA-MB-468; 6,4 in MDA-
MB-157) compared to the luminal cell lines (∆CT: -1,2 in MCF-7; 2,2 in SK-BR-3; 0,7 in T47D) 
(Fig. 3.4.7 A). In line with a very low expression of miR-512-5p across all human breast cancer 
types we found  low miR-512-5p levels across breast cancer cell lines (∆CT: 7,9 in MCF-7; 7,1 in 
SK-BR-3; 8 in T47D; 7,8 in MDA-MB-231; 7,8 in MDA-MB-468; 7,3 in MDA-MB-157) (Fig. 3.4.7B).  
We conclude that basal type breast cancer derived cell lines recapitulate low expression levels 
of miR-296-5p and mi-512-5p in basal breast cancers. This identifies basal breast cancer cell 
lines such as MDA-MB-231 as appropriate model system to study the effect of our miRNAs of 
interest on the cellular level. 
 
 
 
Figure 3.4.7: miR-295-5p and miR-512-5p expression in human breast cancer cell lines. A-B)  miR-295-5p (A) and miR-
512-5p (B) expression levels in luminal (MCF-7, SK-BR-3, T-47D) and basal (MDA-MB-231, MDA-MB-468, MDA-MB-
157) breast cancer cell lines was performed by RT-PCR. miR-295-5p and miR-512-5p expression was normalized by 
RNU49. ∆CT are indicated for each cell lines. 3 independent experiments was performed. Standard deviation are 
shown.  
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3.4.7 Effects of miR-296-5p and miR-512-5p on molecular pathways in basal breast cancer 
cell lines 
 
3.4.7.1  Ectopic miR-296-5p and miR-512-5p reduces telomere length 
To investigate the effect of miR-296-5p and miR-512-5p on telomere regulation we generated 
MDA-MB-231 basal breast cancer cells, stably expressing candidate miRNAs from miR-296 or 
miR-512 mini genes. For this purpose we have PCR amplified the genomic region of miR-296 
and miR-512-1 and cloned these fragments into a retroviral vector that allows overexpression 
of miR-296-5p or miR-512-5p. Experimental MDA-MB-231 cells display high levels of ectopic 
miR-296-5p or miR-512-5p levels, paralleled with reduced hTERT mRNA expression (Fig. 3.4.8 
A). Stable RNAi against hTERT (shTERT) also reduced TERT mRNA levels. After 4 weeks of 
cultivation experimental cells were fixed and subjected to quantitative telomere DNA FISH. 
Importantly, we found that ectopic miR-296-5p and miR-512-5p expression was linked with a 
20% reduction of average telomere length (Fig. 3.4.8 B, left panel). This result was recapitulated 
when subdividing telomere fluorescence intensity distribution into three subcategories 
reflecting short (A: 0-5000 a.f.u %) medium (B: 5001-10000 a.f.u. %) and long (C: >10000 a.f.u. 
%) telomeres. In particular, we found a shift of telomere length distribution from long to short 
telomeres (Fig. 3.4.8 B, right panel) in miR-296-5p or miR-512-5p overexpressing cells. 
Together, this indicates that miR-296-5p and miR-512-5p act as negative regulators of telomere 
length that act via hTERT. 
Parallel experiment using  a retroviral vector containing an shTERT construct reproduced the 
effect of reduced hTERT expression on telomere length in MDA-MB-231 cells (Fig. 3.4.8 C). 
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Figure 3.4.8: miR-296-5p and miR-512-5p reduce telomere length in breast cancer cells. A) MDA-MD-231 basal 
cells transducted with control miR-vector, miR-296-5p, miR-512-5p mini gene expression vector and pMKO.1-
empty or pMKO.1-shTERT vector were analyzed by RT-PCR. miR-296-5p and miR-512-5p expression was 
normalized against RNU; hTERT expression was normalized against actin. B-C) after 1 month telomere length 
measurements in stable MDA-MB-231 was performed by quantitative telomere DNA FISH on interphase cells. B) 
Telomere fluorescence intensity for miR-vector, miR-296-5p and miR-512-5p was analyzed considering each 
telomere (left panel). Individual telomere signal intensities were categorized in three subgroups (right panel). 
Representative images are shown. C) Telomere fluorescence intensity for shTERT was analyzed. p-values and SDs 
are indicated. n=number of nucleus; N= total signals analyzed. Arbitrary fluorescence units (a.f.u.). 
 
 
 
 
118 
 
3.4.7.2 miR-296-5p and miR-512-5p reduce cell proliferation in breast cancer cells 
To evaluate the effects of our candidate miRNAs on cellular growth we performed two rounds 
of transient transfection of MDA-MB-231 basal breast cancer cell lines with mimic-miR-296-5p, 
mimic-miR-512-5p or the respective antago-miRNA siRNAs.  
We found that ectopic miR-296-5p or miR-512-5p induce a significant reduction of cell 
proliferation during the duration of the experiment (Fig. 3.4.9 A,B). In contrast, competing 
endogenous miR-296-5p or miR-512-5p levels by transfecting MDA-MB-231 cells with the 
respective antago-miRNAs significantly increased cell proliferation when compared to control 
mimic-miRNA transfected cells (Fig. 3.4.9 A,B).  
Of notice, the effect of miR-296-5p and miR-512-5p was recapitulated in MCF-7 cells indicating 
a general role for miR-296-5p and miR-512-5p in controlling breast cancer cell proliferation (Fig. 
3.4.9 C).  
 
 
Figure 3.4.9: miR-296-5p and miR-512-5p reduce cell proliferation in human breast cancer. A-B) MDA-MB-231 cells 
were transiently transfected with miR-296-5p (A) or miR-512-5p (B) and their respective antago-miRNAs at days 0 
and 3. Cell counting was performed at day 1, 3 and 6. 3 independent experiments were performed. C) The 
experiment in (A-B) was recapitulated in MCF-7 cells. n=number of experiments. p-values are shown.  
 
3.4.7.3  miR-296-5p/miR-512-5p driven reduction of cell proliferation is rescued by ectopic 
hTERT     
We next set out to demonstrate that impaired cell proliferation is due to direct targeting of 
hTERT by miR-296-5p and miR-512-5p and not due to off-target effects. We consequently 
established MDA-MB-231 cells transduced with a retrovirus encoding the hTERT open reading 
frame lacking the 3’UTR . hTERT overexpression was validated by quantitative RT-PCR in pBabe-
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hTERT MDA-MB-231 cells. As expected, pBabe-hTERT MDA-MB-231 cells show a strong increase 
of hTERT mRNA when compared to pBabe-empty vector cells (data not shwon).    
To test whether the anti-proliferative effect of miR-512-5p and miR296-5p is mediated via 
down regulation of hTERT we transfected MDA-MB-231 pBabe-empty or pBabe-hTERT vector 
with  mimic-miR-296-5p or mimic-miR-512-5p or the respective antago-miRNAs. Six days post-
transfection we found that the anti-proliferative effect of miR-512-5p and miR-296-5p was 
recapitulated in MDA-MB-231 pBabe-empty vector cells (Fig. 3.4.10 A,B). Importantly, 
proliferation of MDA-MB-231 pBabe-hTERT  cells was not affected when cell were transfected 
with mimic- miR-512-5p or mimic-miR-296-5p. Importantly antagonizing endogenous levels of 
miR-296-5p or miR-512-5p by introducing antago-miR-296-5p or antago-miR-512-5p improved 
cell proliferation (Fig. 3.4.10  A,B). Together, this demonstrates that miR-296-5p and miR-512-
5p impair proliferation by targeting hTERT and excludes miR-296-5p or miR-512-5p off-target 
effects. 
 
Figure 3.4.10 Anti-proliferative effect of miR-296-5p and miR-512-5p in human breast cancer is rescued by ectopic 
hTERT. A-B) MDA-MB-231 was transducted with the retroviral pBabe-empty or pBabe-hTERT vector. Overexpression 
of hTERT was validated by RT-PCR (data not shown). 2 cycles of transfection using mimic-miR-296-5p or mimic-miR-
512-5p and respective antago-miRNAs siRNA were performed in MDA-MB-231 stably express hTERT or a control 
construct. 6 days post transfection cell counting was performed. N=independent experiments; standard deviation and 
p-values are shown.  
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3.4.7.4  miR-296-5p and miR-512-5p trigger senescence and apoptosis 
In parallel to cell proliferation experiments we performed FACS analysis to study the cell cycle 
profile of miR-296-5p and miR-512-5p transfected MDA-MB-231. We found that introduction of 
mimic-miR-296-5p leads to an accumulation of cells in G1 phase, and decreased percentage of 
cells in S and G2 phase, indicative for an arrest at the G1-S transition (Fig. 3.4.11). Mimic-miR-
512-5p induces a significantly reduced cell numbers in G1 phase and a significant increase of 
cells in sub-G1, representing a known feature of cellular apoptosis (Fig. 3.4.11). 
 
 
 
Figure 3.4.11: miR-296-5p and miR-512-5p impact on cell cycle in breast cancer cells. 2 cycles of transfection using  
miR-296-5p or miR-512-5p in MDA-MB-231 were performed. Cells were acquired with FACSCalibur and analyzed 
using FlowJo software. 3 independent experiments was performed. p-values are shown. 
 
 
We subsequently were interested in identifying the molecular outcome of cell cycle alterations 
driven by ectopic miR-296-5p or miR-512-5p. Alterations in telomere homeostasis or impaired 
telomerase expression frequently leads to the induction of senescence or apoptosis (Wu P. et 
al. 2005; Del Bufalo D. et al. 2005). Consequently, we performed miR-296-5p and miR-512-5p 
gain of function experiments followed by β-galactosidase staining to detect senescent cells and 
western blotting experiments focusing on markers of cell cycle regulation and apoptosis. 
We found that ectopic introduction of miRNA-296-5p increases the number of β-galactosidase 
positive MDA-MB-231 but also MCF-7 cells, indicative for the activation of senescence. In 
contrast, ectopic mimic-miR-512-5p does not show the activation of a senescence program (Fig. 
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3.4.12 A,B). Western blotting results validated cell cycle analysis performed by FACS in MDA-
MB-231 cells. We found that ectopic mimic-miR-296-5p increases the expression levels of cyclin 
E, that has critical role in G1 phase and in G1- S transition; in contrast  levels of p-CDC2, an 
important cell cycle kinase that is phosphorylated in cell cycle progression, were reduced (Fig. 
3.4.12 C,D). Together, this suggest that arrest in the G1 phase is one of the physiological 
consequence of ectopic miR-296-5p. This conclusion is supported by increased p21 levels in 
miR-295-5p transfected cells. FACS cell cycle profiles revealed increased sub-G1 fractions in 
miR-512-5p MDA-MB-231 transfected cells, suggesting increased apoptosis rates. In line with 
this, western blotting revealed increased levels of cleaved PARP and cleaved caspase-3, 
indicating that miR-512-5p promotes apoptosis (Fig. 3.4.12 C,D). In line with this, re-activation 
of miR-512-5p expression in cell lines derived from gastric cancer induced cells to apoptosis by 
targeting the apoptosis regulator Mcl-1 (Saito Y. et al. 2009). Increase expression of the DNA 
damage marker γH2AX due to DNA fragmentation is feature of cellular apoptosis (Rogakou E.P. 
et al. 2000). In line with this we found increased γH2AX levels in miR-512-5p transfected cells. 
Remarkably, although miR-296-5p promotes senescence we also found increase levels of 
cleaved PARP in miR-296-5p transfected cells (Fig. 3.4.12 C,D).  Together this indicates that miR-
296-5p has a preferential role in inducing senescence at G1-S phase, however, both candidate 
miRNAs, miR-296-5p and miR-512-5p  can promote apoptosis, as indicated by increase PARP-
cleavage. The pro-apoptotic role of miR-296-5p and miR-512-5p is in line with increased 
apoptosis rates in the context of TERT depletion by RNAi (Del Bufalo D. et al. 2005) 
Together, these results indicate that miR-296-5p and miR-512-5p have an anti-proliferative 
effect in MDA-MB-231 cells. 
Future experiments will address whether ectopic hTERT can rescue the impact of  miR-296-5p 
and miR-512-5p on senescence and apoptosis. 
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Figure 3.4.12: Activation of senescence or apoptosis pathway by miR-296-5p and miR-512-5p in breast cancer cells. A) 
2 cycles of transfection using mimic-miR-296-5p or mimic-miR-512-5p were performed in MDA-MB-231. 6 days post 
transfection β-galactosidase staining was performed. A positive control for senescence was generated by treating  
cells with adriamycin. Representative images (left panel) and quantification (right panel) are shown. B) β-galactosidase 
experiment in MCF-7 was performed in parallel to (A). n= number of independent experiments; p= values are shown. 
C) Representative images of  activation of senescence or apoptosis pathway in MDA-MB-231. 2 cycle of transfection 
using mimic-miR-296-5p or mimic-miR-512-5p were performed. S.E (Short Exposure); L.E. (Long Exposure); cleaved 
PARP (*). 
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3.4.7.5  Epigenetic regulation of miR-296-5p and miR-512-5p expression 
miR-512-1 and miR-512-2 are reported to be localized downstream of Alu repeats region that 
are ~280bp in length and contain high density of DNA methayltion (Saito Y. et al. 2009). 
Sequence analyses of 5 kb-long regions upstream or downstream of the miR-296, miR-512-1 
and miR-512-2 locus identified a CpG island located immediately downstream of the miR-296 
locus (Fig. 3.4.13 A) and 2 CpG islands located 2-4 kb upstream of the miR-512-1 locus (Fig. 
3.2.13 B). Importantly, the CpG island downstream miR-296 and  the CpG#2 island upstream 
miR-512-1 locus show reduced DNA methylation in 5’-aza-2’-deoxycytidine (5’-aza) MDA-MB-
231 treated cells (Fig. 3.4.13 A). CpG#1 island does not show any change in methylation (data 
not shown).  
 
Importantly, treatment of MDA-MB-231 cells with the inhibitor of DNA methylation (5’-aza-2’-
deoxycytidine) resulted a concentration dependent increase of miR-296-5p and miR-512-5p 
expression levels, as determined by quantitative RT-PCR (Fig. 3.4.13  A,B). This indicates that 
both miR-296-5p and miR-512-5p are subjected to regulation by DNA methylation. 
 
Treatment with 5’-aza-2’-deoxycytidine increased also expression of hTERT, which is in line with 
a previous data (Dessain S.K. et al. 2000). Remarkably, we found that limiting the endogenous 
increase of miR-512-5p and miR-296-5p in 5’-aza treated MDA-MB-231 cells by transfecting 
antago-miR-296-5p and antago-miR-512-5p mediate a strong increase of hTERT expression 
compared to control miRNA transfected and to 5’-aza treated cells (Fig. 3.4.14 A). This 
demonstrates that endogenous miR-296-5p and miR-512-5p limit hTERT upregulation during 5’-
aza treatment. This highlights that miR-296-5p and miR-512-5p are efficient regulators of hTERT 
expression in MDA-MB-231 cells.  
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Figure 3.4.13: miR-296-5p and miR-512-5p expression regulated by methylation. A-B) MDA-MB-231 cells were 
treated with different concentration of 5’-aza-2’-deoxycytidine for 5 days. miR-296-5p (A) and miR-512-5p (B) 
expression was analyzed by RT-PCR (left panel). 3µM of  5’-aza-2’-deoxycytidine was used to analyzed the 
methylation status of CpG island (bottom panel). Percentage of methylated CpG position are indicated. CpG#1 
data not shown. n=independent experiments; standard deviation and p-values are shown.  
 
Our data suggest that closed chromatin conformation silences the expression of miR-296-5p 
and miR-512-5p in basal breast cancer. We next wished to test whether the combined 
treatment of 5’-aza-2’-deoxycytidine with two histone acetyl transferase inhibitors can mediate 
a stronger reactivation of in miR-296 and miR-512 that subsequently can reduce hTERT 
expression in basal breast cancer cells.  
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To first test the responsiveness of the miR-296 and miR-512-1 and miR-512-2 loci to HDAC 
inhibitors we treated MDA-MB-231 with two inhibitors of class I and II histone deacetylases: 
Tricostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA). SAHA is currently in clinical 
trials on cutaneous T Cell Lymphoma (CTCL) (Khan O. and La Thangue N.B. 2008; Al-Yacoub N. 
et al. 2012). 
We found that TSA treatment specifically increased the expression of miR-296-5p without 
dramatically affecting miR-512-5p expression. Interestingly, SAHA mediated a consistent 
upregulation of miR-512-5p but did not affect miR-296-5p expression (Fig. 3.4.14 B,C). 
  
Remarkably, we found that the combination of 5’-aza-2’-deoxycytidine with TSA or SAHA 
increases miR-296-5p and miR-512-5p expression compared to MDA-MB-231 cells that were 
treated only with 5’-aza (Fig. 3.4.14 B,C). This indicates that combined treatment is an efficient 
manner to increase miR-296-5p and miR-512-5p expression. Importantly, this increased 
expression of miR-296-5p and miR-512-5p in 5’-aza + TSA/ SAHA conditions correlates with 
downregulation of hTERT expression in MDA-MB-231 cells treated 5’-aza and TSA/SAHA  
compared to cells treated only with 5’-aza (Fig. 3.4.14 D).  
These data suggest that releasing of miR-296, miR-512-1 and miR-512-2 from tight epigenetic 
silencing results in a strong upregulation of miR-296-5p and miR-512-5p that can antagonize 
TERT expression. This represents an interesting strategy to modulate TERT expression in human 
cancer. 
Future experiments involving antago-miR-296-5p/512-5p siRNAs will validate that miR-296-
5p/512-5p indeed are responsible for the downregulation of hTERT in condition of 5’-aza/ 
HDAC inhibitor treatment. An important question will also be whether miR-296-5p and miR-
512-5p can modulate apoptosis under conditions of drug treatment via controlling TERT 
expression. 
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Figure 3.4.14: Loss of silencing of miR-296-5p and miR-512-5p by treatment with DNMT and HDAC inhibitor. A) MDA-
MB-231 basal cells were treated for 5 days with 5’-aza-2’-deoxycytidine (5’-aza) (1µM) but two days after treatment 
cells were transient transfected with antago-miR-296-5p or antago-miR-512-5p. three days post transfection hTERT 
expression was analyzed by RT-PCR. B-C) MDA-MB-231 basal cells were treated with TSA (1µM) for 24h or SAHA (5µM) 
for 48h alone or in combination with 5’-aza (1µM, for 5 days). miR-296-5p (B) and miR-512-5p (C) expression was 
analyzed by RT-PCR. D) MDA-MB-231 cells were treated for 5 days with 5’-aza (1µM) alone or in combination with TSA 
(1µM) for 24h or SAHA (5µM) for 48h, then hTERT expression was analyzed by RT-PCR. A-D) 3 number of experiments; 
p-values are shown.      
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These data demonstrate that mRNA degradation of TERT by miR-296-5p and miR-512-5p 
represent a new layer of regulation of telomerase activity in luminal cancer cells. This highlight 
an important mechanism in telomere regulation and cancer progression in human breast 
cancer. Importantly, in this study we show that low expression of miR-296-5p and miR-512-5p 
inversely correlate with high TERT expression that is link with poor prognosis in basal breast 
cancer. 
Remarkably, DNMT inhibitor and HDACi have shown an important impact on miR-296-5p and 
miR-512-5p regulation in controlling hTERT expression, thus these inhibitors may represent an 
important adjuvant in a therapeutic strategy in basal breast cancer.    
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4. Discussion 
Telomeres are specialized structures that are fundamental to protect the chromosome ends. 
Telomeres are bound by the shelterin complex that consists of six main components: TRF1, 
TRF2, POT1, TPP1, TIN2 and RAP1 (Palm W. and de Lange 2008; Sfeir A. et al. 2009; Hwang H. et 
al. 2012; Frescas D. and de Lange 2014). Shelterin specifically localizes to telomeres throughout 
the cell cycle and distinguishes the chromosome ends from normal DNA breaks by repressing 
the DNA damage repair pathway at telomeres (Diotti D. and Loayza D. 2011). 
Alteration of shelterin function leads to altered telomere length, recombination and replication, 
and also to mitotic defects (Royle N.J. et al. 2009; Munoz P. et al. 2009, Diotti D and Loayza D. 
2011). Telomere dysfunction leads to the activation of a DNA damage response at telomere 
with subsequent activation of DNA damage repair leading to increased genomic instability due 
to fragility or end to end fusions. 
In 90% of human cancer, telomeres are maintained by the reactivation of telomerase function, 
highlighting the importance of telomerase in tumor formation.  
Here we set out to identify miRNAs that impact on telomere function in human breast cancer 
by targeting shelterin and telomerase complex compounds. 
 
4.1 miR-155 drives telomere fragility in human breast cancer by targeting TRF1 
Alterations in the expression of shelterin components is a frequent event in cancer (Martinez P. 
et al 2009; Diehl M.C. et al. 2011; Martinez P. and Blasco M.A. 2010). On the mechanistic level, 
impairement of shelterin function results in alterations in telomere length and promotes the 
activation of DNA damage response leading to genomic instability such as chromosome end to 
end fusions (Martinez P. et al. 2009; Okamoto K. et al. 2013). Together, these data highlight a 
critical role of shelterin in the suppression of genomic instability and in cancer formation.   
Shelterin components such as TRF1 and TRF2 are subjected to different post-translational 
modifications such as phosphorylation, ubiquitylation, SUMOylation, PARsylation, that have a 
direct impact on telomere homeostasis (Walker J.R and Zhu X-D 2012). However to date our 
insight on the involvement of miRNAs in telomere regulation in the context of human cancer is 
very limited. Using a high-throughput  screening we  identified miRNAs with high targeting 
specificity for the 3’UTRs of telomere regulators, such as TRF1, TRF2, POT1, TERT and DKC1. 
Subsequently, the clinical relevance of identified miRNAs was studied using breast cancer as 
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model system. Focusing on TRF1 as miRNA target, we found that the oncomiR miR-155 
efficiently regulates TRF1 expression by targeting a partially conserved sequence motif in the 
TRF1 3’UTR, resulting in translational repression.  
miR-155 is a classic onco-miRNA that is processed from a long noncoding transcript encoded by 
the BIC locus that has been linked to lymphomagenesis (Clurman B.E. et al. 1989; Costinean S. 
et al. 2006). miR-155 is a typical multifunctional miRNA that is involved in numerous biological 
processes including  cancer, haematopoiesis, inflammation, immunity, and cardiovascular 
disease (Faraoni I. et al. 2009; Mattiske S. et al. 2012).  
A series of studies highlights a role for miR-155 in human cancer (Faraoni I et al. 2009). 
Remarkably, transgenic mice carrying a miR-155 transgene  initially exhibited a preleukemic 
pre-B cell proliferation and later develop a B cell malignancy (Costinean S. et al. 2006; Sandhu 
S.K. et al 2012). This demonstrates that miR-155 behaves as a classic onco-miRNA. 
In fact, miR-155 was found to be overexpressed in various B-cell malignancies, including 
Hodgkin's Lymphoma and some subtypes of Non Hodgkin's Lymphoma (Kluiver j. et al. 2005; Eis 
P.S. et al. 2005). Moreover, miR-155 is overexpressed in several solid tumors, such as thyroid 
carcinoma (Nikiforova M.N. et al. 2008; Zhang X. et al. 2013), breast cancer (Iorio M.V. et al. 
2005; Volinia S. et al. 2006; Gasparini P. et al. 2014), colon cancer (Volinia S. et al. 2006; Zhang 
G.J. et al. 2013), cervical cancer (Wang X. et al. 2008; Lao G. et al. 2014), pancreatic ductal 
adenocarcinoma (PDAC) (Lee E.j. et al. 2007; Szafranska A.E. et al. 2007; Liu Q. et al. 2014), and 
lung cancer (Zang Y.S. et al. 2012), where it is considered as marker of poor prognosis. These 
results suggest that miR-155 acts as onco-miR that promotes cancer of various origin. 
 
Given the central role in cancer formation, extensive studies focused on the identification of 
miR-155 targets genes. To date miR-155 was shown to have 400 predicted target genes 
underling its role as “multipotent” miRNAs (Lewis B.P et al. 2005; Mattiske S. 2012). Several 
studies provide a functional link between miR-155 and related target genes in breast cancer. 
Up-regulation of miR-155 was demonstrated to exert an anti-apoptotic function by direct 
inhibition of FOXO3a, a major member of the forkhead transcriptional factor family, promoting 
to cell survival and growth in breast cancer (Kong W. et al 2010). Moreover, miR-155 was also 
found to promote pro-tumorigenic inflammatory STAT3 signaling by targeting SOCS1 
(Suppressor of Cytokine Signaling 1). The reduction of SOCS1 by miR-155 increase breast cancer 
cell proliferation (Jiang S. et al. 2010,2012). In addition, miR-155 is involved in epithelial 
mesenchymal transition (EMT) via the TGFβ/Smad4 pathway. In particular, Smad4 can bind to 
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the BIC promoter to drive miR-155 expression, thereby augmenting the TGFβ dependent EMT. 
Moreover, upregulation of miR-155 has been demonstrated to provoke the downregulation of 
RhoA expression, a GTPase  involved in the regulation of actin dynamics, leading to cell 
migration and invasion in mammary epithelial cells (Kong W. et al. 2008). 
In line with functional experiments on the cellular level, miRNA expression analysis using breast 
cancer tissues indicate clinical relevance for miR-155. In particular, high levels of miR-155 were 
found in aggressive breast cancer subtypes such as basal-like and estrogen receptor negative 
(ER-) breast cancer (Blenkiron C. et al. 2007; Zhang C.M. et al. 2013). High miR-155 levels in 
these types of tumors are linked with a poor prognosis, indicating high clinical relevance for 
miR-155 in human breast cancer.  
Given the high importance of miR-155 for human breast cancer, we hypothesized that targeting 
of TRF1 by miR-155 is a clinically relevant event in human breast cancer. This could for the first 
time link miRNAs to the dysregulation of shelterin function in luminal breast cancer. 
In line with luciferase reporter experiments that validated the miR-155 target site in the 3’UTR 
of TRF1, we found that ectopic miR-155 reduces TRF1 protein level in breast cancer cells lines. 
Importantly, the inhibition of miR-155 using specific antago-miRNA increases the TRF1 levels 
demonstrating that TRF1 expression is limited by miR-155 under physiologically normal 
conditions in breast cancer cells.  
miRNAs can regulate protein expression on the RNA level by either mRNA degradation or 
inhibition of translation. We demonstrate that overexpression of miR-155 reduces TRF1 protein 
levels, however it does not change the mRNA levels of TRF1. This indicates that miR-155 acts as 
inhibitor of TRF1 translation that controls TRF1 levels in breast cancer cells. 
Several studies show that miRNA expression is deregulated in human cancer. In particular, most 
miRNAs are found to be downregulated in cancer,  except for a few miRNAs including miR-155 
that appear upregulated (Volinia S. et al 2006; Kong W. et al. 2014). In line with these studies, 
we found that miR-155 is upregulated in Luminal, triple negative and HER2+ breast cancer 
tissues compared to peritumoral tissue. This data suggest that high miR-155 levels could 
destabilize telomere-function in breast cancer by limiting TRF1 expression. 
To provide evidence for a functional link between miR-155 and TRF1, we first analyzed TRF1 
mRNA expression in human breast cancer using gene expression meta-data sets. TRF1 
expression analysis revealed that low TRF1 correlates with poor prognosis in luminal ER+ breast 
cancer. High expression of miR-155 in breast cancer tissues combined with poor survival of 
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cancer patients with low TRF1 expression suggest that miR-155 and TRF1 might cooperate to 
mediate poor prognosis in ER+ breast cancer. In line with this hypothesis, we found that low 
expression of a signature of twenty validated target genes of miR-155 predicts poor prognosis 
in ER+ breast cancer. This suggests that TRF1 is part of a miR-155 signature that predicts poor 
survival in luminal ER+ breast cancer. To provide a more direct evidence for a functional link 
between miR-155 and TRF1, we performed TRF1 Immunohystochemestry (IHC) on ER+ luminal 
breast cancer tissue sections, previously analyzed for miR-155 expression. Importantly, we 
found that tumoral tissues with high miR-155 expression correlates with reduced TRF1 protein 
levels in specimen from ER+ breast cancer tissues. 
Together this demonstrates that miR-155 dependent regulation of TRF1 expression has an 
impact on poor prognosis in luminal ER+ breast cancer patients. After demonstrating a clinical 
relevance for miR-155 dependent regulation in ER+ luminal breast cancer, we wished to 
understand the role of miR-155 in controlling telomere homeostasis in luminal cancer derived 
cell lines. TRF1 has been demonstrated to play a central role in telomere length regulation. In 
fact, TRF1 overexpression induces telomere shortening, presumably by limiting the access of 
telomerase to chromosome ends (Smogorzewska A. et al.  2000). In contrast, the expression of a 
dominant-negative TRF1 mutant that inhibited binding of endogenous TRF1 induces telomere 
elongation (van Steensel B. et al. 1997). 
We found that overexpression of miR-155 reduces TRF1 abundance at telomeres while the 
inhibition of endogenous miR-155 with a specific antago-miRNA increases the amount of TRF1 
compared to the control. The effect of miR-155 on TRF1 did not affect the binding of the main 
components of shelterin, TRF2 and POT1. This indicates that alterations in miRNA expression 
can lead to an altered shelterin conformation/composition at telomeres due to the abundance 
of TRF1 at telomere. In line with the role of TRF1 on telomere length regulation, we found that 
reduction of TRF1 at telomeres, caused by miR-155 overexpression, leads to elongation of 
telomeres in telomerase positive SK-BR-3, a luminal breast adenocarcinoma-derived cell line.  
This demonstrates that miRNAs targeting shelterin can alter telomere length suggesting an 
impact not only in cancer but also in aging. Shelterin components also play a critical role in 
chromosome ends protection from the DNA damage repair machinery (Palm W. and de Lange 
T.  2008). In particular, conditional deletion of TRF1 in mouse embryonic fibroblasts (MEFs) 
resulted a senescence phenotype with a concomitant appearance of DNA damage foci at 
telomeres (Martinez P. et al 2009; Sfeir A. et al. 2009). In line with these reports we found that 
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miR-155 modulates  telomere function by controlling TRF1 expression. In particular, ectopic 
miR-155 expression induces the activation of the two main DNA damage response pathways as 
indicated by the accumulation of phospho ATM and ATR. Their activation leads to the 
phosphorylation of checkpoint kinases CHK1/CHK2 and subsequently to the phosphorylation of 
p53 and γ-H2AX. This is in line with the conditional TRF1 knockout mouse model that shows the 
activation of ATM and ATR (Martinez P. et al 2009). Moreover, we demonstrated that strong 
reduction of TRF1 at telomeres leads to the activation of a telomere DNA damage response as 
shown by the increased appearance of TIFs. Importantly, increased abundance of TRF1 at 
telomere mediated by antago-miRNA siRNAs reduces basal TIFs levels in luminal breast cancer 
cells. These results demonstrate that miR-155  plays a key role in controlling telomere 
protection by regulating TRF1 expression. 
Increased  TIF frequency under miR-155 gain of function condition indicate that DNA damage 
arising from telomere has a relevant contribution to overall DNA damage load in miR-155 
transfected cells. In contrast, reduction of miR-155 function reduce TIF frequency. This 
indicates that telomere dysfunction in cancer cells can be modulated by miRNA dependent 
regulation of shelterin components. This highlights the role of miRNAs in controlling telomere 
function in human cancer.  
Telomeric TTAGGG repeats were described as common fragile sites based on their sequence 
structure and telomere replication timing (Sfeir A. et al. 2009). TTAGGG tandem repeats can 
fold up to G-quadruplex structures, resulting in a slow down or arrest of DNA replication 
(Durkin S.G. and Glover T.W. 2007). Accordingly, the use of G-quadruplex stabilizers or low 
doses of aphidicolin that inhibits DNA polymerase was demonstrated to cause site-specific 
breaks or gaps in metaphase chromosomes that also affect telomeres (Glover T.W. et al. 1984). 
Replication defects at telomeres caused by replication arrest or the uncoupled mechanism 
between polymerases and helicases leads to the activation of ATR (Recolin B. et al. 2014; Sfeir 
A. et al 2009; Martinez P. et al. 2009). 
Among shelterin components, TRF1 has been demonstrated to play a main role in telomere 
replication. Two studies showed that conditional deletion of TRF1 induces increased telomere 
fragility suggesting its involvement in telomere replication. In particular, TRF1 loss of function 
increased telomere fragility, recapitulating the effect of aphidicolin (Sfeir A. et al 2009; 
Martinez P. et al. 2009).   
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Moreover, TRF1 was recently reported to interact and recruit BLM helicase to disassemble G-
quadruplex structures in the lagging strand template ensuring efficient telomere replication 
(Zimmermann M. et al. 2014). Recently, also the helicase RTEL1 has been found to interact with 
the shelterin component TRF2. Specifically, TRF2 recruits RTEL1 to telomeres promoting t-loop 
unwinding and suppression of telomere fragility (Sarek G. et al. 2015). This suggests an 
important role of shelterin components to promote efficient telomere replication. 
In line with these results, we demonstrate that ectopic expression of miR-155 in SK-BR-3 cells 
induces an increase of fragility at telomere that can be rescued by ectopic introduction of TRF1. 
Remarkably, transfection of cells miR-155 and treatment with aphidicolin exacerbates telomere  
fragility, suggesting that miR-155 and aphidicolin act on the same pathway.  
Importantly, introduction of antago-miR-155 reduces telomere fragility by increasing 
abundance of TRF1 at telomere, indicative of improved telomere replication. Moreover, 
antago-miR-155 treatment was able to rescue telomere fragility induced by aphidicolin.  
This highlights the key role of miR-155 in controlling telomere fragility by modulating TRF1 
expression in luminal cancer.   
Abrogation of checkpoint proteins in TRF1 knockout cells leads to chromosomal aberration such 
as breaks, chromosome concatenation and sister chromatid fusions and increases cancer 
formation (Martinez P. 2009). 
This suggest that TRF1 functions as tumorsuppressor that stabilizes telomere function. 
Importantly, we found that ectopic expression of miR-155 in SK-BR-3 mutant for p53 leads to 
increase sister chromatid fusions demonstrating its involvement in controlling genomic 
instability in the context of a luminal cancer model. This effect was rescued with flag-tagged 
TRF1 lacking the respective 3’UTR, indicating that telomere sister chromatid fusion are a direct 
consequence of miR-155 dependent regulation of TRF1. 
Our results show that miR-155 is critically involved in the regulation of telomere fragility and 
genomic instability  which represent critical events in cancer formation and progression. 
In fact, it was found that several genes known to contribute to oncogenesis coincide with fragile 
sites, demonstrating that fragility is a significant feature of human cancer (Barlow J. et al. 2013). 
In conclusion, our work identifies the "oncomiR" miR-155 as the first miRNA able to regulate 
shelterin function impacting on telomere homeostasis. The upregulation of miR-155 promotes 
genomic instability by the reduction of TRF1 protein levels at telomeres. Importantly , the 
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inverse correlation of miR-155 and TRF1 expression is linked with poor clinical outcome in 
luminal ER+ breast cancer.  
Together we propose a model where upregulation of miR-155 induces on one hand accelerated 
cell proliferation and cell plasticity by targeting important cancer related genes such as SOCS1, 
FOXO3A and RhoA. In parallel high miR-155 expression leads to reduced TRF1 levels causing 
telomere fragility and genomic instability, hallmarks of cancer formation and progression.  
This work for the first time links miRNAs and shelterin components in the context of human 
cancer. Future work will try to integrate groups of telomere regulating miRNAs into central 
pathways of human cancer. 
 
 
4.2 Tumor-suppressor microRNAs miR-296-5p and miR-512-p repress telomerase in human 
breast cancer 
 
Reactivation of telomerase represents a critical step in maintaining telomere function in 90% of 
human cancer (Shay J.W. and Bacchetti S. 1997; Hackett J.A. and Greider C.W. 2002).  
Telomerase was demonstrated to be activated in cancer by several mechanisms such as the 
oncogenes Myc and Wnt, that act as transcriptional regulators of telomerase. Moreover, 
epigenetic alterations or hTERT mutations lead to increase the transcriptional activity of hTERT 
promoter (Huang F.W. et al. 2013; Horn S. et al. 2013; Wu K.J. et al. 1999; Hoffmeyer K. et al. 
2012). 
Recent studies have shown that miRNAs contribute to  the regulation of telomerase expression. 
In fact, miR-138 overexpression was demonstrated to act as a negative regulator of the human 
telomerase reverse transcriptase (hTERT), increasing proapototic effects in neuroblastoma 
cancer cells (Chakrabarti M. et al. 2013). In addition miR-1207-5p and miR-1266 have been 
demonstrated to target the 3’-UTR of hTERT in gastric cancer (Chen L. et al. 2014).  
However, the impact of miR-138, miR-1207-5p and miR-1266 on telomere length homeostasis 
is unclear.   
Using a high-throughput luciferase screening to identify miRNAs with high targeting specificity 
for the 3’UTR of hTERT we identify miR-296-5p and miR-512-5p as efficient regulators of hTERT 
expression.  
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miR-296-5p and miR-512-5p play a critical role in cancer and were found downregulated in 
different types of tumor. In particular miR-296-5p, was found downregulated  in lung cancer, 
prostate cancer and breast cancer (Corbetta S. et al. 2010; Hong L. et al. 2010; Lee KH 2014;  
Savi F. et al. 2014). Importantly, low expression of miR-296-5p is inversely correlated with the 
high oncoprotein HMGA1 expression in prostate cancer. HMGA1 is a non-histone nuclear 
binding protein that is significantly overexpressed in and associated with high grade and 
advance stage of prostate cancer (Wei J-J et al. 2011). Moreover, miR-296-5p was 
demonstrated to target specifically the 3’UTR of PUMA, an important pro-apoptotic protein 
(Cazanave  S.C et al.  2011).  
In breast cancer, miR-296 was found to be downregulated to permit the expression of SCRIB, a 
polarity protein implicated in cell motility and plasticity, promoting progression and metastasis 
(Savi F. et al. 2014). Similar to miR-296-5p, miR-512-5p was found to be downregulated in 
cancer, such as gastric and lung cancer (Saito Y. et al. 2009; Adi Harel S. et al. 2015).  
High density of DNA methylation Alu repeats in vicinity to miR-512-1 and miR-512-2 genes was 
proposed to ensure repression of miR-512 expression in human cancer.    
The upregulation of miR-512-5p by DNMT inhibitor was demonstrated to induce the 
suppression of Mcl-1 in gastric cancer. Thus, the silencing of miR-512-5p leads to upregulation 
of Mcl-1, that acts as anti-apoptotic factor promoting cell survival in human cancer (Saito Y. et 
al. 2009). Recently, miR-512-5p was observed to be silenced in lung cancer to ensure low 
expression of its target TEAD4, that positively regulates cell proliferation (Zhao B. et al. 2008; 
Adi Harel S. et al. 2015). 
Given the high importance of miR-296-5p and miR-512-5p in human cancer, we hypothesized 
that downregulation of  miR-296-5p and miR-512-5p could represent a critical event in the 
reactivation of telomerase expression in human breast cancer. 
In line with this, we found  downregulation of miR-296-5p and miR-512-5p expression in 
different subtypes of breast cancer (basal, luminal A, luminal B, her2) compared to normal 
samples. Validating miRNA-hTERT target site interaction, we found that miR-296-5p and miR-
512-5p target defined sequences in the 3’UTR of hTERT. Consistent with this we show that 
ectopic miR-296-5p and miR-512-5p reduce telomerase activity in luminal breast cancer cells. 
This is in line with our finding that MDA-MB-231 basal cancer cell line stably overexpressing 
miR-296-5p or miR-512-5p display significantly shorter telomeres. This demonstrates that miR-
296-5p and miR-512-5p have a critical impact on telomerase activity. 
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 miRNAs can regulate protein expression on RNA level by either mRNA degradation or inhibition 
of translation. We demonstrate that overexpression of miR-296-5p or miR-512-5p reduces 
mRNA levels of hTERT indicating that miR-296-5p and miR-512-5p control hTERT expression via 
the RNAi pathway. Together these data identify miR-296-5p and miR-512-5p as novel regulator 
of telomerase activity.  
Several studies demonstrate that telomerase activity correlates with hTERT expression in 
cancer and represent an important marker of poor prognosis in cancer patients (Wang L. et al. 
2002; Tomoda R. et al. 2002; Tchirkov A. et al. 2004;  Elkak A. et al. 2006). In line with this we 
found that high hTERT expression correlates with poor prognosis across all breast cancer types 
as indicated by a significant reduction of distant metastasis free survival (DMSF) and relapse 
free survival (RSF). Interestingly, this effect was found to be enhanced in the aggressive basal 
subtype of breast cancer.  
DMSF is defined as the period between the onset of a primary tumor to the formation of 
metastasis in distant organs or lymphonodes, while RFS  measures the time period  between 
the healing from the primary tumor and the reappearance of a new one. 
These data indicate that high expression of hTERT promotes breast cancer progression.  
To provide evidence for a functional link between hTERT and miR-296-5p or miR-512-5p we 
analyzed validated miR-296-5p target genes signature or predicted miR-512-5p target genes in 
breast cancer data set. 
Importantly, we found that high expression of a signature of nine validated miR-296-5p target 
genes, including hTERT,  predicts poor prognosis considering all breast cancer subtypes. Again 
this trend was enhanced in basal tumor, considering the KM plotter data set. In parallel to miR-
296-5p, we found that high expression of a signature of eight predicted target genes of miR-
512-5p, predicts poor prognosis exclusively in basal breast cancer.  
We conclude that miR-296-5p or miR-512-5p target gene expression signatures recapitulate 
poor prognosis of high hTERT expression in basal breast cancer. This suggests that hTERT is part 
of a miR-296-5p and miR-512-5p signature that predicts poor survival in basal breast cancer. In 
line with this we found low expression of miR-296-5p or miR-512-5p in basal breast cancer cells. 
 
Ectopic introduction of  miR-296-5p and miR-512-5p in luminal or basal cancer cell lines leads to 
a significant inhibition of cell proliferation, confirming an antiproliferative role of miR-296-5p 
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and miR-512-5p in basal type breast cancer. Impaired cell proliferation is mediated by the 
activation of senescence and apoptosis pathways triggered by ectopic miR-296-5p. Ectopic miR-
512-5p was found to induce exclusively apoptosis.  
These data are in line with the increase of apoptosis in cells silenced for hTERT and treated with 
Bcl2 inhibitors (Del Bufalo D. et al. 2005).  Our data suggest that alteration of miR-296-5p and 
miR-512-5p expression impacts on cell proliferation by modulating hTERT expression.  
In future experiments these data will be confirmed by rescue experiments involving ectopic 
hTERT expression. 
hTERT expression was demonstrated to be upregulated in the majority of tumors and its 
expression is regulated by DNA methylation (Zinn R.L. et al. 2007; Safont M.J. et al. 2011; 
Kirkpatrick K.L. et al.  2003). In fact, treatment of cancer cells with inhibitor of DNA 
methyltransferases (DMNTs) or histone deacetylases (HDACs) such as 5’-aza-2’ deoxycytidine 
and trichostatin A demonstrates an increase of hTERT expression due to the epigenetic 
alterations of the hTERT promoter (Iliopoulos D. et al. 2009). Epigenetic gene regulation 
fundamentally impacts on miRNAs expression (Choudhry H. and Catto J.W. 2011). 
Importantly, we found that miR-296-5p and miR-512-5p are regulated at epigenetic level in 
basal breast cancer cells. Treatment with 5’-aza-2’-deoxycytidine, a DNMTs inhibitor, results in 
upregulation of  miR-296-5p and miR-512-5p expression due to CpG island demethylation in 
vicinity of the miR-296 and miR-512 gene. This is in line with the upregulation of miR-512-5p in 
lung and gastric cancer after treatment with DNMT or HDAC inhibitors (Adi Hare S. et al. 2015; 
Saito Y. et al. 2009). We further found that combined treatment with 5’-aza-2’-deoxycytidine 
and HDAC inhibitors dramatically increases miR-296-5p and miR-512-5p expression. Under 
these conditions of high miR-296-5p and miR-512-5p expression we observed a reduction of 
hTERT expression when compared to cells exclusively treated with 5’-aza-2’-deoxycytidine. 
Supporting this result we observed that reduction of endogenous  miR-296-5p and miR-512-5p 
levels under DNMT inhibitor condition induces an increased expression of hTERT compared to 
the control treated cells. 
These results demonstrate that releasing of miR-296-5p and miR-512-5p from epigenetic 
repression might have a critical role in the regulation of telomerase activity. Additional 
experiments are planned to further support this model. In addition, we will investigate the 
contribution of miR-296-5p and miR-512-5p dependent regulation in controlling apoptosis in 
basal breast cancer. 
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In conclusion, our work identifies miR-296-5p and miR-512-5p as "tumorsupressor-miR" that 
act via hTERT to modulate cell proliferation. 
Importantly, low expression of a miR-296-5p and miR-512-5p target gene expression signature 
is linked with poor prognosis in basal breast cancer type.  
We propose a model where silencing of miR-296-5p and miR-512-5p in cancer allows higher 
expression of hTERT with consequent increase of telomerase expression. This event is expected 
to improve telomere maintenance in basal type breast cancer and also increase resistance to 
apoptosis. In fact, hTERT was demonstrated to have an antiapoptotic function in cancer (Del 
Bufalo D. et al. 2005).  In parallel, downregulation of miR-296-5p and miR-512-5p allows the 
expression of proteins such as Mcl-1, Scrib and TED4 involved in apoptosis protection, cell 
mobility and proliferation thereby promoting cancer progression and aggressiveness. Thus, 
upregulation of miR-296-5p and miR-512-5p by specific DNMT or HDAC inhibitors may be an 
important strategy to inhibit telomerase activity  and promote apoptosis activation in basal 
breast cancer.  
Together my thesis work provided functional evidence that miRNAs have an important role in 
the control of telomere function in human cancer. 
Future work will aim to study the importance of groups of miRNAs in telomere regulation in 
cancer metastasis and organismal aging.  
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